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HÄRTER OH 
GENERAL INTRODUCTION 

GENERAL INTRODUCTION 
Lung cancer is the leading cause of cancer deaths among men in western 
countries (Parkin et al., 1984). While the age-adjusted lung cancer death 
rates for men seem to stabilize, its rapidly growing incidence among women 
will make lung cancer the leading cause of cancer deaths among women also 
in most western countries within the next 5 - 1 0 years (Andrews et al., 
19Θ5; Silverberg and Lubera, 1988). For instance, it is estimated that in 
the USA in the course of 1988 46,000 women will die of lung cancer, as 
compared to 42,000 for breast cancer, the hitherto leading cause of cancer 
deaths among the female population (Silverberg and Lubera, 1988). 
One of the major causes of lung cancer is evidently cigarette smoking. 
Already thirty years ago Hammond and Horn (1958) have investigated the 
correlation between death rates and smoking habits, and have shown that the 
lung cancer mortality ratio of smokers as compared to non-smokers was as 
high as 10 : 1. In light of these data the growing incidence of lung 
cancer among women, who in the last decades have adopted the smoking habits 
of men (Holleb, 1988), can be explained. This can also account for the 
rapidly growing incidence of lung cancer in developing countries (Parkin et 
al., 1984). 
In the Netherlands in 1986 about 34,000 men and women have died of 
neoplasias. Of these, in about 9000 cases (26%) lung cancer was the cause 
of death, divided among men and women in a ratio 8:1 (CBS, 1988). In 1975 
this ratio was 14:1 (CBS, 1986), indicating a rapid change to a more equal 
distribution between male and female death rates for lung cancer. 
LUNG CANCER HISTOLOGY 
The major types of lung cancer, as classified according to the 
W.H.O.-system (WHO, 1982), include a) epidermoid (squamous cell) carcinoma, 
occurring in about 33 to 64X of all cases (Minna et al., 1985), b) 
adenocarcinoma (16-26%), с) small cell lung cancer (20-25X), d) large cell 
carcinoma (9-20%), and e) lung carcinoids (less than 5%). The estimates of 
incidence of each subtype depend on the source of pathological material 
reviewed (Minna et al., 1985). Histologically the main types of lung 
cancer can be characterized as follows: 
a) Squamous cell carcinoma (SQC). Three histological degrees of 
differentiation are discerned: 
1. Well differentiated SQC: Tumors showing orderly stratification, 
obvious intercellular bridges and keratinization with pearl formation. 
2. Moderately differentiated SQC: Carcinomas with features intermediate 
between well differentiated and poorly differentiated SQC. 
3. Poorly differentiated SQC: Carcinomas fulfilling the criteria for 
SQC, but only in part of the tumor, while the bulk of the tumor cells 
has an undifferentiated character. Also tumors, in which these criteria 
are discerned with difficulty, are included within this diagnosis. 
b) Small cell lung carcinoma (SCLC). According to the WHO-classification a 
subdivision can be made into oat cell carcinoma, small cell carcinoma of 
the intermediate cell type, and combined oat cell carcinoma. In 1985, 
however, the pathology panel of the International Association for the Study 
of Lung Cancer (IASLC) has proposed an alternative classification (Yesner, 
1985), which has been adopted in this thesis: 
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1. Classic small cell carcinoma: This group includes the former oat 
cell carcinomas and the intermediate cell type carcinomas, since no 
significant clinical, biological, or ultrastructural differences were 
found between these two subtypes (Radice et al., 1982; Hirsch et al., 
1983; Yesner, 1985). These carcinomas are composed of more or less 
regular small cells, generally larger than lymphocytes. They have dense 
round and oval nuclei (oat cell type), or polygonal to fusiform nuclei 
(intermediate cell type), the chromatin is finely granular and 
distributed throughout the nucleus, nucleoli are inconspicuous, and 
cells have very sparse (oat cell type) to more abundant (intermediate 
cell type) cytoplasm. 
2. Small cell/large cell carcinoma (Variant SCLC): Carcinomas in which 
an admixture of classic small cell carcinoma cells and large cells with 
open nuclei and prominent (eosinophilic) nucleoli is observed. 
3. Combined small cell carcinoma: A small cell carcinoma with a 
substantial component of SQC or adenocarcinoma cells or both. 
c) Adenocarcinoma. A malignant epithelial tumor with tubular, acinar, or 
papillary growth patterns, and/or mucus production by the tumor cells. 
d) Large cell carcinoma. A malignant epithelial tumor with large nuclei, 
prominent nucleoli, abundant cytoplasm, and usually well defined cell 
borders, without the characteristic features of SQC, SCLC, or 
adenocarcinomas. 
e) Carcinoid tumor. A tumor of the diffuse endocrine system derived from 
Kulschitsky-type cells (WHO, 1982), showing a mosaic or trabecular 
arrangement of polygonal cells with granular eosinophilic or clear 
cytoplasm and regular oval nuclei. Nucleoli are typically prominent, while 
mitoses are rare. 
TREATMENT OF LUNG CANCER 
In lung cancer treatment, in contrast to many other types of cancer, no 
great improvements have been achieved during the last decade, showing an 
overall 5-year survival of only 10% (Minna et al., 1985). Therefore, a 
better understanding of the cell-biological behaviour of the different 
types of lung cancer is needed, which might serve as a basis for new and 
more promising treatment regimens. 
To decide upon a treatment protocol, especially the subdivision into SCLC 
and non-SCLC is important. Unlike the other types of lung cancer, SCLC is 
sensitive to chemotherapy. In about 75% of the cases of SCLC an Initial 
response to chemotherapy can be noticed, with a clinically complete 
response in about 35% of all cases (Johnson and Greco, 1986,1987). 
Unfortunately, however, in most cases relapse occurs, resulting in a 
three-year survival rate of only 5-10%, and a five-year survival rate of 
about 1% (Minna et al., 1985). Within SCLC a clinically relevant 
subdivision can be made between classic and variant SCLC (Carney et al., 
1985; Gazdar et al., 1985; Yesner, 1985). The variant-type of SCLC appears 
to be less sensitive to chemotherapy and radiotherapy. As a result the 
median survival time of patients suffering from the variant-type of SCLC is 
significantly shorter than of those with a classic type of SCLC (Radice et 
al., 1982; Hirsch et al., 1983). Also for patients with a combined SCLC a 
poorer prognosis than for patients with classic SCLC is observed (Sehested 
et al., 1986). 
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In non-SCLC treatment with chemotherapy is in general unsuccesful (Minna et 
al., 1985). Therefore, with the exception of high cure rates for surgical 
treatment of truly localized disease, the prognosis for patients with 
non-SCLC is grim (Mulshine et al., 1986). In a small subset of patients, 
however, a response to chemotherapy can be observed (for a review see 
Mulshine et al., 1986). In part, these cases might represent non-SCLC, in 
which SCLC-components occur. A heterogeneous composition is quite common 
in lung cancer. At the cytological (Hess et al., 1981), 
electron-microscopical (McDowell and Trump, 1981; Trump et al., 1982; 
Dingemans and Mooi, 1985; Hammond and Sause, 1985), immunocytochemlcal 
(Hammar et al. 1985; Dunnill and Gatter, 1986; Mooi et al. 1988), and 
even at the histological level (Roggli et al., 1985) a heterogeneity in 
type as well as degree of differentiation can be noticed in more than 50X 
of all cases. 
In our studies we have tried to determine some of the biological properties 
of the different types of lung cancer. We have focussed on lung cancer 
heterogeneity, with special emphasis on the degree and type of 
differentiation. We have used surgically resected tumor samples, autopsy 
material, and cell lines, derived from the main subtypes of lung cancer. 
Immunocytochemlcal as well as biochemical methods, next to conventional 
histological staining procedures have been applied. Most 
Immunocytochemlcal investigations have been performed using monoclonal 
antibodies to intermediate filament proteins, a group of cytoskeletal 
proteins with a tissue- and differentiation-related distribution. 
INTERMEDIATE FILAMENT PROTEINS 
Intermediate filaments are proteinaceous fibrillar structures, measuring 
8-11 nm in diameter, which is between that of the two other major 
constituents of the cytoskeleton, the microfilaments (5 nm) and the 
microtubules (25 nm). About two decades ago intermediate filaments were 
firstly defined as a distinct class of organelles by Ishikawa and coworkers 
(1968). Thereafter, it took about ten years until a thorough 
ultrastructural and biochemical investigation of intermediate filaments was 
undertaken. Since that time, however, an increasing number of papers has 
been published on the expression of the different intermediate filament 
types (For reviews see Osborn and Weber, 1983; Traub, 1985; Wang et al., 
1985). Interest in intermediate filament expression, which is ubiquitous 
to virtually all vertebrate cells (Traub, 1985), arose after the finding, 
that the five different types of intermediate filaments are not randomly 
distributed among vertebrate cells, but that a tissue-specific distribution 
appears to exist (Bennet et al., 1978a,b; Franke et al., 1978; Lazarides, 
1980, 1982; Anderton et al., 1980). Cytokeratins are present in virtually 
all epithelial cells, vimentin occurs in mesenchymal cells, neurofilaments 
occur in neuronal cells, glial fibrillary acidic protein (GFAP) is found in 
astrocytes, and desmin can be found in muscle cells. Since this 
distribution corresponds strikingly well with the major tissue 
classification system based on histological principles, a large number of 
applications has become available, especially since (monoclonal) antibodies 
to the different types of intermediate filaments have been developed. 
Immunocytochemlcal application of these antibodies allows the in situ 
identification of intermediate filament proteins in different tissues. 
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Especially, monoclonal antibodies to the different cytokeratin polypeptides 
appear to be very useful. Cytokeratlns are a family of polypeptides, which 
are characterized by a remarkable biochemical diversity, represented in 
human epithelial tissues by at least 19 different polypeptides. They range 
in molecular weight from 40 to 68 kDa and are designated 1 to 19, 
cytokeratin 1 having the highest molecular weight and the highest 
isoelectric pH, and cytokeratin 19 having the lowest molecular weight and a 
low isoelectric pH (Moll et al., 1982). These different cytokeratlns are 
not expressed randomly throughout epithelia but occur in cell-specific 
combinations. These combinations consist of at least one type I (acidic) 
cytokeratin polypeptide (Quinlan et al., 1985) and at least one type II 
(basic) cytokeratin polypeptide. In this way the cytokeratin pattern of a 
particular epithelium can be used for its identification (Quinlan et al., 
1985). 
The function of intermediate filaments is still a matter of debate. It has 
been suggested that these cytoskeletal structures are involved in forming a 
scaffold that retains cell structure. Recent investigations have shown 
that vimentin is linked to the lamins of the nuclear envelope through the 
nuclear pores, while at the cell periphery these intermediate filaments 
associate with the membrane skeleton. In this way an elaborate system for 
nucleolemmal/plasmolemmal anchorage and communication might be provided 
(Geiger, 1987). 
INTERMEDIATE FILAMENT PROTEINS IN LUNG CANCER 
In the early eigthies investigations on the expression of intermediate 
filaments in neoplasms (Gabbiani et al., 1981; Ramaekers et al., 1982) 
showed that when cells of a certain tissue become malignant, they retain 
their original intermediate filament expression pattern without expressing 
additional intermediate filament proteins. Therefore, carcinomas express 
cytokeratlns, mesenchymal tumors such as sarcomas and lymphomas express 
vimentin, neuronal tumors can express neurofilaments, and myosarcomas 
express desmin. Although since then a considerable number of exceptions 
have been reported, this general rule has proven to be very useful in tumor 
diagnosis. This also holds true for the expression of intermediate 
filament proteins in the different types of lung cancer. 
Early immunocytochemical investigations (Schlegel et al., 1980; 
Bejui-Thivolet et al., 1982; Gusterson et al., 1982; Nagle et al., 1983; 
Said et al., 1983a,1983b; Sappino et al., 1983; Wilson et al., 1985) 
reported on the expression of cytokeratlns in pulmonary squamous cell 
carcinomas, a highly variable expression of cytokeratlns in 
adenocarcinomas, and the absence of cytokeratlns in most small cell lung 
cancers. Later investigations, however (Saba et al., 1983; Van Muijen et 
al., 1984, Blobel et al., 1985; Gatter et al., 1985; Hammar et al., 1985), 
have shown the presence of cytokeratins in all types of lung cancer. One 
of the shortcomings of the earlier investigations, resulting in these 
conflicting reports, was the limited cross-reactivity of the (polyclonal) 
antibodies used with each of the 19 different cytokeratin polypeptides 
(Moll et al., 1982), especially since most of the early cytokeratin 
antibodies were raised against epidermal cytokeratins. In addition, the 
distribution of the cytokeratin polypeptides is not random, but depending 
on degree and type of differentiation of the tissue investigated (Moll et 
al. 1982; Quinlan et al., 1985). Therefore, when investigating 
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cytokeratin expression in tumors we now use a panel of chain-specific 
cytokeratin antibodies covering a broad spectrum of cytokeratin 
polypeptides. 
Another factor which might influence immunocytochemical results using 
intermediate filament antibodies is the type of tissue fixation used. 
Apparently, certain intermediate filament protein epitopes are sensitive to 
different fixation reagents. For instance, most cytokeratin antigens 
(epitopes) are sensitive to routine formaline fixation procedures and 
paraffin embedding, often resulting in a negative reaction in 
immunocytochemical staining assays. 
A third factor influencing the reactivity of antibodies is selective 
masking of epitopes as, for example, described for cytokeratin 18. 
Although cytokeratin 18 is present in basal cells of normal bronchial 
epithelium, one of the cytokeratin 18 antibodies developed in our 
laboratory (RGE53) does not stain these cells, while another cytokeratin 18 
antibody (RCK106) clearly shows a reaction with the same cell type (Broers 
et al., 1988). 
Ve believe that, in using a large panel of different polyclonal and 
monoclonal antibodies from different institutes on (whenever possible) 
freshly frozen, unfixed tissue material most of these problems have been 
overcome. Therefore, we are able to present a reliable portrait of the 
intermediate filament expression patterns in normal bronchial tissues and 
in bronchial carcinomas. 
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ABSTRACT 
The expression patterns of intermediate filament proteins in fetal and 
normal or non-pathological adult human lung tissues are described. In 
early stages of development (9-10 weeks and 25 weeks of gestation) only 
so-called simple cytokeratins such as cytokeratin 7 (minor amounts), 18 and 
19 are detected in bronchial epithelial cells. At later stages of 
development, the cytokeratin expression patterns become more complex. The 
number of bronchial positive for cytokeratin 7 increases, but basal cells 
in the bronchial epithelium remain negative. These latter cells show, 
however, expression of cytokeratin 1A in the third trimester of gestation. 
Developing alveolar epithelial cells express cytokeratins 7 and 18. In 
adult human bronchial epithelium cytokeratins 4, 7, 13, 14, 18 and 19 can 
be detected by chain-specific monoclonal antibodies. 
Vimentin is present in all mesenchymal tissues. In addition, fetal lung 
expresses vimentin in bronchial epithelium, however, to a less extent with 
increasing age, resulting in the expression of vimentin in only few 
scattered bronchial cells at birth. Also in adult bronchial epithelium the 
expression of vimentin is noticed in part of the basal and columnar 
epithelial cells. 
Desmin filaments, present in smooth muscle cells of the lung, appear to 
alter their protein structure with age. In early stages of development 
smooth muscle cells surrounding blood vessels are partly reactive with 
cytokeratin antibodies and with a polyclonal desrain antibody. At week 9-10 
and week 25 of gestation a monoclonal antibody to desmin, however, is not 
reactive with blood vessel smooth muscle cells but is only reactive with 
smooth muscle cells surrounding bronchi. With increasing age the 
reactivity of cytokeratin antibodies with smooth muscle cells in blood 
vessels decreases, while the reactivity with the monoclonal desmin antibody 
increases. 
INTRODUCTION 
Since intermediate filament proteins (IFPs) exhibit a highly specific 
distribution pattern within adult normal and neoplastic tissues [7, 19] 
antibodies to the different types of IFPs have been used to study the 
embryogenesis of specific cells and organs (for a review, see 127]. In 
mammals virtually all epithelial tissues, including those of the upper and 
lower respiratory tract, contain cytokeratins (CKs, [2, 18]) as their IFP 
components. The family of CKs consists of at least 19 different proteins 
[16], which are not randomly distributed among epithelial tissues. For 
instance, CKs 7, 8, 18, and 19 are highly characteristic for many simple 
epithelia. On the other hand, stratified, squamous epithelia are 
characterized by the presence of CKs 4, 10, and 13. (5, 16, 23, 30]. 
Earlier studies of Jackson et al. [9] have shown, that CK 8- and 
18-related proteins are the first IFPs to be expressed in pre-implantation 
mouse embryos. More recent studies have shown that at later stages of 
epithelial differentiation in embryonic life the synthesis of other CKs is 
initiated. Also a transient vimentin expression has been found in several 
embryonal epithelia [8, 11, 12, 13, 21, 22, 24, 31, 32, 33]. In this 
immunohistochemical study we have applied a panel of monoclonal and 
polyclonal IFP antibodies to developing lung specimens, with special 
emphasis on CK antibodies. Most of these CK antibodies are chain-specific, 
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and thus enabled us to detect individual CK polypeptides at the cellular 
level. 
The development of the lower respiratory system starts with the 
formation of the laryngotracheal groove in the ventral wall of the pharynx, 
at about 26 days of gestation. The endodermal lining of this groove gives 
rise to the epithelium and glands of the larynx, trachea, bronchi and the 
pulmonary lining epithelium [17]. First, the laryngotracheal tube 
develops, followed by the development of lung buds at about 4 weeks of 
gestation. Further lung development may be divided into four stages [3], 
including: 
1) the pseudoglandular period (5 to 17 weeks of gestation), during which 
the bronchial divisions differentiate into the air-conducting system, and 
as a result bronchi branch into many small bronchial tubes. Until week 10 
the bronchial buds are lined by unspecialized columnar epithelial cells. 
At week 10 the bronchial pseudostratified columnar epithelium starts to 
develop. At the end of this period all major elements of the lung have 
been formed except those involved with gas exchange; 
2) the canalicular period (13 to 25 weeks of gestation), during which the 
lumina of the bronchi and bronchioli become much larger and the lung tissue 
becomes highly vascular. Terminal bronchioli give rise to respiratory 
bronchioli, while at the end of this period terminal sacs start to develop; 
3) the terminal sac period (24 weeks of gestation to birth), during which 
many terminal sacs develop, initially lined with cuboidal epithelium, 
developing into type I alveolar epithelial cells, while also the type II 
alveolar cells start to develop; 
4) the alveolar period (late fetal period to about two years of age, [26]) 
during which the epithelial lining of the terminal sacs attenuates to an 
extremely thin squamous epithelial layer, and the alveolar-capillary 
(respiratory) membrane becomes sufficiently thin to allow optimum gas 
exchange. 
To study the expression of the individual CK proteins during human lung 
development, we have examined fetuses showing the above mentioned four 
stages of lung development, as well as normal adult lung tissues. 
METHODS 
LUNG TISSUES 
Lung tissue material was obtained from fetuses at week 9-10, at week 
25, a case of premature death (37 weeks of age), and from autopsy of a 
newborn (43 weeks), who died at birth. 
Normal bronchi (15 cases) and normal lung tissue (5 cases) were obtained 
after resection of lungs or lung lobes for different medical reasons. In 
cases of lung carcinomas parts of lung tissues, uninvolved in neoplastic 
processes, were resected. As previously observed by others [14, 34] most 
of these cases show some degree of abnormality such as basal cell 
hyperplasia, secretory cell hyperplasia, stratification and/or epidermoid 
metaplasia. 
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IHHUNOPEROXIDASE TECHNIQUE. 
The indirect immunoperoxidase assays were carried out on cryostat 
sections (about 5 gm, fixed in acetone for 2 min at -20oC) as described 
previously [4, 5]. Also the antibodies used in this study were described 
in these references. Their specificity is indicated in Table 1. Antibody 
LL001, specific for CK 14, will be described elsewhere [Lane et al., in 
preparation]. 
RESULTS 
The IFF expression patterns in lung tissues at different stages of 
development, as detected immunohistochemicall^y, are summarized in Table 1 
and depicted in Figures 1 and 2. 
9-10 weeks (Figs. 1A1-6, and 2A1-6) 
At this stage of lung development epithelial cells show a strong and 
homogeneous reaction pattern is seen with antibodies RCK102 (Figs. 1A1 and 
2A1) , RGE53, RCK106, and LP2K. These CK antibodies are also reactive with 
smooth muscle cells surrounding blood vessels (Fig. 2A6). No reaction 
with the CK antibodies is seen in stromal elements or developing cartilage. 
Monoclonal antibody RCK105 was found to react only weakly with few 
epithelial cells in a developing bronchiolus (Fig. 1A2), while no reaction 
is seen with other epithelial cells (Fig. 2A2), nor with smooth muscle 
cells surrounding blood vessels. Also the other CK antibodies did not 
react with lung cells at this stage (Figs. 1A3,4 and Fig. 2A3). The 
polyclonal desmin antibody pDes recognized all smooth muscle cells, while 
the monoclonal antibody RD301 reacted only with smooth muscle cells 
surrounding bronchi (Fig. 1A5), with muscle fibers surrounding epithelial 
clusters of cells (Fig. 2A5), but, surprisingly, not with most smooth 
muscle cells surrounding blood vessels. The monoclonal antibody to 
vimentin RV202 did not only react with stromal elements and cartilage, but 
also showed a clear reaction with all types of epithelial cells (Figs. 1A6 
and 2A4). Also smooth muscle cells surrounding bronchi and blood vessels 
were clearly positive with this antibody. Comparable reaction patterns 
were seen with the pVim antibody, although less epithelial cells were 
reactive. At this stage and at all following stages the neurofilament 
antibody MNF was only reactive with nerve fibers. 
25 weeks (Figs. 1B1-6 and 2B1-6) 
Again all epithelial cells express CKs, as detected by RCK102 (Fig. IBI), 
RGE53, RCK106 (Fig. 2B1), and LP2K. In addition, these antibodies reacted 
with smooth muscle cells surrounding blood vessels (Fig. 2B6). 
RCK105 now reacts with a significant part of the bronchial epithelial cells 
(Fig. 1B2). Basally located cells, which are occasionally visible in 
hematoxylin and eosin stained cryosections of the larger bronchi, did not 
react with this antibody. Also a positive reaction was seen in part of the 
epithelial cells of the respiratory bronchioli (Fig. 2B2). RCK105 did not 
react with smooth muscle cells (Fig. 2B5). No reactions were seen with 
the other CK antibodies in any of the cell types (Figs. 1B3,4 and Fig. 
2B3). 
RD301 reacted with the muscularis mucosae surrounding bronchi (Fig. 1B5) 
and did not stain smooth muscle cells surrounding blood vessels. pDes, 
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Table 1: Reactivity of intermediate filament antibodies in fetal, neonatal 
and adult human bronchial and lung tissues. 
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LP2K 9-10 + 
(CK19) 25 + + 
37 + + + -/+ 
newborn + + + -/+ 
adult ++ + + -/+ 
6B10 
(CK4) 
9-10 
25 
37 
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-/+ 
-/+ 
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Table 1 (cont.) 
Anti-
body 
(reac-
tivity) 
Age 
RD301 9-10 
(desmin) 25 
37 
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++ s strong reaction in all cells 
+ » reaction in most cells 
-/+ = reaction in part of the cells 
some c.= reaction in some scattered cells 
- = no reaction 
* = polyclonal (rabbit) antiserum 
however, did stain these blood vessel muscle cells next to the muscle cells 
surrounding bronchi. 
The vimentin antibody RV202 was reactive in part of the bronchial 
epithelial cells (Fig. 1B6), in all stromal elements, including cartilage 
and smooth muscle cells, but in general not in epithelial cells of the 
respiratory bronchioli (Fig. 2B4). pVim showed a comparable reaction 
pattern again, however, reacting with less epithelial cells than RV202. 
27 
28 
FIGURE 1 
Reaction patterns of developing human lung bronchi with antibodies to 
intermediate filament proteins in the immunoperoxidase technique. Panel A, 
9-10 weeks of gestation; panel B, 25 weeks of gestation; panel C, 37 weeks 
of gestation; panel D, newborn; and panel E, adult. 
Panel A: The broadly cross-reacting CK antibody RCK102 reacted with all 
epithelial cells (Al, хЗОО), while the CK 7 antibody RCK105 recognized only 
scattered cells (A2, x380). Other CK antibodies such as the CK 14 antibody 
LL001 (A3, x380) and the CK 13 antibody 1C7 (A4, x240) did not react with 
bronchial cells. The monoclonal desmin antibody RD301 reacted with smooth 
muscle cells surrounding bronchi (A5, x325). The vimentin antibody RV202 
reacted not only with stromal elements, but also with epithelial cells of 
the bronchus (A6, xAOO). 
Panel B: RCK102 reacted with all epithelial cells (Bl, x420), while RCK105 
reacted in a heterogeneous manner with these cells (B2, x420). LL001 (B3, 
x380) and 1C7 (B4, хЗЗО) did not react with these cells. RD301 again 
stained smooth muscle cells (B5, x380), and RV202 reacted with part of the 
epithelial cells and all stromal cells (B6, хЗОО) 
Panel C: The CK 18 antibody RCK106 reacted with basal as well as columnar 
cells (CI, x380), while RCK105 reacted with columnar epithelium cells, but 
not with basal cell (C2, x400). LL001 showed a reaction with scattered 
cells in the lower epithelial layer of the bronchus (C3, x350), while no 
reaction was seen with 1C7 (C4, x240). RD301 reacted with smooth muscle 
cells (C5, x220), and RV202 reacted with stromal cells, and with some 
bronchial epithelial cells (C6, x370). 
Panel D: The CK 18 antibody RGE53 recognized all bronchial epithelial 
cells (Dl, x240), while RCK105 reacted with epithelial cells except for the 
basal layer (D2, хЗЗО). LL001 reacted with some basal cells of the 
bronchus (D3, хЗОО), while 1C7 was negative (D4, x250). RD301 reacted with 
groups of smooth muscle cells surrounding the bronchi (D5, x200), and RV202 
reacted with stromal cells and few epithelial cells (D6, x230). 
Panel E: RCK102 recognized all epithelial cells (El, ХІ60), while RCK105 
recognized epithelial cells with the exception of the basal layer (E2, 
ХІ60). LL001, in general, reacted with basal cells only (E3, x340). The 
CK 4 antibody 6B10 reacted in a heterogeneous manner with some basal and 
some columnar epithelial cell (E4, x370). RD301 reacted with the thick 
layer of smooth muscle cells (E5, xl60), while RV202 reacted with all 
stromal cells, but sometimes also with epithelial cell (E6, x200). 
37 weeks (Figs. 1C1-6 and 2C1-6) 
At this stage basal cells are clearly discernable in the bronchi, while 
alveoli start to develop from the terminal sacs, and sero-mucous glands are 
visible. Antibodies RCK102, RGE53, and RCK106 (Figs. ICI and 2C1) reacted 
with all bronchial and alveolar cells and with most of the sero-mucous 
glands. Part of the blood vessel smooth muscle cells reacted with these 
antibodies (Fig. 2C6). 
RCK105 reacted with the bronchial epithelium, except for the basal cell 
compartment (Fig. 1C2), with all epithelial alveolar cells (Fig. 2C2), 
and with most of the sero-mucous glands. Again, no reaction vas seen in 
smooth muscle cells with this antibody. 
29 
30 
FIGURE 2 
Reaction patterns of different lung tissues with antibodies to 
intermediate filaments using the immunoperoxidase technique. Panel A, 9-10 
weeks of gestation; panel B, 25 weeks of gestation; panel C, 37 weeks of 
gestation; panel D, newborn; and panel Б, adult. 
Panel A: RCK102 recognized all epithelial cells of the bronchial tubes 
(Al, x250). RCK105 did not react with these cells (A2, x360), nor did 
LL001 (A3, x360). RV202 recognized not only all stromal cells, but also 
many epithelial cells (A4, x260). RD301 recognized smooth muscle fibers 
present in this bronchial tube tissue (A5, x300), but did not recognize 
blood vessel smooth muscle cells (not shown). RCK102 showed a clear 
reaction with developing blood vessels (A6, x360). 
Panel B: RCK106 recognized all epithelial cells of the respiratory 
bronchioli (Bl, x230), while RCK 105 recognized only few epithelial cells 
(B2, x360). The CK 4 antibody 6B10 did not react with the lung tissue (B3, 
x370), while RV202 reacted with stromal, but not with epithelial cells of 
these respiratory bronchioli (BA, x225). RCK105 did not react with blood 
vessels (B5, хЗЗО), while RGE53 clearly recognized these smooth muscle 
cells (B6, хЗЗО). 
Panel C: RCK106 (CI, x350) and RCK105 (C2, x350) reacted with all 
epithelial cells of the terminal sacs, while antibody ІС7 occasslonally 
reacted with scattered cells only (C3, x300). LL001 reacted with 
myo-epithelial cells of sero-mucous glands (CA, x320), but not with other 
epithelial cells in the terminal sacs. RD301 now started to react weakly 
with some smooth muscle cells suriounding blood vessels (C5, хЗОО), while 
RCK106 stained more blood vessel smooth muscle cells (C6, хЗОО) than RD301. 
Panel D: RGE53 (Dl, хЗЗО) and RCK105 (D2, x270) reacted with all 
epithelial cells of the early alveoli, while 6B10 reacted with isolated, 
scattered cells in these alveoli (D3, xAOO). Sero-mucous glands were 
partly positive with RCK105 (DA, x350). RD301 reacted weakly with smooth 
muscle cells in blood vessels (D5, хЗЗО), while the reactivity of RGE53 in 
blood vessels was lessened (D6, хЗОО) as compared to earlier stages. 
Panel E: RCK106 (El, x250) and RCK105 (E2, x350) reacted with all alveolar 
epithelial cells. 1C7 did not react in alveoli (E3, x250). A cluster of 
sero-mucous glands reacted with RCK105 (EA, xl60), while RD301 reacted 
strongly with part of the blood vessel muscle cells (E5, χ 200). All CK 
antibodies used (E6, xl75; RGE53), did not recognize blood vessel smooth 
muscle cells. 
The CK 14 antibody LL001, which was negative in the earlier developmental 
stages, now reacted with some basal cells in the larger bronchi (Fig. 
1C3), and with myoepithelial cells lining the sero-mucous glands (Fig. 
2CA). 
Antibodies 6B10 and 1C7 (Fig. 2C3), specific for CKs 4 and 13, 
respectively, and negative with all cells sofar, now showed a reaction with 
some scattered cells in the developing alveolar epithelium, while still no 
reaction was seen in larger bronchi (Fig.ICA). 
RD301 reacted with smooth muscle cells surrounding bronchi (Fig. 1C5), and 
now also with some smooth muscle cells surrounding blood vessels (Fig. 
2C5), while pDes reacted with all smooth muscle cells. 
The expression of vimentin was mostly confined to stromal and cartilage 
cells. Only some cells of the bronchial epithelium reacted with RV202 (Fig 
1C6), or with pVim. 
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Newborn (43 weeks, Figs. 1D1-6 and 2D1-6) 
RCK102, RGE53 (Figs. IDI and 2D1), RCK106, and LP2K reacted with all 
bronchial and alveolar epithelial cells in this case, while also most 
sero-mucous glands were positive with these antisera. The reactivity with 
blood vessel smooth muscle cells was lessened as compared to the earlier 
stages of lung development (Fig 2D6). 
RCK105 strongly reacted with all bronchial epithelial cells, again with the 
exception of the basal cells of larger bronchi (Fig. 1D2), while all 
alveolar epithelial cells (Fig. 2D2) and most sero-mucous glands were also 
positive (Fig 2D4). LL001 reacted with part of the basal cells of bronchi 
(Fig. 1D3), and also stained myoepithelial cells in sero-mucous glands. 
6B10 and 1C7, which did not react with bronchial epithelial cells (Fig 
IDA), did react with scattered cells in lung alveoli (fig. 2D3). These 
cells possibly belong to the group of pneumocytes (type I or type II), but 
the exact nature of these cells remains to be examined. 
RD301 recognized smooth muscle cells surrounding bronchi (Fig. 1D5) and 
some smooth muscle cells in blood vessels (Fig. 2D5), while pDes 
recognized all smooth muscle cells. 
RV202 reacted with few scattered cells in bronchi (Fig. 1D6) and with all 
stromal elements and cartilage structures. The number of bronchial cells 
reacting with RV202 was clearly reduced as compared to earlier stages. 
pVim reacted strongly with mesenchymal tissues, but only very weakly with 
few epithelial cells of the bronchial epithelium. 
Normal adult bronchial tissues (Figs. 1E1-6 and 2E1-6). 
Ä considerable heterogeneity was detected in the expression of the 
different CKs in normal adult bronchial tissues. Antibody RCK102 (Fig. 
1E1) and LP2K reacted with all bronchial and alveolar epithelial cells. 
RCK106 (Fig. 2E1) reacted with all epithelial cells, except for part of 
the basal cells in bronchial epithelium, while RGE53 did not react with any 
of the basal cells in this type of epithelium. RCK102, RCK106, RGE53 and 
LP2K reacted with most sero-mucous glands, while no reaction with CK 
antibodies was noticed in smooth muscle cells of blood vessels (Fig. 2E6), 
as seen in the fetuses. RCK105 reacted with bronchial epithelial cells, 
except for the basal layer (Fig. 1E2), with epithelial alveolar cells 
(Fig. 2E2), and with some of the sero-mucous glands (Fig. 2E4). Antibody 
LL001 showed a considerable heterogeneity in its reaction with bronchial 
epithelium, varying from a negative reaction to a positive staining 
reaction with all bronchial epithelium cells. In general, however, basal 
cells of bronchial epithelium were preferently stained (Fig. 1E3), while 
also myoepithelial cells of the sero-mucous glands, but not alveolar cells 
were positive. Antibodies 6B10 and 1C7 reacted in a highly variable 
fashion in bronchial epithelium, ranging from a strong reaction in all 
bronchial epithelial cells, as seen in some cases with 6B10, to a 
completely negative reaction as seen in some cases with 1C7. In general, a 
heterogeneous reaction pattern was observed, as illustrated in Fig. 1E4, 
with more cells reactive for 6B10 than for 1C7. Note from Fig. 1E4 that 
also basal cells may be positive for 6B10. In alveolar epithelial cells as 
well as in sero-mucous glands no reaction was seen with 6B10 or with 1C7 
(Fig. 2E3). The desmin antibody RD301 reacted with all smooth muscle 
cells surrounding bronchi (Fig. 1E5) and with a considerable part of the 
smooth muscle cells surrounding blood vessels (Fig. 2E5), while pDes 
recognized all smooth muscle cells. The vimentin antibodies RV202 and pVim 
in general did not react with epithelial cells. However, in some cases a 
clear reaction was seen with RV202 in basal cells and in some columnar 
epithelial cells of bronchi (Fig. 1E6). 
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DISCUSSION 
The development of chain-specific monoclonal antibodies to CKs and 
antibodies to other intermediate filament proteins has now provided a 
sensitive tool in the examination of differentiating cells in fetal and 
adult human lung tissues. Previous examinations on the expression of CKs 
in lung tissues were, in general, performed with broadly cross-reacting 
antibodies, which could differentiate between epithelial and non-epithelial 
cells (1, 15, 25, ЗА]. More recently polyclonal antibodies with a more 
narrow specificity and monoclonal antibodies were used to distinguish 
between different types of epithelial cells [2, 5, 18, 30]. The use of gel 
electrophoretic techniques has enabled the analysis of different CK 
polypeptides in cytoskeleton extracts of bronchial and lung epithelium [1, 
2, IB]. Using this technique, however, detection at the single cell level 
is not possible. In a recent study we have reported on the use of 
monoclonal antibodies to different CK polypeptides in lung carcinomas [5]. 
From this study it has become clear that cells with a similar histologic 
appearance can express different CK polypeptides. This allows detection of 
subpopulations of cells which are histologically not distinguishable. 
From our results it is clear that in all stages of human lung development a 
uniform staining reaction in all epithelial cells is seen with the CK 19 
antibody, as well with a broadly cross-reacting CK antibody. CK 7 is 
expressed rather weakly and in only few cells at early stage, but develops 
towards a strong staining reaction in all epithelial cells (except the 
basal cells of the larger bronchi) at later stages. 
CK IB is found in all epithelial cells of the developing lung until birth, 
including the basal cells of the developing bronchus. In the adult 
bronchi, however, these basal cells are negative for RGE53 (Compare also 
[2]) and partly negative for RCK106. From these data we conclude that the 
structure of the CK IB epitope recognized by RGE53 changes upon lung 
maturation after birth. Expression of CK 4 and 13 was not detected in the 
fetal lung tissues, with the exception of some scattered cells in early 
alveolar tissues. In adult bronchi CK A is found to be expressed 
heterogeneously in basal and columnar cells, while in some alveoli also CK 
A positive cells are found. CK 13 reacted with only few columnar 
epithelial cells. 
The expression of CK IA occurs in the third trimester and is mainly 
confined to (part of) the basal cells of the bronchi(oli). This CK 
polypeptide, which is absent until at least week 25 of gestation, becomes 
more and more prominently expressed in basal cells of the bronchial 
epithelium upon maturation. However, when examining the fetal lung tissues 
more closely it becomes obvious that basal cells occur in the developing 
bronchus long before these cells become CK IA positive. In fact, the fetal 
and newborn lung tissues that we have examined contained only few CK 14 
positive cells, while in the adult human lung an extensive staining 
reaction is observed in the basal cells. In some cases of adult bronchus, 
areas were detected in which this antigen was also expressed in columnar 
epithelial cells, suggesting the presence of hyperplasia originating from 
basal cells of the bronchial epithelium. This observation is paralleled by 
our finding that most squamous cell carcinomas of the lung also contained 
CK IA (unpublished data). 
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Our findings that only basal cells at later stages of development of 
the bronchus express CK 14 are in line with the hypothesis of McDowell et 
al. [14] that not the basal bronchial epithelial cells, but most probably 
undifferentiated secretory columnar cells are the progenitor cells of all 
other bronchial epithelial cells. Also our observations that most columnar 
cells do not contain CK 14, and that basal cells lose CK 7 and CK 18 upon 
maturation argues against the theory of basal cells as bronchial stem 
cells. 
Vhen comparing our immunohistochemical data with the gel 
electrophoretic patterns, described by Blobel et al. [2], it is clear that 
CK polypeptides occurring In low concentrations or in only a few bronchial 
epithelial cells, i.e. CKs 4, 13, and 14, may be missed in such integral 
biochemical procedures. We do feel, however, that the presence of CKs 4 
and 13, which are characteristic of non-keratinizing squamous epithelia 
[23, 30], in areas of histologically normal bronchus points to some extent 
to an onset of abnormal differentiation. The same may hold true for 
bronchial regions in which CK 14 is detected in columnar epithelial cells. 
Future studies will have to reveal whether or not these CK antibodies may 
be used to detect 'preneoplastic' lesions in the bronchus, such as 
epidermoid metaplasia [14] at an early stage. 
Examination of changes in IFP expression patterns in fetal tissues may 
have relevance regarding the histogenesis of pathologic lesions found in 
the adult epithelium. In the developing (mouse) embryo the first IFPs to 
appear are CK 8- and 18-related proteins [9, 13, 20], present in ectodermal 
and endodermal embryonal tissues. From our results it is clear that the 
expression of so-called simple CKs, i. e. CK 7 (minor amounts), 18 and 19 
occurs in developing fetal bronchial tissues. Comparable CK expression 
patterns are observed in small cell lung cancer and adenocarcinomas of the 
lung [2, 5], while most squamous cell carcinomas express a more complex CK 
pattern. The finding that CK 7 is absent in many small cell lung cancers 
[5], and also almost completely absent in the early stage (9-10 weeks) of 
fetal lung development is in accord with earlier findings on the expression 
of neuroendocrine-related antigens in both small cell lung cancer and early 
fetal bronchial cells [6], suggesting a comparable degree of 
differentiation of both cell types 
In some developing epithelia such as parietal endodermal cells a 
coexpression of CK and vimentin has been seen [12], while also in human 
amnion epithelial cells [24] and developing human embryonic kidney tubules 
[8] this coexpression was observed. Our investigations show that in the 
early stages of development next to the presence of CKs a clear expression 
of vimentin can be noticed in the bronchial epithelium. With increasing 
age of the fetus a decrease both in intensity and in number of vimentin 
positive cells is seen. At birth only few bronchial epithelial cells 
express vimentin. However, in some adult bronchial epithelia again the 
coexpression of vimentin was seen. Coexpression of cytokeratins and 
vimentin is quite common in carcinomas of the lung [10, 29]. Again, it 
remains to be examined whether this phenomenon points to a beginning 
transformation in the bronchus. 
Van Muijen et al. [31] have already described coexpression of CKs, 
vimentin, and desmin in blood vessels of fetal lung. These data could be 
confirmed in this study. In addition, however, using two different 
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antibodies to desmin, differential staining patterns were seen. While the 
polyclonal antibody to desmin reacted with all smooth muscle cells, the 
monoclonal antibody RD301 reacted in early stages only with smooth muscle 
cells surrounding bronchi, and not with blood vessel smooth muscle cells. 
At these stages, these smooth muscle cells were positive with several CK 
antibodies. The reactivity of blood vessel smooth muscle cells with CK 
antibodies decreased with age, while the reactivity with RD301 increased. 
Recent data by van Muijen et al. 131] and Turley et al. [28] strongly 
suggest that this phenomenon has to be explained by true coexpression of 
these IFP, rather than by sharing of epitopes. 
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Small Cell Lung Cancers Contain Intermediate Filaments of 
the Cytokeratin Type 
7Ό the Editor: In view of the well-established neuroen­
docrine nature of the pulmonary carcinoids and small 
cell carcinomas (4) it was of interest to note recent 
reports describing the presence of neurofilaments in the 
cytoskeleton of these cells (2,6). Another paper, however, 
has appeared challenging these observations and claim­
ing that the pulmonary neuroendocrine tumors contain 
cytokeratin rather than neurofilament cytoskeletal pro­
teins (3). Stimulated by these apparently contradictory 
findings we have examined eight small cell carcinomas 
of the lung and four carcinoids. Our data obtained by 
using a polyclonal antiserum raised against skin keratins 
and two monoclonal antibodies reacting with 
(cyto)keratins, as well as three monoclonal antibodies to 
the different neurofilament proteins, indicate that these 
tumors indeed contain cytokeratin proteins. No staining 
was seen with the antibodies to neurofilaments. 
In brief, cryostat sections of freshly resected tumors 
were examined by the indirect immunoperoxidase tech­
nique. The relevant clinical and pathologic data of the 
small cell lung tumors and carcinoids used in this study 
are summarized in Table 1. Samples of human brain, 
peripheral nerves, and neural tumors were also used to 
test the specificity of the neurofilament antibodies. The 
following antibodies were used (1, 5, 7, 8): (a) an affinity-
purified antiserum directed against human skin keratins 
(pK), which reacts with virtually all epithelial tissues but 
not with nonepithclial tissues (8); (b) the monoclonal 
antibody R(;E 53, directed against cytokeratin 18, which 
specifically recognizes columnar epithelial cells from 
digestive, respiratory, and urogenital tracts, endocrine 
and exocrine tissues, and mesothelial cells (7); (c) the 
monoclonal antibody RKSE 60; directed against human 
skin keratins and specific for keratinizing squamous cells 
(8); (d) the monoclonal antibodies BF10 and RT97 di­
rected against different neurofilament polypeptides. In 
immunoblotting assays BF10 was shown to react only 
with the 155-kilodalton (kd) neurofilament protein, 
whereas RT97 reacts mainly with the 210-kd neurofila­
ment protein (1); (e) a monoclonal antibody to neuro­
filaments (MNF) purchased from Euro-Diagnostics B.V., 
Apeldoorn, The Netherlands. This antibody corresponds 
to the monoclonal antibody 2F11 described by Klück fi 
al. (!>). In immunoblotting assays we could show that this 
antibody reacts strongly with the 210-kd neurofilament 
polypeptide and to a somewhat lesser extent with the 70-
kd neurofilament polypeptide. 
Using frozen sections and paraffin sections from hu-
man brain, peripheral nerves, and some neural tumors, 
we found a positive reaction of the monoclonal antibodies 
to neurofilament proteins (BF10, RT 97, and MNF) in 
only the neural tissue. 
In the normal lung the affinity-purified polyclonal 
antiserum to skin keratins shows a positive reaction with 
bronchial, broncholar, and alveolar epithelium. A rela-
tively strong reaction is observed in basal cells of the 
bronchial epithelium. No reaction was seen in nonepi-
thelial tissues. This antibody did strongly stain squamous 
cell carcinomas and adenocarcinomas of the lung. The 
antibody to cytokeratin 18 (RGE 53) strongly stained all 
epithelial components except the basal cells of the res-
piratory epithelium. Nearly all small cell carcinomas as 
well as the carcinoids were positively stained with the 
polyclonal keratin antiserum (Fig. la). The monoclonal 
antibody to cytokeratin 18 (RGE 53) gave a strong diffuse 
and homogeneous staining pattern in all of the examined 
small cell lung carcinomas and in the carcinoids (Fig. 
lb). The monoclonal antibody specific for keratinizing 
epithelium (RKSE 60) did not react with the small cell 
lung carcinomas or carcinoids. None of the neurofila-
ment monoclonal antibodies gave a positive reaction in 
the small cell lung carcinomas or in the carcinoids (Fig. 
1c). They did, however, strongly stain peripheral nerves 
present in the lung tumor sections (Fig. Id). Also, some 
isolated scattered cells in normal and tumor tissue were 
found to be positive with all three neurofilament anti-
bodies. 
In summary, our findings contradict some published 
papers (2, 6) but are in agreement with data reported by 
Blobel et al. (3). It is not clear whether these differences 
are due to technical problems related to the specificity 
of antibodies and fixation procedures or whether we 
indeed have used or selected neuroendocrine tumors that 
express cytokeratins and not neurofilament proteins. 
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Department of Pathology 
University of Nijmegen 
Nijmegen and 
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TABLE 1. CLINICOPATHOLOOIC AND IMMUNOHISTOCHEMICAL DATA OF SMALL CELL LUNG CARCINOMAS AND CARCINOIDS OP THE 
LUNG· 
Reactivity pattern with intermediate filament antibodie· 
Sex Age Diagnosia 
WHO 1982 
Subtype 
classification 
Clinical 
stage 
Pathological 
stage pK RGB 53 RKSE 60 RT 97 BF10 MNF 
2 
Я 
1 
s 
6 
7 
8 
9 
10 
11 
12 
F 
M 
M 
M 
M 
M 
F 
M 
M 
F 
M 
F 
y 
70 
68 
58 
46 
69 
68 
59 
61 
60 
58 
71 
62 
SCLC 
SCLC 
SCLC 
SCLC 
SCLC 
SCLC 
SCLC 
SCLC 
carcinoid 
carcinoid 
carcinoid 
carcinoid 
Intermediate 
Intermediate 
Intermediate 
Intermediate 
Intermediate 
Intermediate 
Intermediate 
Intermediate 
T2NOM0 
TINOMO 
T3N0M0 
T2N0M0 
TINOMO 
TINOMO 
TINOMO 
T2N0M0 
TINOMO 
TINOMO 
TINOMO 
TINOMO 
T2N0M0 
T2N1M0 
T3N2M0 
T2N1M0 
T1N2M0 
T1N2M0 
TINOMO 
T3N0M0 
TINOMO 
TINOMO 
TINOMO 
TINOMO 
+ 
+ 
++ 
++ 
++ 
+/-
+ + 
+ + 
++ 
+++ 
+++ 
+++ 
+ (-
++ 
+++ 
+++ 
+++ 
+++ 
" Abbreviations: SCLC, small cell lung carcinoma; WHO, World Health Organization; pK, polyclonal rabbit antiserum to human skin keratins; 
TINOMO, «3 cm and no invasion; T2N0M0, >3 cm and extension to hilar region; T3N0M0, gross extension, effusion, and atalectasis. 
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FIG. 1. Photomicrographs of cryo­
stat sections of small cell lung carcino­
mas stained by the immunoperoxidaee 
technique using the polyclonal keratin 
antiserum in), the monoclonal antibody 
to cytokeratin 18 ih), and monoclonal 
antibody to neurofilaments (BF10; e and 
d). Note positive reaction of BF10 with 
peripheral nerves but not with the tu­
mor. о and 6, X200; c. x!00; d, ХІ50 
»«ι 
*kt 
-
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Antibodies to Epithelial, Neuronal, and Neuroendocrine Antigens1 
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ABSTRACT 
Lung caneen were Investigated for their heterogeneity as expressed 
by their immunoreaclivity For cylolteratins and neurofilament proteins, 
as well as for the neuroendocrine difTerenliallon antigen MOC-1. Using 
broadly cross-reacting antibodies, cytokeratins were detected In nearly 
all cases of lung carcinomas Keratinizalion could be detected only In 
cases of moderately to well-difTerenlialed squamous cell carcinoma (SQC) 
using a monoclonal antibody to cytokeratln 10, while a monoclonal 
antibody reactive with cytokeratln IS, and specific for glandular epithelia, 
reacted with adenocarcinomas, small cell lung carcinomas (SCLC), and 
lung carcinoids. In SQC this antibody could detect non-squamous cell 
dirTerentiation, showing increasing numbers of positive cells with decrease 
of histológica])) detectable SQCdifTerentiation. Cells positive for neuro-
filaments were demonstrated In some of the poorly dilTerentlated SQCs 
and in some of the cases of SCLC, possibly representing the variant type 
of SCLC. Also in some of the lung carcinoids neurofilament proteins 
were present, colocallzing with cytokeratins. MOC-1 was present in all 
SCIX~ and lung carcinoids. This antibody could also detect neuroendo-
crine difTerentiation in all combined small cell carcinomas, in one poorly 
difTerentiated adenocarcinoma, and in about 30% of the poorly difTeren-
liated SQCs. Therefore, lung cancer heterogeneity can be delected using 
a panel of well-defined antibodies to Intermediate filaments in combina-
tion with the MOC-1 an! i bod). The use of these antibodies in diagnosis 
can have prognostic significance and can lead to a more selective thera-
peutic approach. 
INTRODUCTION 
Human lung cancer is the main cause of cancer death in 
western countries and its occurrence is especially rapidly grow-
ing among women (I). DifTerenl subtypes of lung cancer can be 
classified according to their histological appearance. The four 
major subtypes are SCLC, 1 large cell carcinoma, SQC, and 
adenocarcinoma (2). The three latter subtypes are often referred 
to as пол-SCLC. Individual lung tumors may show a profound 
heterogeneous composition. For instance, according to the 
work of Hess et ai. (3) in cytological specimens about 5 0 % of 
all lung tumors can be classified as admixtures of epidermoid 
and adenocarcinoma tous subtypes, while also at the electron 
microscopic level up to 5 0 % of lung tumors classilied as S Q C 
on the basis of routine histology appear to contain character­
istics of ade η oca rei π о m a tous differentiation (4). Another ad­
mixture of different tumor subtypes can be found in combined 
small cell carcinoma (5), an entity of lung cancer in which 
S C L C and non-SCLC differentiation are found simullaneously. 
Also in tumors which are histologically indistinguishable from 
non-SCLC, (neuroendocrine features, such as the production 
Received 7/14/86, revised 11/14/86, 3/4/87. accepted 3/10/87 
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' The abbreviations used are SCLC, small cell lung cancer, SQC, squamous 
cell carcinoma, PBS, 0 I м phosphate buffered saline, pll 7 4; FITC, fluorescein 
isoihiocyanate, PAP, peroxidase anti peroxidase; ABC, avidm biotm complex 
of peptide hormones or the presence of marker enzymes, can 
be detected (6, 7). Because of differences in treatment and 
prognosis, difTerentiation between S C L C and non-SCLC is of 
utmost clinical importance (8). SCLC express neuroendocrine 
features, among which is the production of neurosecretory 
granules delectable in the electron microscope (9). Also the 
production of neurotransmitters, neuropeptides, amine precur­
sor uptake and decarboxylalion-related enzymes, and cell sur­
face markers such as those detected by the monoclonal antibody 
specific for neural and neuroendocrine cells MOC-1 (10) indi­
cate this type of differentiation. Another indicator of the neu­
roendocrine nature of tumor cells is the coexpression of both 
cytokeratins and neurofilament proteins, intermediate filament 
proteins generally specific for epithelial and neuronal cells, 
respectively (11-16) . 
S C L C can be subdivided into two different tumor types, 
namely the classic and the variant type of SCLC (5). The variant 
type of SCLC, occurring in about 6 - 1 5 % of all S C L C at first 
diagnosis ( 17, 18), consists of a mixture of small cell and large 
cell components and occurs in up to 3 0 % of all S C L C after 
chemotherapy and/or radiotherapy (19). Within S C L C cell 
lines the classic and variant subtypes can be distinguished from 
each other on the basis of the presence of cytokeratins and the 
absence of neurofilaments in the classic subtype and the absence 
of cytokeratins in the variant cell lines, which may contain 
neurofilaments (20, 21). Also coexpression of cytokeratins and 
neurofilaments in some SCLC cell lines has been suggested (22, 
23). 
In order to investigate the degree of heterogeneity in lung 
tumors and to delect the two different subtypes of SCLC we 
have applied immunocytochemical techniques in a large series 
of lung tumor specimens. We have tested for the presence of 
di Herent subtypes of cytokeratins, the presence of neurofila­
ments, and the occurrence of the MOC-1 antigen (10). Our 
results are discussed in the light of lung cancer histogenesis and 
differenliation, and their significance for refinement of clini-
copathological diagnosis is addressed. 
MATERIALS A N D M E T H O D S 
Normal Lung. Snap frozen specimens from normal human lung tissue 
from two di (Teren t patients were stored in liquid nitrogen and 4-7 μ m 
frozen sections were used in the immunoperoxidase technique The 
frozen sections were fixed in acetone (-20*C, 5 min). Normal tissue 
material was resected with tumor material 
Lung Tumors. Fresh surgical specimens of 218 cases of lung cancer 
were snap frozen and stored in liquid nitrogen. Next paraffin sections 
of 76 routinely processed lung cancers from the Pathology Departments 
in Nijmegen and Nieuwegein, partly overlapping with (he frozen section 
material, were used. In addition, 93 cases of paraffin-embedded lung 
tumors were obtained from Dr. J, Wilde, Zentralklinik fur Herz- und 
Lungenkrankheilen, Bad Berka, G.D.R Autopsy material (61 speci­
mens m total) from primary tumors and metastases of up to 12 different 
body sites from 6 patients with a histological diagnosis of SCLC were 
investigated for the presence of cytokeratins and neurofilaments. 
All lung tumors were classified on the basis of routine histological 
A7 
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hcmaioxyltn-eosin staining according lo the latest WHO classifkalion 
(2). 
Antibodies Ihed in 1 his Study. The antibodies used in this study are 
summarized in Table I and have been described extensively before (10, 
14. 20, 21, 24-32) Antibodies pKcr, RCKI02, RÜE53, RKSE60, 
MNF, and MOC-I arc available from Euro Diagnostics B. V. (Apel-
doorn. The Netherlands), CAM5 2 »as from Beclon and Dickinson 
(Frcmbodcgcm, Belgium), and pNFI60 was a generous gift from Dr. 
Υ. N alt a/ato (Gunma, Japan) 
Immunofluorescence and Immunoperoxlda« lechnlque for Frozen 
Scellons. I he indirect immunofluorescence technique and immunoper-
oxidase technique for fresh frozen tissue sections, fixed in acetone 
(-20*C, 5 mm), ha\c been described extensively before (21). Dilutions 
of the primary antibodies were made in PBS (see Table I). 
As second antibodies in the indirect immunofluorescence technique 
either FlTC-conjugaled goat anli-rabbit IgG (1 25; Nordic, Tilburg, 
Ihe Netherlands) or FITC-conjugated rabbit anti mouse IgG (1:25; 
Nordic) »ere used. In control experiments PBS was used instead of the 
primary antibody. 
In (he immunopcroxidase technique swine anti-rabbit immunoglob­
ulin conjugated to peroxidase (DAKOpatts, G lost nip, Denmark) di­
luted I 25 in PBS containing 10% normal goat serum or rabbit anti-
mouse immunoglobulin conjugated to peroxidase (DAKOpatts) diluted 
1 25 in PBS with 5% human AB serum were used in the second step. 
In order to detect coexpression of different types of intermediate 
filament proteins we have used the double immunofluorescence tech­
nique as described before (33) using the mouse monoclonal cytokeratm 
antibody RGE53 or RCKI02 in combination with the rabbit neurofil­
ament antibody pNF160. As second antibodies a mixture of FITC-
conjiigatcd goat anti rabbit IgG (diluted 1 25; Nordic) and Texas Red-
conjugated sheep anti mouse immunoglobulin (diluted 1:50; New Eng­
land Nuclear, Boston, ΜΛ) was used 
ParafTln-einbedded Specimen« Cytokcralin antibodies pKer, RCK 
102. and CAM5 2 and the neurofilament antibodies MNF and pNFl 60 
arc the only antibodies of those summarized in Table 1 that can be 
applied successfully to formalin-fixed and parafïïn-embedded material 
using the PAP method (34) or the avidin biolin labeling technique (35) 
PAP Technique (34) Paraffin-embedded tumor material was cut into 
6 jim-lhick sections and fixed onto glass slides using Ortho tissue 
adhesive (Ortho Diagnostic, Raman, NJ). After dcparafïinmng in 
xylene and a descending alcohol series, sections were incubated for 30 
mm in 100% methanol containing 2% hydrogen peroxide 
Sections used for the detection ofcytokcratins were prctreatcd with 
0 1% Prnnase (Sigma Chemical Co., St. bou is. MO) in 0.05 м Tm-
ΝηΠ buffer, pi I 7.6, for 15 mm at 37"C Pronase activity was termi­
nated by uashing in I ns-Naf I at 4"C for 30 min Τ hen, after a washing 
with PBS ihe sections were premcuhated for 30 mm with 10% normal 
swine serum in PBS and incubated overnight with the primary anti-
scrum at 4'C Antibody dilutions were made in PBS containing 10% 
normal swine serum (see Table 1). 
Alter »ashing in PRS. set lions which were incubated with a mono­
clonal aniibody in the first step were incubated with rabbit anti mouse 
immunoglobulin (DAKOpatts) diluted I 200 in PBS containing 10% 
normal swine serum for W min After another washing step in PBS all 
sections were incubated with swine anti-rabbit immunoglobulin 
(DAKOpatts) diluted 1:30 in PBS with 10% normal swine serum for 
30 min. washed again, and incubated with the rabbit PAP complex 
(DAKOpalts) diluted 1:100 in PBS with 10% normal swine serum for 
30 min. Peroxidase activity was detected for 5 min using 500 mg/hter 
3,3'-diaminobenzidine dissolved in 0 05 N Tris-NaCI containing 0 65% 
imidazole (Merck, Darmstadt, West Germany), and 0.015% hydrogen 
peroxide as a substrate. Cells were counterstained for 30 s with Harris* 
hematoxylin (Merck) and after dehydration were embedded with Per-
mounl (Fisher Scientific Co., Springfield, NJ). 
ABC Technique (35). Labeling with the ABC technique was per­
formed using the Vectastam ABC kit (Vector Laboratories, Inc., Bur-
Imgame, CA) After depara (Tin i zing and preincubation with 10% nor­
mal goat serum or 10% normal horse serum for 60 min, primary 
antibodies were applied overnight at 4'C using the same dilutions as 
for the PAP staining method. After a washing with PBS followed by a 
preincubation step with PBS containing 10% normal goat serum or 
10% normal horse serum for 15 min the following conjugates were 
applied: btotinylated goat anti-rabbit IgG diluted 1:250 in PBS contain­
ing 10% normal goat serum for 30 min; or biolinylated horse anti-
mouse IgG diluted 1:200 in PBS containing 10% normal horse serum 
for 30 min. After a second washing and preincubation step avidin-
biotinylated peroxidase complex in PBS containing 10% normal horse 
serum or 10% normal goat scrum was added for 30 mm at an avi-
din-biotinylated horseradish peroxidase-PBS ratio of 1 1: 100. Detection 
of peroxidase activity was performed as described for the PAP tech­
nique. 
R E S U L T S 
Normal Lung Tissue 
The reactivity patients of Ihe antibodies described above in 
normal lung tissue are summarized in Table 2. Antibodies ρ К er, 
RCK 102, and CAM5.2 react with all epithelial elements but 
not with nonepithelial components. RGE53 reacts with ihe 
columnar epithelial cells but not with basal cells of the bronchial 
lining. Also a positive staining reaction can be observed with 
this antibody in seromucous glands of the bronchi and in type 
I and type II pneumocyles within the alveoli. RKSE60 does not 
react with any of the epithelial cells of Ihe normal lung. M N F 
and p N F I 6 0 react only with nerve fibers. The MOC-I aniibody 
reacts with nerve fibers and with bronchial cells of the dispersed 
neuroendocrine system, the so-called Kulchitsky cells (10). 
Τ hese Kulchitsky cells are also positive with the cytokeratin 18 
antibody RGES3 (36). 
Squamous Cell Carcinomas 
All S Q C s show a diffuse reaction pattern (meaning a reaction 
in virtually all tumor cells) with the broadly cross-reacting 
cytokeratin antibodies pKer (Fig. la), RCK 102, and CAM5.2 
in both frozen and paraffin sections (Tables 3 and 4) In well 
differentiated S Q C a focal staining reaction (a reaction in part 
of the tumor cells) is seen with the monoclonal antibody 
RGE53, which is reactive only in frozen sections. The percent­
age of cells positive for RGE53 varied from zero (in two cases) 
Table 1 Spetifiaty ofannbodtes used in this study 
Antibody 
pKer 
R ( K i n 2 
С ΛΜ< 2 
R(.KS1 
RKSr«0 
M N f 
p M IM) 
мое I 
ImmunoRlobulm Mib-
cla« (sprci?<) 
Го1>( lunal (rabbit) 
lg<;i (mou«) 
IgG2a (moust) 
ІЯ(,І (mou«) |R(*I (mouse) 
leGI (mou») 
Pol>clonal (rabbit) 
IgOl (mouse) 
Antigen recognized 
Several C)tokeralins 
Cytokeralins 5 and 8 
Several Qlokerallns 
Cytokeratin 18 
Cytokeratin 10 
NeurofilamenM, M. 68.000 
and 200.000 
Neurolìlamenls. Ai, 160.000 
Cell surface 
Tissue specificity 
Most epithelial tissues 
Nearly all epithelial tissues 
Nearly all epithelial tissues 
Glandular epithelia, not with squamous epithelia 
Keratinizing epithelial cells 
Nerve fibere and neuronal tissues 
Neuronal and neuroendocrine tnsues 
Reactivity in I 
ІЮІЦ 
Froren (dila 
lion) 
+ (1 10) 
+ (15) 
+ (undiluted) 
+ (undiluted) 
-f (undiluted) 
+ (15) 
+ (1600) 
+ (15) 
issue sec-
ParafTln 
(dilution) 
+ (140) 
+ (1 10) 
+ (15) 
_ + (1:10) 
+ (• 2000) 
-
Ref 
24 
21 
25 
26 
27-29 
14. 20. 
M . ) l 
21.32 
10 
N E U R O E N D O C R I N E C O M P O N E N T S IN L U N G CANCER 
to about one-half of the tumor cells. The staining reaction was 
mainl> locali/cd in the basal cells of the tumor nests (Fig. \h). 
The overall percentage of tumor cells in well-differentiated 
SQCs reactive with RGE53 is low, however. In most cases of 
ТіЫс 2 Reacltvit) pattern of different antibodies to cytokeratins, neurofilaments, 
and surface protein m frozen sections of normal lung tissues 
Tissue t>pe 
pKcr. M N F 
RCK102 and 
a n d C A M 5 . 2 RGE53 RKSE60 pNFIÓO MOC I 
Bronchi and broiK'hiúles 
( olumnar cuboidal 
cpilhelmm 
Basal cells 
kuk liiiskv cells 
Cartilage 
Mucous glands 
Abeoli 
Pneumocyles I and II 
Macrophages 
All stromal elements 
Nerve fibers 
' Data from report of De Leij el al. (36). 
I ig I Peroxidase anti peroxidase staining 
on a paraffin section (a) and immunopcroxi-
dasc (ft f) and immunofluorescence (jf. A) 
staining pattern« m fro7en sections of SQCs 
a, tvlokeralms detected in рагаГПп sections 
with the polyclonal c>iokeralm antibody pKer. 
χ 275 ft. focal staining reaction of a small part 
of the tumor celts with the monoclonal anti 
body to cytokeratin 18. R G F S 3 . in a well 
difTercnhatcd SQC χ 290 с. RKSE60 stains 
only keratmmng cells within these well difTer-
eniiatcd RQC. x 170 In poorly differentiated 
SQC (marly ) all tumor cells react with RGE5.1 
id. x 220). while in sume of these poorly 
difTcrenti.ited lumnrs arras reacting with the 
M ( K I antibody (f. χ 175) or with the neu 
rofilamcnt antibody MNI (f. x 275) can be 
observed g. A, double label immunofluores 
conce leilmiqncin frozen sections demonstrat 
ine cocxprcssion of o t o k c r a h n s (j(. x 275) 
and noomlilaments (A. X 275) in some tumor 
tells of poorl] differentiated S ( X , while many 
tumor (ells contain only cytokeratins and no 
neurofìlamenls 
well-differentiated SQCs tested in frozen sections (13 of 15 
(Table 3)] keratinizing areas can be demonstrated using the 
monoclonal antibody RKSE60 [Fig. Ic], while no reaction was 
found with MOC-1 or with neurofilament antibodies. The 
moderately weII-differentialed SQC contained keratinizing 
areas In about one-half of the cases of frozen sections as detected 
by RKSE60 [44 of 85 (Table 3)]. However, in frozen sections 
also many tumors [23 of 85] react diffusely with RGE53 [Table 
3], while the presence of the MOC-1 antigen [!3 of 77 (Table 
3)) and neurofilaments could be demonstrated [5 of 77 (Table 
3)] also, albeit in a lower number of cases as compared to poorly 
differentiated SQCs (17% versus 28 % for MOC-1 and 6% versus 
13% for neurofilaments; see below). 
In contrast to the well-differentiated SQCs, in a great number 
of histologically poorly differentiated SQCs tested in frozen 
sections a diffuse staining reaction with RGE53 can be observed 
[14 of 27 (Table 3; Fig. lrf)|, while in only a minor number of 
these latter tumors [8 of 28 (Table 3)| keratinizing areas or 
single keratinizing cells could be detected with RKSE60. Also 
the presence of the MOC-1 antigen was demonstrated in 7 of 
25 cases of frozen sections of these poorly differentiated SQCs 
t i « è ^ 
' '^ ^ w^Nx 
"
:
· ^ • ' І ^ І С ^ 
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Tabic 3 Exprtmon ofcyiokeratitu wumfìlamtnts and the MOC І 
IN LUNG CANCER 
antigen in freien sections of Human lung tumon 
pKtr 
F + · 
D + 
RCKlOl 
F+ 
D + 
CAMS 2 
F+ 
I>+ 
RGES3 
F+ 
D + 
RKSEM 
F+ 
D + 
M O C I 
F+ 
D + 
M N F 
F + 
D + 
pNFItO 
D + 
Sq« 
Well 
0/15 
15/15 
0/1 
l/l 
2/2 
0/2 
13/15 
0/15 
13/15 
0/15 
0/10 
0/10 
0/12 
0/12 
0/4 
0/4 
ïamous cell carcinoma 
Moderately well 
difTereiiiiated 
5/«5 
80/85 
0/25 
25/25 
0/2 
2/2 
57/«5 
23/«5 
44/S5 
0/85 
9/77 
4/77 
5/77 
0/77 
0/20 
0/20 
Poorly 
dilTeranlialal 
2/28 
26/28 
0/14 
14/14 
11/27 
14/27 
8/2« 
0/28 
7/25 
0/25 
3/23 
0/23 
2/6 
0/6 
2/8 
6/« 
0/5 
5/5 
0/1 
l / l 
2/8 
4/8 
4/8 
0/8 
1/6 
0/6 
0/7 
0/7 
Adeno-
carcinoma 
6/43 
37/43 
0/29 
29/2» 
0/4 
4/4 
4/45 
39/45 
0/45 
0/45 
1/39 
0/39 
0/39 
0/39 
0/17 
0/17 
SCLC 
4/20 
11/20 
1/16 
15/16 
3/20 
16/20 
0/20 
0/20 
3/19 
16/19 
4/20 
0/20 
1/5 
0/5 
SCLC 
squamous 
3/4 
1/4 
0/3 
3/Э 
3/4 
1/4 
0/4 
0/4 
4/4 
0/4 
0/4 
0/4 
0/2 
0/2 
Large n i l 
0/2 
2/2 
0/2 
2/2 
0/2 
2/2 
0/2 
0/2 
0/2 
0/2 
0/2 
1/2 
Carcinoid 
2/10 
8/10 
0/9 
9/9 
2/10 
(/10 
0/10 
0/10 
9/9 
9/9 
1/9 
3/9 
0/4 
1/4 
" F+ f o o l reaction, D + reactKM ш vtrtually all cells. 
Table 4 Patterns of Intermediate filament protein expression of different types o4 
tung cancer in paraffin sectumi 
Non SCLC Neurocndocnn. 
tumon 
Squamous 
cell carci Adeno-
noma carcinoma 
UndilTciTn 
tialed card 
in some cells within poorly difTerentiated SQCs, while other 
tumor cells expressed only cylokeratins No cells expressing 
only neurofilaments and no cylokeratins were seen (compare 
Fig 1, g and A) 
SCLC Carcinoid AdcDosquamous Cell Cvclnonus 
pKer 
F + · 
D + 
RCKI02 
F+ 
D + 
CAMS 2 
F+ 
D + 
M N F 
F+ 
D + 
7/32 
25/32 
16/27 
10/27 
2/5 
3/5 
2/27 
0/27 
4/16 
11/16 
6/9 
3/9 
11/27 
15/27 
15/27 
8/27 
46/91 
32/91 
13/20 
4/20 
23/51 
24/51 
1/20 
0/20 
0/9* 
1/23 
0/23 
3/72 
0/72 
2/3 
0/3 
0/2 
2/2 
1/2 
1/2 
0/2 
0/2 
2/3 
0/3 
p N H 6 0 
F+ 6/14· 
D + 0/14^ 
* F+, focal reaction D+ reaction in virtually all tumor cells 
' Only elected cases of poorly dilTeientiBled tumon were tested 
(Fig I r Table 3) Strikingly, the presence of neurofilaments 
could also be observed in 3 of 23 cases (Table 3, Fig If), but 
no overlap was found between those cases staining for M O C - I 
and neurofilamenls, except for one case in which a coexpression 
of M O C I and neurofilaments in the same tumor occurred In 
most tumors only a focal reaction with these two antisera was 
observed Also in paraffin sections the presence of neurofila­
menls could be demonstrated in 2 of 27 cases using M N F and 
m 6 of 14 cases using p N F I 6 0 (Table 4) 
Double immunofluorescence studies using anlisera to cyto-
keralms and neurofilaments on frozen sections demonstrated 
that coexpression of cylokeratins and neurofilaments occurred 
Lung tumors, histologically showing adenomatous and squa­
mous cell differentiation also exhibited this bipartite nature 
immunohistochemically Most of these tumors are diffusely 
positive with pKer [6 of 8 (Table 3)] and RCK102 [5 of S (Table 
3)] and have both keratinizing areas detectable with R K S E M 
[4 of 8) and areas reacting diffusely with RGES3 [4 of 8] In 
one case also the presence of the M O C I antigen could be 
demonstrated, albeit in a small part of the tumor (see Table 3). 
Adenoorclnomas 
Most adenocarcinomas show a diffusely positive staining 
reaction with the antibodies pKer and R C K I 0 2 (Fig 2a), both 
in frozen and in paraffin sections (Tables 3 and 4) Also a 
diffuse staining reaction is seen in most frozen sections with 
the antibody RGES3 [39 of 45 (Table 3, Fig 2ft)), although in 
some poorly differentiated adenocarcinomas [4 of 45 cases], 
only a focal positive reaction with RGE53 was found, while in 
two cases no reaction with RGE53 was observed Also no 
reaction was seen with RKSE60 (0 of 45 (Table 3)], indicating 
the absence of keratimzation m these tumors The adenocarci 
nomas d'd not react with the antibody to M O C 1, except for 
one case, in which some scattered tumor cells were positive 
with this antibody or with the neurofilament antibodies in 
frozen sections In paraffin sections a focal staining reaction 
for neurofilaments was observed in 3 of 9 cases of poorly 
differentiated adenocarcinomas (Table 4) These selected cases 
were initially diagnosed as SCLC but upon revision appeared 
to be poorly differentiated adenocarcinomas 
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Small Cell Lung Cancer 
NearU all cases of SCLC examined showed the expression 
of C)tokera(ins. The polyclonal antibody pKer reacted in 15 of 
20 cases on fro/en sections while RCKI02 reacted in all cases 
of frozen sections examined (16 of 16 (Table 3; Fig. За)). In 
paraffin sections the presence of cytokeratins could be detected 
in 78 of 91 cases using pKer (Table 4; Fig. 3*), in 17 of 20 
cases using RCKI02 {Table 4), and in 47 of 51 cases using 
СЛМ5.2 (Table 4). RGE53 reacted in nearly all cases available 
as frozen sections [ 19 of 20 (Table 3; Fig. ЗЛ)). while no reaction 
was seen with RKSE60 [0 of 20 (Table 3)]. In all cases of frozen 
sections [19 of 19] a staining reaction was observed with the 
MOC-1 antibody [Fig. 3c\, although in 3 cases a reaction was 
seen in only part of the cells. In some cases of SCLC reacting 
only focally or not at all with cytokeratin antibodies a focal 
Fig 2 Immunnpcrnxidasc siaimnft on fro 
zen sections of adenocarcinomas of the lung 
Note the strong staining rcact'on of both the 
broadly cross reacting monoctonal cytokeratin 
antibodv RCKI02(a. x 250) and the monocle 
nal antibody RGE53 (ή. x 275). 
I ie V Imnumopcroxidnse and imnmno-
fluorcsccncp staining patterns m frozen sec 
linns (it Í/. g. h) and peroxidase anti рсгочі 
d:isc slaining piticrns m pwaffin sections (c. 
/ l of small cell lung cnnccr Nnie the npic.il 
gr.nn\ st.nning ге.кііоп in all tumor cells with 
the braadlj ι ross reacting monoclonal eylo-
keraim nniibod) R( K102 [a. * Î I 0 ) and \\uh 
mosi импчг cells using the monoclonal antl 
body toot-ikcrat ln IR R<,ISMft. X 27fi). In 
all cases ihc presente of ibe M ( K I antigen 
could be demonstrated (r, χ 215). while in 
some cases nciirofilamenl proteins were de­
lected in part of the tumor t i l ls , using the 
monoclonal antibody M N I (rf. X VIS) (he 
presente of tytnkcratins could also be demon 
sirntcd in parafTm setlions of S( I < using the 
polyclonal cytokeratin antibody pKer (e. x 
19(1). while additionally in some tumors a re­
action with the neuroniament antibody 
pNM60w3sobscned(/; x .190) Double label 
іттипоПиогечепсе studies using the mono 
clonal tylokeralin antibody R( Kl(>2 (j?. x 
2.15) in combination with the polytlonal neu 
rnfìlanicni antibody ρΝΓΙ60 (Α. χ 215) show 
a eoexpression of cytokeratins and nenrofila 
ments in some cells ( о т ж з in ц and Л). while 
most neurofilament positive cells arc negative 
for cytokeratins 
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staining reaction with the neurofilament antibody MNF was 
seen (4 of 20 cases (Table 3; Fig. id)]. Also in paraffin sections 
neurofilaments could be demonstrated, reacting in 1 of 20 cases 
with MNF and in 3 of 72 cases with pNF160 (Table 4; Fig. 
3/). 
Using the double immunofluorescence technique in froien 
sections of SCLC containing neurofilaments it could be dem­
onstrated that coexpression of cytokeratins and neurofilaments 
seems to occur in only a few tumor cells (compare Fig. Jg with 
Fig. ЗА). 
Combined Small Cell Carcinomas 
Mixed Small Cell-Squamous Cell Carcinomas. This tumor 
type with admixtures of SCLC- and non-SCLC (squamous cell) 
differentiation could be demonstrated histologically in four 
cases. Immunohistochemically their bipartite nature was char­
acterized by a diffuse staining reaction with RGES3 in all tumor 
cells in one part of the tumor, similar to the staining reaction 
found in poorly diffcrenlialed SQC (Fig. 4a), while in other 
parts a speckled reaction pattern is seen, similar to the staining 
reaction of SCLC (Fig. 4Л). In all cases a staining reaction with 
the MOC-1 antiserum was observed. As far as we can conclude 
from the 4 cases examined at least Ihe histologically evident 
SCLC parts of the tumors showed a MOC-1 staining reaction 
(Fig. 4f), while in the poorly differentiated SQC areas only 
scattered MOC-1-positive cells were seen. The presence of 
neurofilaments could not be demonstrated. 
Mixed Small Cell-Adenocarcinomas. In one case histologi­
cally this tumor type could be distinguished, showing a staining 
reaction with Ihe cylokeralin antibodies pKer and RGES3. In 
part of this tumor a reaction with MOC-1 occurred, while 
neurofilaments could also be demonstrated in some tumor cells 
in frozen sections and in paraffin sections (results not shown). 
Large Cell Undifferentiated Carcinomas 
This group comprises all lung carcinomas in which at the 
light microscopic level no signs of differentiation could be 
observed. In frozen sections these types of tumors reacted 
diffusely with the cytokeratin antibodies pKer, RCKI02, and 
RGE53, while in one case a reaction with MNF was also 
observed. In paraffin sections most cases reacted with pKer (13 
of 16 (Table 4)1 and all cases reacted with CAM5.2 [16 of 16). 
In addition, one case in paraffin sections showed neurofilament-
positive cells. 
Lung Carcinoids 
All lung carcinoids examined contained cytokeratins, as con­
cluded from a positive reaction with pKer (Fig. Sa), RCK102, 
and RGE53 (Fig. 5b) in frozen sections. Also, in all cases of 
frozen sections (9 of 9) the MOC-1 antigen was present (Fig. 
5c), while in 4 of 9 cases neurofilaments could be detected (Fig. 
5d). Also in paraffin sections the three cases of lung carcinoids 
examined were positive for cytokeratins (Table 4; Fig. 5«), and 
two cases also reacted with the pNF160 neurofilament antibody 
(Fig. 5/). In contrast to SCLC, a clear coexpression of cyto­
keratins and neurofilaments was delected in virtually all cells 
of lung carcinoids using the double immunofluorescence tech­
nique (compare Fig. 5g and Fig. 5A). Both cylokeralin and 
neurofilament fluorescence patterns showed a dot-like concen­
tration of these intermediate filament proteins in close prox­
imity to the nucleus. 
Comparison of Primary Lung Cancers with Their Metastases 
In order to obtain an impression of the role of lung tumor 
heterogeneity in the metastatic process and to see if metastases 
showed a similar or different immunochemical reactivity pat­
tern, we have examined 61 tumor specimens from 6 patients 
known with a primary SCLC. At all primary sites of the tumors 
as well as in all metastases the presence of cytokeratins could 
be demonstrated, although in variable amounts. In one case the 
presence of neurofilaments next to cytokeratins could be dem­
onstrated at the metastatic site in the adrenal gland, while no 
neurofilaments were observed at other metastatic sites or at the 
primary tumor site of the same patient. 
DISCUSSION 
It has been suggested that in Ihe future biomarkers will permit 
differentiation between different subtypes of major tumor 
groups (37). 
The use of such markers on lung tumors, however, has 
occasionally led to confusing or contradictory results. In our 
studies we have used well-characterized biomarkers with known 
specificity for certain subtypes of lung tumors. As a general 
marker for epithelial differentiation broadly cross-reacting cy­
tokeratin antibodies, which react with both simple (columnar) 
and squamous epithelia, were used. Keratinizing areas in SQCs 
can be detected by our monoclonal antibody to cytokeratin 10, 
RKSE60. Adenocarcinomas on the other hand contain merely 
simple epithelium-type cytokeratins such as cytokeratin 18, 
I ig 4 Imiminnp^rfuidase slaimng pal 
Icrns in frnicn scttitins otcombined small celt 
squamous celi carcinoma Noie Ihe dilTuse 
staining reaclion with the monoclonal cyloker­
alin anlihody R(iF51 in one pan of Ihe Inmor 
In. x 780) and the grain> staining reaction, 
typical for SCI <. ssilh this antibody in another 
part of Ihe tumor (ft. X .160) In all cases of 
combined small cell squamous cell carcinoma 
a positive staining with the MOC I antibody 
was observed (c. χ 160) 
*Шк*&т 
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f i g 5 Immunopcroxidase and immuno­
fluorescence slamine reactions in fro/en sec­
tion·; {a d. g, h) and peroxidase m n peroxi­
dase staining reactions in рагаГГіп sections (c 
/ ) of lung carcinoids Note the ()pical dot like 
immunostaining patterns with the monoclonal 
c>tokernlinantibodiesRCKI02(a. x 1^5) and 
R i i E M (Λ. χ 170) The membrane surface 
antigen MOC I reacts with all carcinoids in a 
characteristic manner (r. χ 220) In some of 
these tumors also the monoclonal neurofila 
ment antibody MNF reacts in a typical dot 
like fashion (</, x 220) In parafTm sections the 
presence of cytokcratins can be demonstrated 
using the polyclonal antibody pKcr (e, χ Í90), 
while in some tumors coexpresston of neuro-
filaments also can be detected with the poly 
clonal p N r t 6 0 antibody ( ƒ x 390) Double 
label immunofluorescence studies clearly dem 
unstrale this cocxprcssion of cvtokeratins and 
neurofilaments using R( K I02 (je. x 23S) and 
pNFt60 (Α. χ 215) m the same tumor cells. 
generally not occurring in squamous epithelia or in SQCs ( 2 7 -
29). Cytokeratin 18 is also found in neuroendocrine tumors 
such as SCLC and lung carcinoids (38). 
Recently, several monoclonal antibodies have been developed 
against SCLC cell surface antigens such as SM-1 (39), T F I - 4 
(40), L A M 8 (41), and M O C - 1 (10), each of them suggested to 
be more or less specific for SCLC. One of these, the monoclonal 
MOC-1 antibody, used in this study, appears to be a marker 
for neuroendocrine differentiation and reacts with normal neu­
ronal and neuroendocrine tissues, as well as with neuroendo­
crine lung tumors (10). In SCLC and SCLC cell lines also 
neurofilaments have been detected (42,43). Cell culture studies 
suggest that these intermediate filament proteins occur in the 
variant type of SCLC (20, 21). Furthermore, in some lung 
carcinoids neurofilaments have been described to be coex-
pressed next to cvtokeratins (11). Therefore neurofilament an­
tibodies were also added to the panel of biomarkers used in this 
study. The fact that these latter antibodies as well as some of 
the cytokeratin antibodies are reactive in paraffin sections al­
lowed us to perform a retrospective study using a large series 
of paraffin blocks. In this way we could obtain an impression 
about the frequency of occurrence of cytokcratins and neurofil­
aments in lung cancer. 
Our studies with these antibodies elucidate some of the 
confusion concerning intermediate filament protein expression 
in SCLC. Some authors demonstrated only neurofilaments in 
SCLC and in SCLC cell lines (42, 43), while others (38, 44. 
45) have demonstrated only cytokeratin intermediate filaments 
and neurofilaments in SCLC. Also coexpression of both cyto­
kcratins and neurofilaments in SCLC cell lines has been sug­
gested (22, 23). These discrepancies have been partly explained 
by our recent findings (20, 21) that classic SCLC cell lines 
contain cytokcratins, while variant SCLC cell lines may contain 
neurofilaments and are negative for cytokcratins. Our results 
with tissue sections of SCLC, showing that about 5 - 1 0 % of all 
SCLC examined contain focal areas positive for neurofilaments, 
seem to point to the variant-type differentiation of SCLC in 
these tumors. The frequency of the presence of neurofilaments 
matches quite well with the frequency of the variant type of 
SCLC as observed at first diagnosis by Radice cf a/. ( 17) and 
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Hirsch et al (18) One should keep in mind, however, that a 
Otnkcratin negative reaction may be a fixation artifact (24), 
which may explain possible false negative findings (42, 43, 46, 
47) 
Our results in paraffin sections show that, when using the 
proper antibodies in most tumors cytokeratms can be demon 
slrated Some of the lung tumors investigated had been stored 
for up to 23 years in formalin, and vet in most cases cytokeratms 
and in some cases neurofílaments were demonstrable The 
pNH60 antibody reacts with more cells and lung tumors than 
the MNI monoclonal antibody, probably due to the fact that 
both antibodies recognize different neurofilament proteins or 
that the polyclonal antibody pNFI60 recognizes more antigenic 
determinants than the monoclonal antibody 
Also with respect to the intermediate filament protein content 
of lung carcinoids discrepancies in the literature have arisen 
Some authors demonstrated neurofilaments in lung carcinoids 
(48), others only cytokeratms (38, 44, 49) while Lehto et al 
(II) reported the coexprcssion of neurofilaments and cytoker 
alms in three cases of such neoplasms Our results clearly 
demonstrate that indeed coexpression of cytokeratms and neu 
rofilaments can occur, howetcr, only in some of the cases 
Coexpression of cytokeratms and neurofilament proteins 
seems to be restricted to (neuro)endocrine tumors and has been 
shown to occur in neuroendocrine skin carcinomas [Merkel cell 
tumors (12-15)), in some pancreatic islet tumors [insulinomas 
(16)] and in parathyroid adenomas (SO) The possible cells or 
origin for these tumors, ι e, Merkel cells in skin (S I ), pancreatic 
islet cells and parathyroid gland cells (50), respectively, express 
onlj cytokeratms and do not contain neurofilaments These 
findings arc m parallel with the detection of only cytokeratms 
m the so called Kulchitsky cells of the lung (36, 52), a possible 
candidate for the cell type from which SCI С and lung carci 
noids arise Apparently (neurojendoenne cells have the poten 
liai to induce neurofilament expression as a result of malignant 
growth 
Although not immediately obvious from histopathological 
examinations, lung cancers may show a profound heterogeneity 
when examined at the ullrastruclural or immunocytochemical 
level I Ictcrogcncity of lung cancer has been reported previ 
ously, however, also after histological examination of different 
sites of entire lung tumors by Roggi) et al (53), who showed 
that only M% of all lung carcinomas examined were homogc 
neons I his large heterogeneity was also observed m cytological 
specimens (3) and after electron microscopic examinations (4) 
In some cases within the same tumor cell squamous cell differ 
cntiation, adenomatous and small cell differentiation can be 
observed at the ullrastruclural level (54) 
In our study, histological examination of lung cancers re 
vcalcd a combined phenotype only in about 6% of the cases 
from which frozen sections were available After the immuno 
hislochcmical procedures, m about 66% (144 of 218) of all 
tumors, tested as frozen sections a more or less heterogeneous 
staining reaction was seen In 29% of histologically homoge 
ncous SQC a nonsquamous differentiation (adenocarcinoma or 
SC 1 С) is observed m virtually all tumor cells using the RGE51 
antibody, while nearly all cases of SQC showed at least a partial 
staining reaction with this antibody A neuroendocrine or neu 
roñal differentiation was detected by MOC 1 and the neurofil 
ament antibodies m 12 and 5% of the SQC cases, respectively 
I he degree ofhclcrogcneity seen with these immunohislochem 
ical techniques in SQC s increased with decreasing degree of 
differentiation (see Table 1) The finding that in 28% of the 
cases of poorly dilTerentiated squamous cell carcinoma and in 
one case of poorly differentiated adenocarcinoma cells express 
ing MOC I are found suggests that these latter tumors contain 
cells w ilh neuroendocrine differentiation The presence of neu 
rofilaments in the moderately to poorly differentiated SQCs 
and m some poorly differentiated aednocarcmomas might point 
to the occurrence of the variant type of SCLC within poorly 
differentiated non SCLC 
Also in histologically homogeneous adenocarcinomas heter 
ogcneity could be detected, as concluded from focal staining 
reactions with ROE53 in some tumors indicating a less pro 
nounced adenocarcinomatous differentiation in large parts of 
these tumors 
Lung tumors, histologically recognizable as combined SCLC 
non SCLC, also showed a combined nature immunohistochem 
ically Since normally combined small cell carcinomas are 
treated as SCLC (8) it is our belief that poorly differentiated 
carcinomas containing MOC 1, and therefore having features 
in common with the "large cell neuroendocrine tumors" as 
described before (55), should be treated as SCLC using com-
bined chemotherapy and radiotherapy This opinion is sup 
ported by the findings by Hammond and Sausc (55) who could 
demonstrate that histologically undifferentiated large cell car 
onomas containing neuroendocrine elements (neurosecretory 
granules) at the electron microscopic level behaved clinically 
like SCLC Interestingly, coexpression of neurofilaments and 
MOC I in poorly differentiated lung carcinomas was quite rare 
This is in parallel with our findings in SCLC cell lines that the 
variant type of cell lines expressed only low amounts of MOC 
I as compared to the classic SCLC cell lines (21) Therefore it 
might well be that variant SCLC cells gradually lose their 
expression of MOC 1 with ongoing (de)dilTcrentiation 
We have examined autopsy material of patients with SCLC 
to delect a possible differential expression of cytokeratms and/ 
or neurofilaments in metastases as compared to the primary 
tumor site It is well known that m up to 30% of all cases which 
were first diagnosed as SCLC non S O С components can be 
observed at autopsy, especially after chemotherapy or radio 
therapy ( 19) These mixed tumors respond less well to combined 
therapy and have a worse prognosis than pure SCLC (56) 
The absence of neurofilaments in all but one case of metas­
tases indicates that transition from classic SCLC (which are 
positive for cytokeratin) to the variant SCLC (positive for 
neurofilaments) is not a frequent event in the course of the 
disease, at least as far as we can conclude from our limited 
study 
In summary, we can state that the main lung tumor types can 
be distinguished from each other on the basis of the panel of 
intermediate filament and surface protein antibodies used in 
this study A profound heterogeneity can be delected with these 
antibodies in lung tumors, especially in poorly differentiated 
(squamous cell) carcinomas Within SCLC the variant subtype 
may possibly be distinguished by the absence of cytokeratms in 
large parts of the tumor and the presence of neurofilaments in 
some cases The immunocytochemical detection of neuroen 
doenne components in histologically nonneuroendoenne tu­
mors as well as subtyping within SCLC may become of clini 
copathological significance 
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Cytokeratins in Different Types of Human Lung Cancer as Monitored by 
Chain-specific Monoclonal Antibodies1 
Jos L. V. Broers,2 Frans С. S. Ramackers, Mirjam Klein Rot, Tineke Oostendorp, Anita Huysmans, 
Goos N. P. van M ui jen, Sjoerd Sc. Wag en aar, and G. Peter Vooijs 
Dtpartment of Pathology. University Hospital Nijmegen/J L· У. В, F С. S. И. M К R, Т. О, Α. H, С. Ν. Ρ * M.. G. Р. К/, and Department of Pathoiogy, St. 
Antonius Hospital Nieuwegein, {S Se WJ, The Nethertands 
ABSTRACT 
The expression of cytokeratins (CKs) In humen lung cancer wis studied 
using chain-specific monoclonal antibodies to СКч 4, 7.8,10,13,18, and 
19. When applied to adenocarcinomas (ЛСЧ) of the lung, high levels of 
CKs 7, 8, 18, and 19 were detected in all tumors, while CK 4 was found 
In high concentrations In some ACs. CK 10 and 13 were completely 
absent, or onl) present In low numbers of cells. .Small cell lung cancers 
(SCLCs) and lung carcinoids contained CK 18 and sometimes 8 and 19, 
but no CK 7 in most cases. Three out of four tumors, histologically 
classified as SCLC, and expressing CK 7 In a variable number of cells 
were found by electron microscopic studies to contain regions with AC 
and/or squamous cell carcinoma (SQC) differentiation. The monoclonal 
ant f bod) specific for CK 7 can therefore possibly help to distinguish AC 
difTerentiation within SCIC. CKs 10 and 13 were completely absent In 
SCLCs and lung carcinoids, while few CK 4-posltive cells were found in 
some SCLCs and In one lung carcinoid. Within SQCs (he monoclonal 
antibodies repealed a pronounced heterogeneity bi CK expression. CKs 
4, 7, 8, 10, 13, 18, and 19 couM be delected, all hough not evenly 
distributed among all tumor cells. Highly differentiated SQCs expressed 
high levels of the С Ks specific for squamoid differentiation, i.e., CKs 4, 
10, and 13 In variable numbers of cells. With decreasing histologically 
detectable SQC difTerentiation these markers were gradually lost, while 
the number of cells containing CKs 7, 8, 18, and 19 Increased. 
Application of this panel of monoclonal antibodies can therefore dis­
tinguish not only the main subtypes of lung cancer, but can also Indicate 
Ihe degree of differentiation and the degree of heterogeneity. Illese 
findings can be used as a diagnostic aid In lung tomor pathology, which 
may have an impact oo treatment and prognosis. 
INI ROUUCTION 
Lung cancer is now generally accepted to be a very hetero-
geneous i>pe of cancer, in which a cooccurrence of the di fièrent 
subtypes is rather a rule than an exception. The three main 
subtypes are SCLC,' AC, and SQC. While after histological 
examinations heterogeneity is found in about 10-15%, this 
number increases to about 50% after cylological examinations 
(1), electron microscopy (2, 3), or when using refined immu-
nohistochemical techniques (4, 5). Because of difTerences in 
treatment and prognosis of Ihe difTerent types of lung cancer, 
detection of each subtype, especially SCLC, within individual 
lung tumors is of clinical importance. 
Virtually all epithelial tissues, both normal and malignant. 
contain CKs, which form the intermediate filament cytoskele-
lon within the epithelial cell. This family of human CKs consists 
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 The ahbrctiaiions used are SC 1 С', small cell lung caneen ЛС', adenocarrt-
noma, С К. c>lnkeratin. МоЛЬ. monuclonal antibod), PBS, 0 05 м phosphaie-
bufiered saline (pH 7 4), SQC, squamous cell carcinoma, SDS, sodium dodecyl 
sulfate 
of 19 different polypeptides, which have been numbered t 
through 19 by Moll et al. (6). These CKs are not randomly 
distributed in the different epithelia, but appear to be charac­
teristic for certain types of epithelial differentiation. For in­
stance, relatively high molecular weight CKs are characteristic 
for more complex, stratified epithelia and SQCs, while rela­
tively low molecular weight CKs, such as CK 18, are specific 
for simple, columnar epithelia (6) and ACs (7). A possible 
method to detect CKs is the biochemical demonstration based 
on (two-dimensional) gel electrophoresis as performed previ­
ously for lung carcinomas (8-11). This integral biochemical 
approach, however, is limited to defining the total of CKs 
expressed by a carcinoma specimen as a whole. CKs which are 
only expressed by a small subset of cells may go undetected 
(12). Immunohistochemically, Ihe presence of a certain CK, 
corresponding to a particular type of differentiation, is detect­
able at Ihe cellular level with MoAbs to a specific subtype of 
CK, which have recently been developed (7, 12-22). Since the 
detection of type and degree of differentiation can be of clinical 
importance, the use of this panel of MoAbs can add lo a more 
specific treatment for certain tumors. 
MATERIALS AND METHODS 
Long Ίissues. Fresh samples of normal bronchi (five cases), normal 
lung (three cases), and lung tumors were snap-frozen and stored in 
liquid nitrogen until use. Lung tumore examined in (his study were 
classified on histological basis according to the WHO classification 
(23) From lung carcinoids, SCLC, AC, poorly dilTerentiated SQC, 
moderately dilTerentiated SQC. and well-difTcrcntiated SQC, 10 cases 
each were examined. In addition, five adenosquamous carcinomas, 
three large cell carcinomas, and four combined SCLC/SQC were ex­
amined. Frozen sections approximately 5 μπι thick were cut on a 
cryostat, air dried, and stored at -20*C before use. 
Cytokeratln Antibodies. The following mouse monoclonal antibodies 
were used in this study (sec also Table I): (a) RCK102 is a broadly 
cross-reading CK antibody of the Igd subclass, which recognizes CKs 
5 and 8, and as a result stains virtually all epithelial tissues (13). (b) 
RCKI05(lgG,; 13) in immunoblotting reacts only with CK 7 and stains 
a subgroup of glandular epithelia and their tumors, next to transitional 
bladder epithelium and bladder carcinomas, (e) LE41 (Igd; 14, 15) 
reacts with difTerent types of epithelial tissues and in immunoblotting 
recognizes only CK 8. (rf) RGE53 (IgG,; 7, 16) and RCK106 (IgG., 
13) are monospecific for CK 18 in immunoblotting. In general, these 
two antibodies recognize columnar epithelial cells from digestive, res­
piratory, and urogenital tracts, endocrine and exocrine tissues and 
mesothelial cells, as well as their tumors. Generally no reaction is found 
in squamous epithelia or squamous cell carcinomas. («) LP2K (15) and 
ΒΛΙ7 (Igd; 17, 18) stain mosl simple epithelia and basal cells in 
stratified squamous epithelia that are not keratinizing, and recognize 
only CK 19 in immunoblotting assays. ( ƒ) RKSE60 (Igd; 16, 19, 20) 
reacts only with keratinizing epithelial cells, and recognizes CK 10 in 
immunoblotting. (g) 6B10 (Igd; 21) reacts with noncomifying squa­
mous epithelium, and with certain ciliated pseudostratified epithelia 
such as cylindrical epithelium of bronchi, and recognizes only CK 4 in 
immunoblotting (λ) Antibodies IC7 (Igd.; 21) and 2D7 (IgG»; 21) 
both react with noncomifying squamous epithelia. These antibodies 
recognize only CK 13 in immunoblotting studies. 
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Tabic I SpttlJUity of monoclonal cylokeratm antibodies astd in this study 
Annbody 
RCKI02 
RCKI05 
LE4I 
RGES1 
RCKIM 
LP2K 
BAI 7 
RKSE60 
6BI0 
IC7 
2D7 
Immunoglobulir 
subclus 
l«G, 
IgG, 
leo, 
IgG, 
IgG, 
IgG, 
IgG, 
IgG, 
•>Gb 
I g G . 
Anligtn 
recognized Tissue speciiîcily 
Cylokeratm 5 + g Nearly all epilhehal (issues 
Cylokeralin 7 Some glandular eptthelia 
Cytokeralm β DilTrrent epithelial tissues 
Cylokeralin 11 Glandular epilhelia not with squamous cell 
epilhelta 
Cylokeralin 18 Glandular epithelia not with squamous cell 
epilhelia 
Cylokeratm 19 Most simple epithelia 
C)tokeralin 19 Most simple epithelia 
Cylokeratm 10 Keratmiring epilhelnl cells 
Cylokeratm 4 Noncornir)ing squamous epilhelia, pseudo-
slratiCied epithelia 
Cylokeralin 13 Noncormfylng squamous epithelia 
Cylokeralin I ) Noncornirylng squamous epithelia 
13 
13 
14 IS 
7 16 
13 
IS 
17 18 
It 19 20 
21 
21 
21 
ImmunopcroxMise Technique In the indirect immunoperoxidatt 
lechnique cryostat scellons were l ì ied in accione al room temperature 
(Э times S s) and mcubaled with the primary monoclonal antibodies for 
3 0 - 4 5 m m at room temperature All primary antibodies were applied 
as undiluted culturmg supemanL After repealed washing with 0 OS M 
phosphate buffered salme ( p H 7 4) (PBS), sections were mcubaled with 
rabbit anlt mouse serum conjugated lo peroxidase ( D A K O p a t l s , Den 
mark) diluted I 25 in PBS with 5 % human AB-senim, and incubated 
for 3 0 - 4 5 m m 
After washing in PBS, peroxidase activity was detected with 3 amino-
9-ethylcarbazole (Aldrieh Chemical Co ) 4 0 mg of 3 amlno-9-ethylcar 
ba7ole was dissolved in 10 ml W N dtmethylformamide (Merck, Darm 
stadi F R O ) and added to 190 ml of sodium acetate buffer (0 OS M, p H 
4 8S) Hydrogen peroxide was added lo в final concentration of 0 0 1 % 
After an incubation for 10 m m cells were rinsed with tap water, 
counterstamed with hematoxylin, and mounted with Kaiser's glycerol 
gelatin ( M e r c k ) 
Gel Electrophoresis and Immunoblottlng Assays Cytoskeleton prep­
arations from solid lung tumors were made as follows After microdis 
seeling lumor areas 20 urn thick frozen scellons were immediately 
extracted for IS m m at 0 ' C using a high salt bulTer ( 1 5 м К О 0 S% 
Triton X 100, S т м E D T A , 0 4 т м phenylmethylsulphonyl fluoride, 
and 10 т м T n s H C l ( p H 7 2) cintrifuged for S m m at 1000 χ g. and 
washed twice with cold ( 4 ' C ) low salt bulTer (S т м F D T A , 0 4 т м 
phenylmethylsulphonyl lluonde and Ш т м Tris H C l p H 7 2), essen 
lially as described by M o l l and Franke ( I O ) 
Afler cenlnfugation ( 3 0 0 0 χ g for 10 m m ) and washing in PBS, the 
cytoskeleton preparation was dissolved by boiling during 5 m m m S D S 
sample buffer (24) 
One dimensional gel electrophoresis was performed in 1 0 % poly 
acrylamide slab gels containing 0 1 % S D S as described by Laemmli 
(24) Ί ο compare the amounts of protein loaded on each lane, gels were 
stained with Coomassie Brilliant Blue R2S0 (Gurr Hopkin and W i l 
hams Chadwell Heath, Essex, U К ) as described before (25) Two 
dimensional gel electrophoresis was performed essentially as described 
by О harrell (26) In the (irsi dimension, isoelectric focusing was 
performed m 4 % Polyacrylamide (Biorad, California, U S A ) rod gels 
containing 2 % ampholines, p H 3 5 - 1 0 ( L K B , Bromma, Sweden) For 
the second dimension, the rod gels were applied directly onto Ihe 
slacking gel of S D S Polyacrylamide gels and covered with a 1 % agarose 
solution in running buffer 
For immunoblotling experiments Ihe eleclrophorelically separated 
polypeptides were Iransferred to a nitrocellulose sheet (Schleicher and 
Schuil Membrane Filters BA 85 Dassel F R G ) by overnight blotting 
at 250 mA using an electrophoresis buffer containing 25 т м T n s H C l , 
192 т м glycine and 2 0 % methanol ( p H 8 3), essenlially as described 
by Towbm (1 at (27) The nitrocellulose sheets were then immunohis-
tochemtcally stained essenlially as described previously (25) In short, 
blols were premcubated for 9 0 m m wilh PBS containing 0 0 5 % Tween 
20 (Sigma) All reagents were diluted m this solution which was also 
used for the washing steps After incubalion overnight with undiluted 
culturmg supematants of the primary antibodies R C K I M 1C7, 
R C K 1 0 2 , or R C K I 0 5 , or with L P 2 K , diluted 1 10, blots were washed, 
incubated for 1 h with rabbit anti mouse peroxidase (DAKOpatts, 
Denmark) diluted 1 200, washed again, and stained with 4^1ιΙοπ>Ί· 
naphthol 
RESULTS 
N o r m a l Bronchial and L u n g Tissues T h e c y l o k e r a t m expres 
ston p a t t e r n s o f n o r m a l b r o n c h i a l e p i l h e l i a a n d lung alveolar 
e p i t h e l i u m are presented i n T a b l e 2 a n d i l lustrated i n F i g 1 
T h e c y l o k e r a t m anl ibodies are not reactive w i l h o t h e r t h a n 
e p i t h e l i a l tissues R C K 1 0 2 ( F i g I , A a n d B), R C K 1 0 6 ( F i g 
I f ) , L P 2 K a n d Β Λ 1 7 react w i t h all bronchial a n d lung epithe 
h a l tissues, w h i l e R C K 1 0 5 ( F i g 1 С ) a n d R C E 5 3 ( F i g l . C a n d 
H) recognize al l b r o n c h i a l a n d lung e p i t h e l i a l tissues except 
the basal layer m the b r o n c h i a l c o l u m n a r e p i t h e l i u m L E 4 I 
recognizes o n l y superficial cells o f the bronchial c o l u m n a r 
e p i t h e l i u m a n d (sero-)mucous glands, w h i l e again basal cells as 
wel l as l u n g alveoli are not recognized 6 B 1 0 ( F i g I D ) , I C 7 
a n d 2 D 7 ( F i g I f ) react w i t h some cells o f the b r o n c h i a l 
e p i l h e h u m , but are negative w i t h most alveolar e p i t h e l i a l cells 
( F i g 1/) R K S E 6 0 does n o t react w i t h a n y type o f e p i t h e l i a l 
cells m n o r m a l lung 
L u n g T u m o r s Results o f the i m m u n o h i s l o c h e m i c a l staining 
procedures i n l u n g t u m o r f r o z e n sections w i t h the different C K 
ant ibodies are s u m m a r i z e d i n T a b l e 3 a n d i l lustrated i n Figs 
2 , 3, a n d 4 O n the basis o f histological e x a m i n a t i o n s , S Q C s 
were subdivided i n t o three groups, ι e, wel l d i f f e r e n t i a t e d S Q C , 
m o d e r a t e l y di lTerentiated S Q C , a n d poorly difTercntialed S Q C 
I n al l S Q C s e x a m i n e d , a reaction was seen w i t h the C K 5 + 8 
a n t i b o d y ( F i g 2 , A a n d D) T h e C K 10 a n t i b o d y , specific for 
k e r a t i n i z i n g e p i t h e l i a l cells, reacts m o r e w i t h wel l di lTerentiated 
S Q C ( F i g 2B) t h a n w i t h m o d e r a t e l y and p o o r l y dilTerentiated 
S Q C , w h i c h i n general do not react w i t h this a n t i b o d y ( F i g 
IE) T h e same holds I m e for the t w o M o A b s to C K 1 3 , w h i c h 
react m m o r e cases a n d w i t h m o r e cells o f wel l difTerentialed 
S Q C as c o m p a r e d to p o o r l y di lTerentiated S Q C ( c o m p a r e Figs 
Table 2 Reactivity pattern of different antibodies to cytokeratins in froten 
sentons of normal bronchial and normal lung tissues 
Bronchi and bronchioli 
Cylokeralin Columnar Basal Mixed Lung Stromal Nerve See also 
antibody epithelium cells glands alveoli éléments Tibers Rel 
RCK102 
RCK IOS 
L M I 
RGES3 
КС MO« 
IP2K 
ВЛ17 
RKStòO 
6BI0 
IC7/2D7 
4 13 
13 
u ι; 
4 7 16 
13 
IS 
17 
4 16 
21 
21 
* ± positive reaction m part of Ihe cells 
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'^Ъі 
Fig I I m πι u nope го χ ida чс slainmft pat 
Icrns in normal bronchial and lung epithelium 
The broadly cross reacting С К antibody 
RCKI02 reacts with all bronchial epithelium 
cells (.4. x 240), with scromucous gt.inds </?, 
x 280). as well я% with lung alveolar epithelial 
cells (not shown) In general, antibodies to 
cytokeratms t>pical for "s imple" epithelia ( C 
k\ G. and //) reacted with more cells o í normal 
bruni bus than (he antibodies to cytokeratins 
characteristic for stralified epithelta {D, F, and 
/ ) The ( K 7 antibody RCKIOS reacts with 
the columnar cells but not with the basal cells 
of bronchial epiihetium (C. ^ 2R0), while the 
CK 18 antibody RCKI06 reacts with all bron 
chial epithelial cells ( ¿ . x 110) In contrast, 
the other С К 18 aniibodv. Ιίί,Ι 5Д, reacted 
similarly to Rt К IOS. and was also negative in 
basal cells of normal bronchial epithelium (G. 
x 210) In lung alveolar tissues, antibodies 
suchas Rf Κ10ή{//. χ UO), but also R O E M , 
LP2K and RCKI05 recogm/e pneumoc>tes of 
the alveolar epithelium {arrows) 1 he CK 4 
anlibod). 6BI0, recognizes some basal as well 
as some columnar cells of normal bronchus 
<ƒ>, X 3.10), while the ( Κ Π antibody 2D7 
onI> occasionally recognized some columnar 
cells (Γ, x 350). In general, no cells were 
stained with 6BI0 in alveoli (/, χ 330). 
b 
• « 
Wtr Ik > Г ) A . ШВ^Л Ì \ It ' 
- m 
и ^ 
2, С and F). In contrast, the antibodies to CK 19 react with 
more cases and with more cells within each tumor in poorly 
differentiated SQC (compare Figs. 2, G and J). The CK 8 
antibody also seems to react with more cells in poorly differ­
entiated SQC. However, the overall reaction of this antibody 
was quite weak in all cases. The CK 18 antibodies exhibited a 
very strong staining reaction in most, and sometimes in all 
tumor cells of poorly differentiated SQC, and staining of only 
a small percentage of the cells in well-differentiated SQC (com­
pare Figs. 2, Я and K; see also Reference 4). The antibody to 
CK 7, which reacts with scattered cells in only a few well-
differentiated SQCs, however, stains a considerable percentage 
of most poorly differentiated SQCs (Figs. 2, /and L). 
All ACs showed a staining reaction in virtually all tumor cells 
with the CK 5+8 antibody (Fig. 3/4), while none of these tumors 
reacted with CK 10. Only some scattered cells of some ACs 
reacted with the MoAbs to CK 13 (Fig. ЗЯ). Using the CK 4 
antibody, a very heterogenous reaction pattern was observed in 
ACs, varying from a reaction in almost all tumor cells (Fig. 
3C) to a completely negative reaction (not shown). The anti­
bodies directed against CK 19 (Fig. 3D), CK 18 (Fig. 3£), CK 
8 (not shown), and CK 7 (Fig. 3 f ) reacted with all ACs in 
virtually all tumor cells, although with one MoAb to CK 19 
(ΒΑ 17) and with the antibody to CK 8, a relatively weak 
reaction in less tumor cells was seen. 
The cancers which were histologically classified as adeno-
squamous carcinomas showed also immunohistochemically this 
bipartite nature, as expressed in the presence of areas with 
cornifying epithelium which were focally CK 10 positive (Fig. 
3G), and other areas which were positive with the CK 7 anti­
body (Fig. 3H). 
The SCLCs examined for this study all contained CKs, 
reacting in virtually all cells with the CK 5+8 antibody (Fig. 
4/Í). The CK 10 and 13 antibodies were negative, while the CK 
4 antibody showed in some isolated cells reactivity with these 
SCLCs (Fig. 4B). The antibodies to CK 19 reacted with varying 
numbers of cells (Fig. 4C), while the CK 8 antibody reacted 
only very weakly in some of these tumors. The antibodies to 
CK 18 reacted with nearly all SCLCs (Fig. 40). Most SCLCs 
did not react with the antibody to CK 7 (Fig. 4F). However, in 
61 
ΟΤΟΚΡΗΑπΝ HFTEROGENEITY IN LUNG CANCER 
Tibie J Reactmty of cytoktraun anubodits m fron •н sections of Литая lung caneen using the indirect tmmunoperoxtdast technique 
RCKI02 
- • 
F + · 
D + ' 
RKSE60 
-F+ 
D + 
1C7 
-F+ 
D + 
2D7 
-F+ 
D + 
6BI0 
_ F+ 
D + 
LP2K 
_ F+ 
D + 
BAI7 
F+ 
D+ 
LE4I 
^ F+ 
n+ 
RGE5J 
_ F+ 
D + 
R C K I M 
_ F + 
D + 
ИСК 105 
F+ 
D + 
Cytokcralin 
no 
5 + « 
10 
1) 
13 
4 
1» 
19 
8 
I I 
IS 
7 
Squamous cell careinomt 
Well 
(» - 10) 
0 
10 
difTerennation 
Moderately Poor 
(n - 10) (n - 10) 
0 0 
0 0 
0 0 
Я 7 
2 3 
0 0 
7 S 
3 5 
4 1 
б 7 
0 2 
Aden,)/ 
squamous 
( я - 5 ) 
0 
0 
5 
Adenocarcinoma 
(« - 10) 
0 
0 
10 
10 
0 
0 
» i 
0 
S 
2 
0 
1 
9 
0 
0 
I 
9 
0 
to 
0 
1 
7 
2 
0 
0 
10 
0 
3 
7 
0 
0 
10 
SCLC 
«ι - 10) 
0 
2 
1 
10 
0 
0 
10 
0 
0 
10 
0 
0 
6 
4 
φ 
3 
6 
1 
J 
4 
' 
7 
3 
0 
1 
2 
7 
2 
4 
4 
< 3 
1 
SCIC/ 
squamous 
( « - 4 ) 
0 
1 
3 
4 
ft 
υ 
4 
0 
0 
4 
0 
0 
2 
2 
0 
1 
1 
2 
1 
2 
1 
4 
0 
0 
1 
2 
1 
0 
1 
3 
1 
1 
2 
Large 
cell 
carcinoma 
С - З ) 
0 
^ 3 
3 
0 
0 
3 
0 
0 
3 
0 
0 
3 
0 
0 
0 
0 
3 
0 
0 
3 
1 
2 
0 
0 
2 
1 
0 
0 
3 
0 
0 
3 
Car .· lid 
ι r io) 
0 
0 
10 
10 
0 
0 
9 
1 
0 
9 
1 
0 
9 
1 
Φ 
4 
5 
1 
1 
2 
0 
4 
6 
0 
0 
J 
7 
0 
0 
10 
7 
1 
1 
' -.no reaction in tumor cells 
' F+, heterogeneous local reaction 
' D + , homogeneous difTuse reaction 
four cases a reaction with a varying number of cells was seen 
(Fig. ΛΕ). In three of these cases, electron microscopical ex­
amination revealed the presence of cells with AC and/or SQC 
dilTerentialion, next to the typical neurosecretory granules. 
Carcinomas classified as combined SCLC/SQC on histolog­
ical grounds showed a heterogeneous reaction pattern with the 
different CK antibodies in accordance with their histological 
heterogeneity. Most strikingly, large areas were completely 
positive with the antibodies to CK 18 (Fig. AG), while other 
parts did not react with these antibodies, but were locally 
positive with the antibody to CK 4 (Fig. 4//). 
The CK expression of the three large cell carcinomas exam­
ined was characterized by a positive reaction with MoAbs to 
the "simple" CKs 7, 8, 18, and 19, and a negative reaction with 
the MoAbs to CKs 4, 10, and 13 (not shown). 
All lung carcinoids examined reacted with the CK 5+8 anti­
body (Fig. 4/), while in only one case a reaction was observed 
with the antibodies to CKs 4 and 13. Antibodies to CK 8 (Fig. 
47) and CK 19 (Fig. 4A') showed variable reaction patterns, 
while the antibodies to CK 18 were positive in all cases exam­
ined (Fig. iL). CK 7 was detected in three lung carcinoids 
Immunoblotting Studies. Results of the one-dimensional im-
munoblotting experiments on cyloskeleton preparations of tis­
sue sections of SCLC, AC, and moderately to well-dilTeren-
tialed SQC are shown in Fig. 5. In the three SCLCs examined 
the presence of CK 18 was proven using RCK106 (Fig. 5/4, 
lanes 1-3). The two ACs reacted strongly with this antibody 
(Fig. 5/t, lanes 4 and 5), while the three SQCs showed a relative 
weak reaction (Fig 5A, lanes 6-8). 
Λ subsequent incubation of this immunoblot with LP2K 
showed the presence of CK 19 in one SCLC (Fig. 5B, lane 2), 
in the two ACs (Fig. SB, lanes 4 and 5), and in the three SQCs 
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Гщ 2 Immunopcroxith-îc stmmng pat 
icrns m »cil differonii^icd sguamnns cell car 
сіпотач (SQC s ,Â. И, C. G. H. and / ) , and m 
роогГ) different ia led SQC s (/>, /Г, Г, J, К, and 
I.) of the lung The broadly cross reacting CK 
antibodv RC KI02 reacts wilh all tumor cells 
in both well difrerentiatcd {A. x 270) and 
poorl) dilTcreiiiiated SQf s {lì. χ 290) Only 
in well diffcrcmnud SQCs IteratintzinK areas, 
reacting »Uli the t К I0aniib<)d> RKSI 60 are 
seen (R, x 2^0). while no reaction is seen wilh 
(his antibody m poorly difTcrenhated SQ< s ( F , 
x W)) I arge arcas of well diiTcrcnliatcd 
SQC s are stained with (he С Κ Π antibody 
2I>7 (f , χ .140). while in poorly difTerenliated 
SQC s only scattered positive cells can be found 
(Γ. X 270) The С К 19 antibody I Г2К reacts 
wilh only a few cells in well differentiated 
SQC s (fi. χ 140), while Іагцс parts of poorly 
differenliated SQC s show a completely rosi 
li^e reaction (Λ x 2S0) In most well difTer­
enliated SQC s some cells react with the CK 
18 antibody RCVESl (/Л * 2M)) In poorly 
differentiated SQCX however, the рсгсепіяце 
of С К 18 positive tumor cells increases to al 
most 100'- (A. x г^П) The CK 7 antibody 
RCK10S d o t s ПО! r e a d with most well differ­
entiated SQC s (/, x 2S0). but shows a com 
pletcly positive reaction in sonic poorly differ 
enhalcd SQC s (/, x 24)). И and /, staining 
patterns with RC»I-M and R( К10Ч in parallel 
sections of the same region of a well difTcrcn-
tiatcd SQC Note the positive reaction of CK 
18 and no staining for С К 7 
І^ 
з 
l g 
'-къ · 
(Fig. 5B, lanes 6-S). Subsequent incubation of this immunoblot 
with IC7 showed the presence of CK 13 in two SQCs (Fig. 5Й, 
lanes 6 and 7), and the absence of this CK protein in the other 
SQC (Fig. 5β, lane S). Also, the other lung tumors shown here 
were negative (Fig. 5Я, lanes 1-5). 
Incubation of a similar immunoblot with the antibody 
RCKI05 showed a weak reaction for CK 7 in two SCLCs (Fig. 
5C, lanes I and 2), a much stronger reaction in the two ACs 
(Fig. 5C, lanes 4 and 5), and only trace amounts in two of three 
SQCs (Fig. 5C, lanes 7 and Я). One SCLC and one SQC were 
negative (Fig. 5C. lanes 3 and 6, respectively). The findings of 
the immunoblolting match very well with the reactivity of the 
individual tumors with the CK antibodies in the immunoper-
oxidase staining. 
Two-dimensional immunoblolting data on SCLC and AC are 
shown in Fig. 6. From these immunoblottings it is clear that 
this SCLC (showing AC differentiation on the basis of electron 
microscopy as well as on the basis of immunohistochemistry) 
contains small amounts of CK 19 (Fig. 6.4), next to CK l8(Fig. 
6/7) and CK 7 (Fig. 6C). Additional immunostaining with 
RCKI02 (not shown) resulted in a spot in the CK 8 region. The 
AC contains CK 19 and CK 18 (Fig. 60), while additional 
bands were stained at the CK 8 (Fig. 6i') and CK 7 (Fig. (>F) 
level. Note that especially in the AC immunoblot breakdown 
products of CK 18 and CK 19 (more acidic spots with a lower 
molecular weight, see also Ref. 28) are also stained with their 
respective antibodies. 
DISCUSSION 
We have examined a selected group of lung carcinomas for 
their CK expression using a panel of MoAbs specific for one 
CK polypeptide. Until a few years ago, the presence of CKs in 
SCLCs and ACs of the lung was a matter of discussion. For 
instance, some investigators (29-31) could detect CKs in for­
malin-fixed, parafTin embedded squamous cell carcinomas, but 
not in some ACs or in most SCLCs. Since then, the use of 
other fixation techniques such as cold methanol fixation, or 
even better, the examination of unfixed, frozen sections in 
immunohistochemistry, has improved the detection level for 
CKs in tissue sections considerably. In addition, better defined 
CK antibodies, not only recognizing the "larger" more acidic 
CK polypeptides, but also recognizing the CKs occurring in 
simple epithelia, have become available. Investigations using 
these techniques and antibodies have led to a general consensus 
that (nearly) all lung carcinomas express CKs (4, 5, 8-10, and 
32-35). A biochemical examination by Blobel et al. (8, 9) and 
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I IR 1 ImmunDpcrcixrdasr slnming рлі 
terns of \( ч ( l / ι ¡ind aclcncisiiipamous ceil 
ι ,иі niiiin.iv ((, and //) of Ilio Inni: ЛС s arc 
c(>iii|ilt |<Ί\ pmttlvE wiih ihr broadly cross 
ГПКІІПС«
 к
 ПІіПюд) R( K I 0 2 ( 4 . x 360). In 
some adcnocartinomas. some scattered cells 
rc-ul with the ( Κ Π antibody 21)7 (Я. χ 150) 
\п cxircmch hclcroftcncoiis reaction is seen 
viith the С К 4 anlibod) 6BI0. \ar>ing from a 
posiluc reaction in all cells of some tumors 
{( x HO) lo я completely negative rcaclion 
in other cases (not shown) ΛΙΙ ACs react 
Blronftl] «uh I h c i К l9antibod\ I P2K (D. X 
Э60). With lhe( К 18 antibody Rf K106(E. x 
350),md With the« К 7 antibody RCKIOSfT, 
x 210) In adenosqnamous cell carcinomas 
o<.Lastonally kcralmi7inft arcas are deteclable 
«Kb Ihe < К IOantibcxK RKSt Г<0(О. x HO). 
while other areas of Ihe same tumors arc pos 
ime with the t К 7 antibody RCK10S (//, x 
.130) 
С^ю „ν ? Î 2 
» " «г -
M o l l and Franke (10) using two-dimensional gel electrophoresis 
suggested the presence of CKs 7, 8, 18, and 19 in AC's, the 
presence of CKs 4, 5, 6, 8, 13, 14, 15, 17, 18, and 19 in SQCs, 
the presence of CKs 7 (minor relative amounts), 8, 18 and 
sometimes 19 in SCLCs, and of CKs 7 (minor relative 
amounts). 8, 18, and ! 9 in lung carcinoids. The CK distribution 
within each tumor at Ihe cellular level, however, could not be 
examined by this integral gel electrophorctic technique. 
In this study we have used chain-specific MoAbs for CK 
polypeptides 4, 7, 8, 10, 13, 18, and 19, each of them recogniz­
ing only one single CK polypeptide. This panel of MoAbs 
enabled us to examine the presence of CKs within each t>pe of 
lung tumor at a cellular level, and to detect a possible hetero­
geneous CK expression within each tumor. Such a heterogeneity 
has become apparent from earlier studies, which have shown 
that many, i f not most, lung carcinomas contain more than one 
type of differentiation, when examined with other than conven­
tional (histological) detection techniques. 
When using MoAbs one should always be aware of false-
negative reaction patterns as a result of epitope masking. For 
instance immunoblott ing experiments, using RCK102, seem to 
prove the presence of CK 8 in all lung cancers. However, the 
reaction pattern with L E 4 I , a monospecific antibody for CK 8, 
is in general very weak, while even in many cases no reaction is 
seen. Therefore it seems likely that in these tumors the CK 8 
epitope recognized by L E 4 I is largely masked. Similarly, mask­
ing of epitopes recognized by one of the CK 19 antibodies, 
B A I 7 , may explain why this antibody in general reacted with 
less tumors and with less tumor cells than LP2K, the other 
M o A b to CK 19. Epitope masking may also explain why the 
CK 18 antibody R G E 5 3 d i d not recognize basal cells of normal 
bronchial epithelium, while the other CK 18 antibody, RCK 
106, showed a clear staining reaction in these cells. 
From our results described here, it is obvious that a large 
heterogeneity in the expression of the different CK polypeptides 
within most lung carcinomas can occur. For instance the pres­
ence of CK 7, normally occurring in ACs, varied in SQC from 
no positive cells in well differenliated SQCs, to a positive 
reaction in all tumor cells for poorly differentiated SQCs. This 
suggests the presence of varying degrees of A C differentiation 
within most SQCs. 
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Fit; 4 Immunopemxidase slaiinnft pal 
terns of small cell lung canters (SC LC4; A-F), 
combined small eclt/squamous cell carcinomas 
{C and H). and lung carcinoids (/-AT), Most 
SCLCs are completely positive with the 
broadly cross reacting antibody R f К102 {A, x 
290) In some cases a focal reaction is seen 
with the CK 4 antibody 6 B I 0 (Д, x .470). 
Varying numbers of cells arc positive with the 
С К 19 antibody LP2K (С, x .170) Most S C I C 
react with the CK 18 antibody RCK106(O, X 
335). but do not react with the С К 7 antibody 
R< K I 0 5 ( F , x Л 5 ) In some SC 1 С. in which 
at the electron microscopic leve) a combined 
SC LC was demonsualed. focal areas reacting 
with CK 7 were prcsenl (/Γ, χ 250) Combined 
SCLC/SQC showed the presence of CK 1Я. as 
detected by RCKI06. in large parts of the 
lumor ((/. χ 370). while also areas not rcai-lmg 
with this antibody were seen. These areas, on 
the other hand, contained CK 4 in some cells 
(//, x 370) ЛІ1 lungrnrcinoids are completely 
positive with RCK102(/. x 370), while about 
half of (he cases react with I F4I {J, x 250), 
and with LP2K (Χ. χ 290). In addition, all 
lung carcinoids react wilh RC Κ Ι 0 6 ( Λ , x 370). 
Note the tvpical doi like appearance of С К 19 
(A) 
:vms Л 
" · b 
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Another example of heterogeneous CK expression is the 
presence of CK 7 in some SCLCs, suggesting the presence of 
A C components in these malignancies. This finding is sup­
ported by the fact that in three of four SCLCs in which CK 7 
is found, also at the electron microscopical level AC differen­
tiation could be observed. On the basis of many other studies, 
comparable findings were reported. For instance, at the electron 
microscopic level in up to 5 0 % of all histologically pure SQCs, 
A C differentiation can also be detected (2), while in some 
tumors even tripartite (i.e., SQC, SCLC, and AC) differentia­
tion can be found within the same tumor cell (36). This heter­
ogeneity can also be found in the expression of peptide hor­
mones produced by SCLCs and some non-SCLCs (37), the 
heterogeneity in expression of neuron-specific enolase and bom­
besin within SCLC (38), and even at the light microscopical 
level when whole tumors are examined (39). 
In spile of the large heterogeneity, our results still indicate 
that SQC differentiation, A C differentiation, and SCLC differ­
entiation can be distinguished on the basis of expression of 
different CK polypeptides. Histological squamous cell differ­
entiation is found in parallel with the presence of CKs 10 and 
13 and to a lesser extent CK 4, while pure ACs always express 
CKs 7, 18, and 19. S C L C diflerentiation is characterized by the 
presence of CK 18 and the absence of CKs 10 and 13, and CK 
7 in most cases. These findings suggest that the presence of CK 
7 may be used to detect A C differentiation. This hypothesis is 
supported by investigations on the cylokeratin expression in 
A C and SCLC cell lines, which showed that CK 7 was present 
in all five AC cell lines examined, while only one out of 17 
SCLC cell lines showed a reaction in part of the tumor cells.' 
In summary, the use of a panel of monospecific CK antibodies 
can immunohislochemically distinguish the main subtypes of 
lung carcinomas, but can also detect the degree and type of 
heterogeneity within each tumor. Therefore, application of this 
panel of CK antibodies is a useful aid in tumor diagnosis. 
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Fig. S. One dimensional immunoblotling 
kssiys using difTerenl chain-specific CK anti­
bodies on cyloskeletal preparations from three 
small cell lung cancers (SCLCs; lanes 1-5 of 
each panel), two ACs (lanes 4 and 5 of each 
panel), and three moderately to well-difTeren-
tiated squamous cell carcinomas (SQC's; lanes 
6-8 of each panel). Comparable amounts of 
cytoskelft.it proteins from each sample were 
applied. In A, reaction patterns of these lung Д D 
tumors with the CK 18 antibody RCKI06. 
Note the very strong reaction of the ACs (lanes 
4 and 5), the weaker reaction in the SCLCs 
{lanes 1-3), and the weak but evident reaction 
in the SQC's liane* 6-8). The arrow denotes a 
breakdown product of CK 18. In 0. the same 
immunnblot was subsequently incubated wilh 
the CK 13 antibody IC7 and the CK 19 anti- и -
body LP2K. Note the presence of CK 13 in ~ 
two SQCs (lanes Л and 7). and the absence of iß— и, ЁЦИГШ •ЩЁГ ^ - 1ö" 
this protein in the other SQC(/onf 5). as wel! " ' ^ l^m %*» -JQ. 
as in the SCLCs and ACs (lanes l-S). In lane 
7 some degradation bands of CK 13 are clearly 
visible (arrows). CK 19 appears to be present 
in one SCLC (lane 2), in the two ACs (lanes 4 
and 5). and in all three SQCs (lanes 6-8). 
Again, also breakdown products of CK 19 are 
detected (arrow). A parallel immunoblot waa 
incubated with the CK 7 antibody RCKI OS, as 
shown in С Two of three SCLCs show a weak 
reaction at the CK 7 level (lanes I and 2), 
while the third SCLC is negative (lane S). 
Interestingly, the two SCLCs in which CK 7 is 
present, show, at the electron microscopic 
level, evidence for focal AC different iat ion. 
The two ACs react very strongly with this 
antibody (lanes 4 and 5), while in two SQCs 
trace amounts of CK 7 can be detected (lanes 
7 and 8), Arrows, breakdown products of CK 
7. 
1 2 3 4 5 6 7 8 1 2 3 4 5 6 7 8 1 2 3 4 5 
Г 
IEF 
Fig. 6. Two-dimensional immunoblots of a 
C)toskcictal preparation from a small cell lung ^ m 
cancer (SCLC, Α-C) with AC differentiation, D 
and of a cytoskeletal preparation from an AC S 
(D-F). The immunoblot of the SCLC prcpa-
 1 Q . Q 
ration was first incubated with LP2K (A), re- "-¡L ' Ч ^ 
suiting in a weak reaction with CK 19. followed 1 9 Ί 3 ^ 9 
by an incubation with RCKI06, resulting in • 4f 
clear recognition of CK 18 (fi). Thereafter the 
same blot was incubated with IC7, not reacting 
with this preparation, and with RCKIOS, re­
sulting in a clear reaction at the CK 7 region _ u 
( O Additional staining with RCK102 re U 
suited in a weak reaction at the CK 8 region 
(not shown). The immunoblot of the AC prep­
aration was first incubated with LP2K, fol­
lowed by an incubation with RCK 106 resulting 
in clear CK 19 and CK 18 spots, respectively 
(D). Note that breakdown products of these о 
two CKs. migrating towards the acidic side of 8 
the blots, are also immunostained. Subsequent ^ 
incubation with RCK 102 resulted in a weak 1 8 _ ^штш 18. 
CK 8 band (£ ) . while additional staining with "ЧІ -j
 i Q Τ« M 19 ЧГ. 1 -η 
RCKIOS resulted in a clear CK 7 spot (F). -mMl· " * * " Ч ^ Ш 
Incubation of this immunoblot with IC7 did 
nol result in additional spots. 
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Differential expression of intermediate filament proteins 
distinguishes classic from variant small-cell lung 
cancer cell lines 
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ABSTRACT The expression οΓ Intermediate filament pro· 
teliu In classic and variant-type small-cell lung carcinoma 
(SCLC) cell lines was studied using Immunocytochemlcal 
techniques, two-dimensional gel electrophoresis and Immuno-
blottlnf; assays. Classic SCLC cell lines contain cytokeralin 
proteins hut no neurofilaments. In contrast, variant cell lines 
do not contain detectable amounts of cytokeratlns but partly 
express neurofilaments and vlmentln. These results explain 
apparent discrepancies on the Intermediate filament content of 
SCLC described In the recent literature. The application of 
antibodies to fresh biopsy specimens of SCLC may in the future 
allow the identification of the variant type of cells In clinical 
SCLC specimens and may have a major Impact on therapeutic 
strategy and prognosis In these patients. 
DilTerential expression of intermediate filamenl proteins are 
characteristics of diderent tissues and tumors denved there­
from Antibodies to keratin, vimentm, desmin, glial fibrillary 
acidic protein, and the neurofilament proteins can distinguish 
between cells of epithelial, mesenchymal, and neural ongin 
As malignant cells retain their tissue-specific intermediate 
filament proteins, it is possible to use these antibodies in 
tumor diagnosis Several studies have reported on the char­
acteristics of intermediate filament proteins of small-cell lung 
carcinoma (SCLC) cells (1-8) Results so far have been 
inconsistent, probably because ofthe use of different anlisera 
and detection methods Furthermore, it has been recognized 
that SCLC is often a very heterogenous tumor m which in a 
considerable number of cases a large-cell type can be distin­
guished (9-12) 
SCLC accounts for 20-25% of all new cases of primary 
lung cancer, and unlike the other major forms of lung cancer, 
it is highly sensitive to both chemotherapy and radiation 
therapy (13) Recently, several laboratories have reported on 
their success in the establishment of continuous cell lines of 
SCLC (1,14-16) In general, SCLC cell lines grow as floating 
aggregates of cells, show electron-microscopically detectable 
dense core vesicles, and express elevated levels of a variety 
of biomarkers including the key amine precursor uptake and 
decarboxylation (APUD) enzyme, L-3,4 dihydroxyphenylal-
anine decarboxylase (dopaOCase), bombesin-like im-
munoreactive substances (BLI), neuron-specific enolase 
(NSEase), and the BB isoenzyme of creatine kinase (CK-
BB) With few exceptions these markers are not expressed in 
cell lines of non-SCLC (14, 17-19) 
In a recent study of a large panel of SCLC cell lines, it has 
been shown that these cell lines can be subdivided into two 
major categories, ι e , classic (70% of all lines) and variant 
(30%) cell lines (20) Variant cell lines do not express elevated 
ТЪе publication costs of this article were defrayed in pari by page charge 
payment This article must therefore be hereby marked advertisement" 
in accordance with 18 U S С 11734 solely to indicate this fact 
levels of dopaDCase or BLI but continue to express elevated 
levels of NSEase and CK-BB (11, 20) In addition and m 
contrast to classic cell lines, variant cell lines have a much 
looser morphology m ii/ro, a higher cloning efficiency, and 
faster doubling time and are radioresistant in vitro (11, 20, 
21) Finally, amplification of the c-myc oncogene (20 to 
25 fold) at the DNA level and increased c-myc mRNA 
expression have been observed in variant but not in classic 
SCLC cell cultures (22) 
These data suggest a more malignant behavior for the 
vanant SCLC cell lines, which may in part be related to c-myc 
amplification and expression in these cells As clinical cor­
relates of this variant phenotype (most probably represented 
by the large-cell type within SCLC) may exist and be 
associated with a worse prognosis (12, 23), the development 
of assays that can distinguish classic and vanant phenolypcs 
of SCLC in biopsy specimens may be of therapeutic signifi­
cance 
Since different types of intermediate filament proteins have 
been shown to occur in different types of tissues and tumors 
(24-26), detection of such constituents in SCLC was likely to 
give an indication about the nature ofthe different cell types 
present in such malignancies In light of previously-published 
data (1-5), antibodies directed against cytokeratlns and the 
neurofilament proteins are especially interesting in this re­
spect 
MATERIALS AND METHODS 
Cell Lines. The establishment and characterization of the 
NCI cell lines have been described in detail elsewhere (10,11, 
14, 15, 17-22) NCI-H69, NCI-H128, NCI-H449, GLC-1-
M13, GLC-7, GLC-8, and GLC-12 have been classified as 
classic SCLC cell lines, while NCI-H82, NCI N417, NCI-
H524, GLC-1, GLC-2, and GLC-4 have been charactenzed 
as vanant SCLC cell lines The charactenzation of GLC-1, 
GLC-2, GLC-4, GLC-1-M13, GLC-7, GLC-8, and GLC-12 
will be described elsewhere GLC-1-M13 was obtained by 
limiting dilution of GLC 1 in serum-free medium 
In these studies, cell lines were grown in RPMI 1640 
medium (GIBCO) supplemented with 15% fetal bovine serum 
(GIBCO) and maintained in a humidified incubator at 37°C in 
5% COj/95% air 
Estimation of NSEase activity has been desenbed (18) 
dopaDCase specific activity was calculated as nmol of "C 
released from L-["CJdopa per hr per mg of protein as 
desenbed (27) c-myc expression was determined as de­
senbed (22) 
Abbreviations SCLC, small-cell lung carcinoma, NSEase, neuron-
specific enolase, dopaDCase, L-3,4-dihydroxyphenylalanine 
decarboxylase 
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Antisera. Antisera used in this study were as follows (ι) An 
alTinity purified polytlonal antiserum directed against human 
skin keratins (pK| I his antiserum reacts with virtually all 
epithelial tissues but not with nonepilhclial tissue (2S) In 
most cases of SCLC froren sections, this anlisemm stains the 
tumor cells when used in immunocytochemical procedures 
Π) In) Monoclonal antibodies KCH 51 and CK1R 2, both 
directed against cylokeralin 18, which spccil'ically recognize 
columnar epithelial cells from digestive, respiratory, and 
urogenital tracts, endocrine and exocrine tissues, and 
mcsothchal cells No reaction is found in squamous epithelial 
or noncpithclial tissues (28) 1 he antibodies react with SCLC 
m frozen sections Π) (ш) Monoclonal antibodies directed 
against different пеигоПІаілепІ polypeptides, BFIO and 
R197 were provided by Brian Anderton (London) In 
immunoblotling assays BFIO was shown to react only with 
the ISS-kDa neurofilament protein, while R l^? reacts mainly 
with (he 210 kDa neurofilament protein (29) A third mono­
clonal antibody to neuroiilamcnls (MNF) was purchased 
from l uro Diagnostics (Apeldoorn (he Netherlands) In 
immunoblotling assays, we could show that this antibody 
reacts strongly with the 210-kDa neurodlament polypeptide 
and lo a somewhat lesser extent with the 68 kDa neurofila­
ment polypeptide No reaction was found with vimenlin, 
cylokcralins or with human callus keratins When frozen 
sections and paraffin sections from human brain, peripheral 
nerves and some neural tumors were used a positive 
reaction of monoclonal antibodies to neurofilament proteins 
(ВГ10. RT97, and MNI ) was found only in the neural tissue 
No positive reaction of these neurofilament antibodies was 
seen in frozen sections of SCI С (iv) A rabbit antiserum to 
bovine lens vimentin Preparation and specificity of this 
scrum have been described (25 28) (ι) Antisera to chicken 
gizzard desmm and human glial fibrillary acidic protein were 
prepared as described before (25) 
Indirect Immunnlluorescence Technique. I he cell lines, 
which grow as loose or light floating aggregates, were either 
spun down m growth medium using a cytospin centrifuge 
(Shandon Southern Instmments. Scwickley, РА,450гртГог 
5 mm) or brought onto microscope slides by using the 
Cytopress system Cells were fixed by dipping m methanol 
( 20X) and acetone (three times), air dried and incubated 
with the primary antiserum for 30 mm After repeated 
washing in phosphate buffered saline (Ρ,/NaCI), either goat 
anti rabbit antibody coupled to fluorescein isothiocyanalc 
(Г11С) (Nordic. Tilburg I he Netherlands) diluted 1 25 in 
Ι',/N.iC I or rabbit anti mouse antibody coupled to Π ГС 
(Noidic. Iilburg I he Netherlands) was used as a secondary 
antibody After incubation for 10 mm, the cells were washed 
again in Ρ,/Natl mounted in CielvatoK Monsanto) containing 
1.4 diazobicyclo[2 2 2lodane at НЮ mg/ml (DABCO, Jans-
sen Pliai maceutica Bccrsc Belgium) 
Slides were viewed with a 1 eitz Dialux 20 FB microscope 
equipped with epifluoiesccnt illumination Pictures were 
taken on 400 ASA Iri-X film (Kodak) with an automatic 
camera 
(ìel Flectrophoresls and ImmunoMoltlne Assa>s. Cytoskel-
etal preparations from the cultured cell lines were made by 
extracting cell pellets with 1% Inlon X 100 in Ρ,/NaCI 
One dimensional gel electrophoresis was performed in 10% 
NaDodSOVpolyacrylamide slab gels as described by Lacm-
mh (10) Two dimensional gel electrophoresis (31) was per­
formed by applying the 4% Polyacrylamide rod gels after 
isoelectric focusing directly onto the stacking gel of the 10% 
NaDodSOVpolyacrylamidc gel Gels were stained with 
Coomassic brilliant blue R250 
Imniunoblottmg assays were performed essentially as 
described by Towbin el al (12) All washing steps between 
incubations were performed with Ρ,/NaCI containing 0 5% 
Inlon X KM) Ihe immunoblots were incubated overnight 
with the primary antibodies, CK 18 2, as undiluted culture 
supernatant, or MNF, diluted 1 20 m 1 ris HCl buffer (pH 7 6) 
containing 0 3% gelatin and 0 5% Inlon X 100 They were 
then incubated 1 hr in rabbit and mouse antibody coupled to 
peroxidase (DAKO patls, Denmark) diluted 1 200 m Ρ,/NaCI 
containing 0 3% gelatin and 0 5% Triton X 100 Peroxidase 
activity was delected by its reaction with 0 01% 4 chloro-1-
naphtol (Merck), 0 06% HjOj in Pi/NaCI for 10-30 mm 
RESULTS 
Immunoduorescence. The intermediate filament character 
istics of seven classic and six variant SCLC cell lines and two 
adenocarcinoma (non SCLC) cell lines were studied by use of 
a panel of monoclonal and polyclonal antibodies The results 
of these studies are shown in Table 1 and Fig 1 All seven 
classic SCLC cell lines contained cytokeratins, as demon­
strated by a polyclonal antiserum to human skin keratins and 
a monoclonal antibody to human cylokeralin 18 (RGE53) 
Both these antisera reacted wilh intracellular filaments In 
most cases not all cells of the classic SCLC cell lines reacted 
with the cylokeralin antibodies used and no neurofilament 
proteins were detected (Fig 1 A and B) In addition, desmm, 
glial fibrillary acidic protein, and vimenlin could not be 
demonstrated in classic cell lines 
The intermediate filament characteristics of variant SCLC 
cell lines were different from those of classic SCLC cell lines 
m thai none of them were positive for cytokeratins (Table 1 
and Fig I O while several were positive for vimenlin The 
staining pattern with the vimenlin antiserum varied consider­
ably within the variant SCLC cell lines In NCI-H82 and 
NCI H524, only a few cells reacted weakly positive In 
NCI N417, some cells reacted strongly with the vimentm 
antiserum while most of the other cells were only weakly 
stained or were negative In contrast, GLC-1 and GLC-2 
exhibited a strong filamentous staining pattern in all cells with 
the vimentm antiserum The vanant SCLC cell lines showed 
considerable heterogeneity when stained with antibodies to 
neurofilaments Of Ihe six vanant SCLC cell lines evaluated, 
three cell lines, NCI-H82, NCI H524, and GLC-2, were 
found to give a filamentous staining reaction with the 
neurofilament antibodies m a considerable percentage of the 
cells (Fig ID) but the number of cells stained with the 
different monoclonal neurofilament antibodies varied con 
sidcrably For example, the antibody MNF stained almost all 
cells m NCI-HR2 and GLC 2 while the antibody BF10 stained 
only a small number of cells m these cell lines The remaining 
three cell lines, NCI N417, Gl C-l, and GLC-4, were nega­
tive for both cytokeratm and neurofilaments 
In both adenocarcinoma cell lines a strong filamentous 
staining reaction with the antisera to cytokeratins and the 
antiserum against vimentm was observed No reaction was 
seen with the antisera to neurofilament proteins, glial fibril­
lary acidic protein, or desmm 
Gel Electrophoresis and Immunoblotling. In two-
dimensional gel electrophoresis, all cell lines appeared to 
contain Ihe microfilament protein actin (indicated as A m Fig 
2 a, b. and с ) In classic SCI С cell lines, variable but always 
low amounts of cytokeratins 7, 8, 18, and 19 could be 
demonstrated (Fig 2 a and b) In conlrasl, no cylokeralin 
spots were observed in two dimensional gels of the vanant 
SCLC cell lines (Fig 2c) In classic and variant SCLC cell 
lines, two striking protein spots occurred at the level of 
vimentm (57 kDa, pi 5 7), however the presence of vimentm 
could not be confirmed by immunoblotling assays of cylo-
skeletal preparations of (hese cells (results not shown) When 
taking into account Ihe negative reaction of classic SCLC cell 
lines with antibodies to vimentm m the immunofluorescence 
technique, it is very unlikely that these protein spots repre­
sent vimenlin The two protein spots do not occur in 
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Fio 1 Immunofluorescence microptiiphs of classic SCI.С cell lines (A and Bi and variant SCl.C cell lines (C and Í)) incubated with antibodies 
tocytokeratm ( Л and ί )and toneuiolilamcnt prolein(ßand ƒ)) Note the strong lilamenlous reaction of classic SCLC with cylokeratin antibodies 
(/4. polyclonal keratin antibody on NCI H449) and no reaction with neurofilament antibodies (B. MNF on NC1-H69). On the contrary, variant 
SCl.Ccell lines are negative for the cytokeratin antibodies (C. RÜF51 on NC1-N417) but can be stained with neurofilament antibodies (D. MNF 
on NCI-M82). (Bar - U) μτη ) 
two dimensional gels of non-SCLC cell lines (results not 
shown). 
Immunoblotling assays could confirm our findings with the 
immunofluorescence technique. The presence of cytokeratin 18 
Table 1 Iniermediatc filament protein expression by immunofluorescence, presence of NSBase and dopaDCase activity, and c-myc 
oncogene expression in classic and variant SCLC cultures and in adenocarcinoma cultures 
Intermediate filament expression 
Cell line 
Classic SCIC 
NCI-H69 
NCIH128 
NCI H449 
GlC-1-МИ 
GLC-7 
OLC-8 
CiLC-12 
Variant SCLC 
NCI H82 
NCI-N417 
NCI H524 
G1.C1 
GIC-2 
GLC4 
Non-SCLC 
NCI-H21 
NCI-H125 
NSF.ase 
I 
i 
+ 
+ 
+ 
t 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
-
-
dopaDCase 
activily' 
2(.4 
174 
И 
(16 
<0 1 
<0.1 
<0.1 
<0 1 
C-niVi 
expression 
-
-
-
+ 
+ 
+ 
-
Cylokeratin 
pK 
+ 
+ 
+ 4 
+ + 
+ 
+ 
+ 
-
-
-
-
-
-
t 
+ + 
RGE53 
+ 
+ 
+ + 
+ + 
+ 
+ 
+ 
-
-
-
-
-
-
+ 
+ + 
Neurofilaments 
BF10 RT97 MNF 
_ _ _ 
_ _ _ 
_ _ _ 
_ _ _ 
_ _ _ 
_ _ _ 
_ _ _ 
+ + + + 
- - -
+ + + 
_ _ _ 
+ + + 
_ _ _ 
_ _ _ 
- - -
Vimentm Desmin OFAP 
+ 
+ + 
+ + 
- . no reaction in immiinofluorescence test; +, filament staining m a varying number of cells; + + , strong filament staining in virtually all cells. 
GFAP, glial fibrillary acidic protein 
•Expressed as nmol of l 4C released from t -I'^ldopa per hr per mg of protein assayed. 
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FIG. 2. Details of two-dimensional gels showing cytoskeletal proteins from classic SCLC cell lines (a and b) and a variant SCLC cell line 
(c). Note the presence of cytokeratins 7, 8, 18, and 19 (indicated as such) in the two classic SCLC cell Unes (a, NCI-H128; b, NCI-H69) and 
the absence of cytokeratins in the variant SCLC cell line (e, NCI-H82). lEF, isoelectric focusing; A, actin. 
could be demonstrated by using monoclonal antibody CK18-2 
but only after heavily overloading the gels with cytoskeletal 
proteins (Fig. 3, lanes 1, 2, and 3). No reaction was seen with 
CK18-2 in immunoblotting of the variant SCLC cell lines 
(results not shown). Immunoblotting assays with the variant 
SCLC cell lines using the antibody MNF resulted in a clearly 
positive reaction with NCI-H82 at the 68-kDa level (Fig. 3, lane 
5), while a very faint reaction was observed with NCI-H524 
(Fig. 3, lane 6), and no reaction could be seen with NCI-N417 
(Fig. 3, lane 4). These immunoblotting data agree with the 
results of the immunofluorescence experiments in which NCI-
H82 was completely positive foranlibody MNF, NC/-N417 was 
completely negative, and in NC1-H524 only a small number of 
cells were stained with this antibody. Classic SCLC cell lines 
did not react with antibody MNF (results not shown). 
DISCUSSION 
In the past few years, several investigators have tried to 
elucidate the origin of SCLCs. After the demonstration of 
neuroendocrine granules in these neoplasms by Bensch el al. 
(33), the presence of other neuroendocrine markers was 
described (34). The nature of the intermediate filament 
proteins in these tumors is still a matter of discussion. 
Antibodies to intermediate Filament proteins have become 
FIG. 3. immunoblots of a cytokeratin antibody and a neurofila­
ment antibody on cytoskeletal preparations from classic and variant 
SCLC cell lines. Note the positive reaction of NCI-H449 (lane 1), 
NC1-H128 (lane 2), and NCI-H69 (lane 3) with the monoclonal 
antibody to cytokeratin 18 (CK18-2). This antibody was negative on 
heavily overloaded gel blots from variant SCLC cell lines. With the 
monoclonal neurofilament antibody MNF a protein band from the 
variant SCLC cell line NC1-H82 (lane 5) migrating in the 68-kDa 
region is immunostained. A very faint reaction was also seen with 
NCI-H524 (lane 6) while no reaction is seen with MNF and 
NCI-N417 (lane 4). 
available that react in a tissue-specific manner (24); for 
example, antibodies to cytokeratins react only with epithelial 
tissues and carcinomas while antibodies to neurofilament 
proteins react with tissues of neural origin and some neural 
tumors (25, 26). Application of such antibodies to SCLCs has 
resulted in contradictory findings (1-8). Lehto et al. (4) have 
reported the expression of neurofilament protein and no 
cytokeratin in such neoplasms while others (2, 3, 5) have 
obtained the opposite result; i.e., only cytokeratin intermedi­
ate filaments and not neurofilaments are identified. 
Our findings explain these discrepancies and have led us to 
suggest the following hypothesis. The SCLC solid tumors and 
SCLC cell lines that have been described as containing 
neurofilaments but not cytokeratin (1, 4) most probably 
represent the variant type of SCLC, while those tumors and 
cell lines described as having cytokeratin and no neurofila­
ments (2,3, 5) most probably represent the classic type of this 
neoplasm. However, the inability to detect the presence of 
cytokeratins in SCLCs (1, 4, 6, 8) may be due in part to the 
low amount of cytokeratins present in SCLCs as demon­
strated by our immunoblotting assays and two-dimensional 
gel electrophoresis. Furthermore, fixation procedures can 
result in the destruction of cytokeratin antigenic sites. Fi­
nally, the type of cytokeratin antiserum used is very critical 
in the detection of these intermediate filaments. 
Vimentin intermediate filaments could be detected only in 
the non-SCLC and the variant SCLC cell lines, not in the 
classic SCLC cell lines. It should be stressed, however, that 
in three of the variant SCLC cell lines, only a few cells 
contained these filaments. Coexpression of vimentin fila­
ments with other types of intermediate filaments is often 
observed in cultured cells (35) and it seems to be the result of 
adaptation of the cells to the environment or to the survival 
of cells as individuals that are not part of a cohesive tissue or 
cell cluster (36). Our findings with the anti-vimentin antibody 
suggest a correlation between growth pattern and morphol­
ogy of the cells in viiro and the expression of this intermediate 
filament type. Cells growing attached to the surface of the 
culture dish (such as the non-SCLC H23 and GLC-1 and 
GLC-2 lines) express vimentin, while those growing as 
floating aggregates express much less or no vimentin at all. 
Within this latter group, a subdivision can be made even 
between cells growing as loose clusters (most variant cell 
lines) that contain small amounts of vimentin in a few cells 
and cells growing as tightly packed floating aggregates (the 
classic cell lines) that are negative for vimentin. 
The coincidence of the cell and tissue specificity of 
intermediate filament proteins with the current concepts of 
embryologie derivation of the different cell lineages allows us 
to speculate about some aspects of the ongoing discussion 
dealing with the histogenetic origin of SCLCs. Since primary 
SCLC and all classic SCLC cell lines contain cytokeratins 
(refs. 2, 3, and 5 and this paper), it is obvious that these cells 
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are epithelial in nature Therefore, (he origin of SCLC from 
a hematopoietic stem cell as suggested by Ruff and Pert (37) 
seems to be unlikely t urlhermore, the presence of 
cylokeralm filaments and absence of neurofilnmenls within a 
tissue or tumor does not deny us neuroendocrine nature 
(compare refs 1 and 7) since several neuroendocrine tissues 
and tumors have been shown to contain cytokeratin inter-
mediate filaments (38 39) Other neuroendocrine tumors, 
such as Merkel cell tumors, may contain both cytokeratin and 
neurofilament types of intermediate filament proteins (40, 
41) Van Muijcn el al ( ì ) have reported the coexpression οι 
cylokeralms and neurofilament proteins m an epidermoiH rell 
carcinoma of the lung, while Bergh el al (1) have described 
a cell line derived from a large-cell carcinoma of the lung that 
also shows this coexpression 
Therefore, (he presence of neurofilaments and absence of 
cytokeralins m the vanant SCLC cell lines raises several 
questions with respect to the origin and dilTcrcnliated state of 
these cells Fudire studies with other markers will have to 
show whether these cells are derived from cells that originally 
contain both cylokeratms and neurofilaments, as suggested 
by Bergh el al (1) or whether (hey have (de)dilTerentiated 
from cells positive for cytokeratin only via an intermediate 
cell type that is negative for both cylokeratms and neurofila­
ments The fact that the variant SCTX shows a particularly 
low sensitivity to chemo- and radiotherapy (12, 21. 23) and 
that patients with such tumors have a significantly worse 
prognosis than patients with classic SCLC makes it particu­
larly important to recognise the variant phenotypc in diag­
nostic biopsies The application of antibodies to cytokeratin 
and neurofilament proteins and other intermediate filament 
proteins in a rapid immunohistochemical technique may 
therefore become a valuable tool m the pathological diagnosis 
of these tumors 
We lhank Mirjam Klein Rot Лпііа lluysmans Gerì Schaart and 
Olof Mocsker for excellent lechnnal assislance and Yvonne Stam-
mes for secretarial help v. ilh Ihe preparation of (he manuscript 1 his 
study was supported by a gram from The Netherlands Cancer 
Foundation. The Queen Wilhelmma Fund (KWF1 
1 Bergh J , Nilsson К Dahl D Andcrsson I . Virtanen. I 
A l e h t o V Ρ (І9в4Нігі> /иіг« 51, 1ft7-316 
2 Blobel, G Gould V F Moll R I ce. I . Hus/ar. M . 
Geiger В & I ranke, W (198S) /oh /mr« 52, 19- SI 
3 Uroers J lluysmans Л , Moeskci Ο Vooijs Ρ Wagenaar, 
S Λ Ramaekers, I (l98S)/nfc Imcsl 52, 113-11S 
4 1 ehto V Ρ Slenman S Mictlinen M Dahl, D & 
Virlanen I (1983) Am J Pillimi 110,111-118 
5 Van Muijen G N P Ruiter, D J van Leeuwen, С , Puns, 
Ι Λ Rietsema, К & Wamaar, S О (1984) Am J fallwl 
116, 361-369 
6 Gusterson В , Mitchell, D , Warhurton, M A Sloane. J 
(1982) I'm Али t Ardi A 394. 269-277 
7 Saba S R Espino™ С G , Richman, A V A Azar, H A 
(1983) Am J Clin l'alhol 80, 6-П 
8 Nagle R В , McDaniel К M Clark, V A * Paine, С M 
(]981Mm J Clin Pallini 79. 4S8-^66 
9 AbelofT M 1) , Fgglcslon, J С , Mendelsohn G , Cltmger. 
I) S Л Baylm, S В (1979) Am J Med 66,7^7-762 
10 Gazdar Л F , Carney ϋ Ν . Gucuon J G A Baylm S В 
(1981) m Small Cell Can moma ofllie Ziintf.eds Greco, F A , 
Oldham R К A Bunn Ρ A (Gruñe A Stratlon, New York), 
pp 145-175 
Proc Sail. Acad Sci. USA 82 (1985) 
11 Gazdar. A F , Zweig. M H . Carney, D Ν , Van 
Steirteghen, А С , Baylm, S В A Minna, J D (1981) Cancer 
Re ν 41, 2773-2777 
12 Radice. Ρ A , Matthews. M J , Ihde, D С , Gazdar, A F , 
Carney, D N , Dunn, Ρ A , Cohen, M H , Fossieck, Β Ε , 
Makuch. R W A Minna. J D (1982) Сялгег 50, 2894-2902 
13 Minna.J D Higgms G A.GIatstein E ; (1982)mCancer, 
Principe* and Practice of Oncohev vus De Vita, V Τ , 
HrS'-ian, S A Rosenberg, S A (Lippincolt, Philadel^,^', 
ρμ 396-475 
Г. Gazdar A F . Camey, D N . Russell, E К , Sims, Η L , 
Baylm S В . Bunn Ρ A . Jr . Guccion. J G A Minna. J D 
(1980) Cancer Pei 40, 3502-3507 
15 Carney, П N , Bunn, Ρ A , Jr , Gazdar, A F , Pagan, ] A 
A Minna, ! D (1981) Proc Nail Acad Sa USA 78, 
3185-3189 
16 Pettengill, О S , Sorenson. G D . WOrster-Hill, D H , 
Curphrey Τ J , Noll. W W , Cate, C C A Maurer, L H 
(19B0I Cancr IPhiladelrhla) 45, 906-918 
17 Baylm, S R , AbelofT, M D . Goodwin, G , Camey, D N A 
Gazdar, A F (1980) Cancer Лет 40,1990-1994 
18 Marangos. Ρ J . Gazdar, A F A Carney, D N (1982) Can­
ter Leu 15, 67-71 
19 Moody. Τ W . Pert, С В , Gazdar, A F , Camey, D N A 
Minna J D (1981)íciemr 214, 1246-1248 
20 Carney, D N . Nau, M M A Minna, J D (1984) in Human 
Tumor Сіоптц, eds Salmon, S E A Trent, J M (Gruñe A 
Slratton, New York), pp 67-82 
21 Carney D N . Mitchell, J В A Kinsella, T. J (198Э) Cancer 
Rei 43,2806-2811 
22 I itile. С D . Nau M M . Camey. D Ν , Gazdar. A F A 
Minna, J D (1983) Nature (London) 30*, 194-196 
23 Hirsch. F R . 0sterlind, К A Hansen. H H (1983) Cancer 
52, 2144-2150 
24 Franke, W W , Schmid, E , Schiller. D L . Winter, S , 
Jarasch, E D . Moll, R . Denk, H , Jackson, В A lllmensee, 
К (1982) Cold Spring Harbor Symp Quam Biol 4*, 431^(53. 
25 Ramaekers. F C S . Puts, J J G Moesker. О . Kant, A , 
lluysmans, A . Haag. D . Jap. Р Н К . Herman. С J A 
Vooijs, G Ρ (1981) Hislocliem J 15, 691-713 
26 Osbom M A Weber. К (1983) Lab ¡mesi 48, 372-394 
27 Baylm. S В , Stevens, S A A Shakir. Κ M M (1978) 
Вин hun Biophys Acia 541, 415-419 
28 Ramaekers, F . Huysmans, A , Moesker, О , Kant, A , Jap. 
Ρ , Herman. С A Voogs. Ρ (1983) Lab Invest 49, 353-361 
29 Anderlon. Β Η . Bremburg. D . Downes. M J . Green, Ρ J , 
Tomlmson. Β E . Ulrich, J , Wood, J N A Kahn, J (1982) 
Nature (London) 298, 84-86 
30 Lacmmli U К (1970) Nature (I on don) 227, 680-685 
31 О Farrell, Ρ H (1975) J Bml Chem 230,4007-4021 
32 Towbm H . Slaehelm T A Gordon, J (1979) Proc Nati 
Atad Sci USA 76, 4350-4354 
33 Bensch. К G Comn, В , Panente, R A Spencer, H (1968) 
Canrerll, 1163-1172 
34 Gould, V E , l.innoila, R I . Memoli, V A A Warren, 
W II (1983) Lab Inveii 49, 519-537 
35 Franke W W . Schmid, E , Winter. S , Osbom, M A Weber, 
К (1979) Exp Cell Rei 132,25^(6 
36 Une, E В . Hogan. В L M , Kurkinen, M A Garrels. J I 
(1981) JVaUrr (London) 303, 701-703 
37 Ruff, M R A Реп, С В (1984) Science 225, 1034-1036 
38 Kahn. H J , Gamdo, A . Huang, S -Ν A Baumal, R (1983) 
lab ¡mesi 49, 509-510 
39 Holler, H A Denk. H (1984) VirtAoHt ArrA A 403, 235-240 
40 Miellinen. M . Lehlo, V Ρ , Virtanen. I , Asko-Seljavaara. S , 
Pitkanen.J A Dahl, D (1982) Ultraitruit Palhol 4,219-225 
41 Green. W R , Lmnoila. R 1 A Tnche. T J (1984) 
Ullraslruct Palhol t, 141-152 
75 

CHAPTER SEVÍ 
INTERMEDIATE FILAMENT PROTEINS IN CLASSIC- AND VARIANT-TYPE 
SMALL CELL LUNG CARCINOMA CELL LINES. 
A BIOCHEMICAL AND IMMUNOCHEMICAL ANALYSIS USING A PANEL 
OF MONOCLONAL AND POLYCLONAL ANTIBODIES. 
J.L.V. Broers, D.N. Carney ), M. Klein Rot, G. Schaart, 
2 
E.B. Lane ), G.P. Vooijs, F.С.S. Ramaekers. 
Department of Pathology, University Hospital Nijmegen, 
The Netherlands 
) Department of Medical Oncology, Mater Misericordiae Hospital, 
Dublin, Ireland. 
2 
) Imperial Cancer Research Fund Laboratories, London, U.K. 
Reprinted by permission from 
The Journal of Cell Science 83: 37-60, 1986 
Copyright · 1986 by The Company of Biologists Limited 
77 

3 i ell Sn 83 37-60 (J986) 
Pnnted m Great Britain © The Company o/Biologists Umtted 1986 
INTERMEDIATE FILAMENT PROTEINS IN CLASSIC 
AND VARIANT TYPES OF SMALL CELL LUNG 
CARCINOMA CELL LINES: A BIOCHEMICAL AND 
IMMUNOCHEMICAL ANALYSIS USING A PANEL OF 
MONOCLONAL AND POLYCLONAL ANTIBODIES 
J L V BROERS 1 , D N CARNEY2, M KLEIN ROT 1 , G SCHAART 1 , 
E В LANE 3 , G Ρ VOOIJS1 AND F С S RAMAEKERS 1 · 
'Department of Politologi, Unnentty of Nijmegen, The Netherlands 
Hìepartment of Medicai Oncology, Mater Misencordiae Hospital, Dublin, Ireland 
Imperial Cancer Research h und Laboratories, London, LK 
SUMMARY 
The intermediate filament protein (IFP) characteristics of a panel of lung cancer cell lines 
including adenocarcinoma (two cell lines) and small cell lung cancer (SCLC, three classic and three 
variant cell lines) were examined using one- and two dimensional gel electrophoretic techniques, 
immunocytochcmical techniques and immunoblotting assays A panel of 28 monoclonal and 
polyclonal antibodies to the five different t)pes of IFP were used The results of our studies 
indicate that these human lung adenocarcinoma, classic SCLC and variant SCLC cell lines can be 
differentiated on the basis of their pattern of IFP 
The main conclusions from this study can be summarized as follows (1) The two adeno-
carcinoma cell lines contain cytokeratins 7, 8, 18, and sometimes 19, next to vimentin intermediate 
filament (IF) (2) The three classic tjpe SCLC cell lines contain only cytokeratin IPs but not 
\iincntm IF or neurofilaments (NFs) Cytokeratin polypeptides 7, 8, 18 and 19 could be detected 
(3) All three variant type SCLC cell lines do not contain detectable amounts of cytokeratins In 
contrast, two out of three variant SCLC cell lines contain neurofilament proteins All three variant-
t\pe SCLC cell lines contain vimentin ΙΓ (4) Using immunoblotting assays with monoclonal and 
polyclonal antibodies to defined NF proteins the presence of the 68x 103Λ/
Γ
 and the 160X 101 A/
r 
NF polypeptide could be demonstrated in two variant SCLC cell lines 
As patients with SCLC variant phenotype have a poorer prognosis after cytotoxic therapy than 
patients with 'pure' SCLC, the use of antibodies to IFP in staining fresh lung tumours, especially 
anaplastic ones, may differentiate the two subtvpes of SCLC Such a distinction would have a 
major impact on therapy selections and may be of prognostic importance 
INTRODUCTION 
Small cell lung cancer (SCLC) accounts for 20-25 % of all new cases of primary 
lung cancer Unlike the other major histological types of lung cancer (collectively 
referred to as non-SCLC), S C L C is highly sensitive to both chemotherapeutic 
agents and radiation therapy, so that up to 90 % of patients with S C L C will achieve a 
• Author for correspondence 
Key words cvtokeratin, vimentin, neurofilaments, immunocytochermstry, gel electrophoresis, 
immunoblotting 
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clinical remission after cytotoxic therapy. Although several histological subtypes of 
SCLC have long been recognized, including the oat-cell or lymphocyte-like variety 
and the intermediate cell type (World Health Organization, 1982), in several studies 
no significant differences have been observed among these subtypes in clinical 
presentation, response to therapy or overall survival (Radice et al. 1982; Hirsch 
et al. 1983). However, in up to 10% of all newly diagnosed patients with SCLC 
histological examination reveals features of a mixed small cell/large cell (SC/LC) 
carcinoma (Radice et al. 1982; Hirsch et al. 1983). Patients with this histological 
appearance have a significantly poorer response rate and shorter survival than 
patients with 'pure' SCLC. 
Recently, investigators have reported on the growth in vitro and detailed biological 
characterization of SO cell lines derived from patients with SCLC (Carney et al. 
1985). On the basis of their expression of the key amine precursor uptake and 
decarboxylation (APUD) enzyme L-dopa decarboxylase (DDC) these cell lines 
could be subdivided into two main groups: namely, classic and variant SCLC cell 
lines. Classic SCLC cell lines express elevated levels of DDC, bombesin-like 
inimunoreactive (BLI), neurone-specific enolase (NSE) and the BB isoenzyme of 
creatine kinase (CK-BB). These cell lines have typical SCLC morphology, have a 
relatively low cloning efficiency and prolonged doubling time, and are radiosensitive. 
Variant SCLC cell lines lack DDC and BLI but (unlike non-SCLC) continue to 
express elevated levels of NSE and CK-BB. Variant cell lines have a morphology 
similar to large cell undifferentiated carcinoma. Moreover, these cell lines have a 
more malignant growth behaviour in vitro and in vivo, are radioresistant and are 
amplified for the c-myc oncogene (Carney et al. 1985, and references therein). As 
some of these variant SCLC cell lines arose from biopsy specimens with a mixed 
SC/LC morphology, it is likely that these variant cell lines are the in vitro 
counterparts of the in vivo SC/LC carcinoma. As patients with this phenotype have 
a worse prognosis, and as difficulties may arise in their recognition on histological 
evaluations, it is clear that other assay systems, including immunohistochemical 
techniques that may distinguish the different phenotypes (classic versus variant) of 
SCLC, may be of clinical and prognostic importance. 
Intermediate filaments (IF) occur in almost all cell types and appear to have a 
tissue-specific protein composition (Osborn & Weber, 1983). On the basis of their IF 
protein pattern the tissue origin of a given cell type can be determined, using 
biochemical and immunocytochemical techniques. For example, epithelial cells 
contain IFs of the cytokeratin type while cells of mesenchymal origin contain 
vimentin as their IF" protein. Vimentin is also expressed in many cell types when 
introduced into tissue culture (FVanke et al. 1979). Muscle tissue contains IF of the 
desmin type, glial cells contain glial fibrillary acidic protein (GFAP) as their 11' 
subunit, and the IFs in neural cells consist of the neurofilament (NF) protein triplet 
(Dahl & Bignami, 1977). Normally, tumours derived from these tissues retain their 
typical intermediate filament protein pattern (Osborn & Weber, 1983; Ramaekers 
et al. 1983b), although some exceptions have been described (Holthöfer et al. 1983, 
1984). This also holds true for cell cultures obtained from such neoplasms. 
Intetvtediate filaments in SCLC cell lines 
Table 1. Characteristics of the lung carcinoma cell lines used in this study 
D DC-act 
ВЫ 
NSE 
CK-BB 
c-myc expr. 
Rad. surv. (n)* 
MOC-If 
Adenocarcinoma 
NCI 
11-23 
<0 1 
< 0 0 1 
<1Û0 
94 
η.t. 
2 0 
-
NCI 
H-125 
<0·1 
<0Ü1 
<100 
68 
— 
2 0 
-
NCI 
Н-69 
240 
1-7 
817 
15 921 
— 
11 
+ 
Classic SCLC 
NCI 
Η-128 
646 
15 
2045 
11768 
— 
1-2 
+ 
NCI 
Н-449 
98 
0·8 
1998 
13 207 
— 
10 
+ 
NCI 
11-82 
0-6 
0-2 
317 
6340 
+ 
I M 
+ 
Variant SCLC 
NCI 
N-417 
< 0 1 
< 0 0 1 
580 
8024 
+ 
5-6 
+ 
NCI 
H-524 
<0-l 
< 0 0 1 
234 
8631 
+ 
n.t. 
+ 
Data extracted from Carney et al. (1985). Activity of L-dopa decarboxylase (DDC-act) was 
expressed as units mg- 1. Production of bombesin-like immunoreactive (BLI) was expressed as 
pmolmg' . Presence of neurone-specific enolase (NSE) and the BB isoenzyme of creatine kinase 
(CK-BB) were expressed as ngmg- soluble protein, n.t., not tested. 
*», extrapolation number; for definition see Carney et al. (1983). 
f Our data. 
Therefore, immunohistochemical staining of intermediate filaments in tumours and 
cell lines has proved to be a useful tool to determine their origin. 
Results in using antisera to intermediate filament proteins (IFPs) for typing the 
origin of SCLC have been contradictory (Altmannsberger et al. 1984; Banks-
Schlegel et al. 1985; Berghe/a/. 1984; ВегпаЫ al. 1983; Blobel et al. 1985; Broers 
et al. 1985rt,A; Gusterson et al. 1982; Lehto et al. 1983, 1984; de Leij et al. 19856; 
van Muijen et al. 1984; Schlegel et al. 1980), probably due to the use of different 
(siib)types of tumours, different fixation methods and the use of different antisera. 
Recently (Broers et al. 1985α) we have shown that classic and variant SCLC cell 
lines can be distinguished from each other on the basis of a differential expression of 
I F F . Classic cell lines express cytokeratins and no neurofilaments, while variant 
cell lines do not contain detectable amounts of cytokeratins, but may express 
neurofilaments. 
T o exclude false-positive or false-negative reactions, we have now extended this 
study elaborately by testing well-characterized cell lines with different fixation 
methods using a large panel of monoclonal and polyclonal antibodies to IFF, 
especially to different types of cytokeratins and neurofilament proteins, and we have 
used biochemical and immunochemical techniques to confirm these findings. The 
cell biological significance of our findings is discussed and the application of these 
antibodies to future management of patients is suggested. 
MATERIALS A N D METHODS 
Cell lines 
Methods used for the establishment and characterization of the cell lines used in this study have 
been described (Carney el al. 1985; Gazdar et al. 1980; see also Table 1). Three cell lines, NCI-
1169, NCI-II128 and NCI-H449, are classic SCLC cell lines, while NCI-H82, NCI-N417 and 
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NC1-H524 are variant SCLC cell lines. Cell lines NCI-H23 and NC1-H125 were derived from 
patients with adenocarcinoma of the lung and form typical adenocarcinomas when inoculated into 
nude mice (Carney el al. 1985). 
All cell lines were maintained in Roswcll Park Memorial Institute Medium 1640 (RPM1-1640, 
GIBCO, Paisley, UK) supplemented with 15% foetal bovine serum (GIBCO, Paisley, UK) and 
maintained in a humidified incubator at 37°C in 5 % CO2. All SCLC cell lines grow as floating 
aggregates of cells, while the two adenocarcinoma cell lines grow as attached monolayer cultures. 
Intermediate filament antibodies 
The following antibodies were used in this study. 
Α. Л panel of antibodies directed against cylokeratins 
(1) An affinity-purified polyclonal antibody directed against human skin keratins (pKer). This 
antibody reacts with virtually all epithelial tissues, but not with non-epithelial tissues (Ramaekere 
et al. 19836). In most cases of SCLC frozen sections this antibody stains the tumour cells when 
used in immunocytochemical procedures (Broers ft al. 19856). 
(2) A monoclonal antibody RCK102, directed against cytokeratins from a human lung cancer 
cell line (MR21, kindly provided by Dr С. Gropp, Marburg, FRG). This antibody stains virtually 
all epithelial tissues, but not non-epithelial tissues. When tested on cultured epithelial cells this 
antibody shows a fibrillary staining pattern identical to that seen with the polyclonal antibody 
pKer. 
(3) The monoclonal antibody RGE53 directed against cytokeratin 18 specifically recognizes 
columnar epithelial cells from digestive, respiratory and urogenital tracts, endocrine and exocrine 
tissues, and mesothelial cells. No reaction is found in squamous epithelial or non-epithelial tissues 
(Ramaekersef al. 1983ο). This antibody reacts with SCLC in frozen sections (Broers et al. 19856). 
In immunoblotting assays RGE53 was shown to react with a 45xl03Af
r
 cytokeratin protein 
(cytokeratin 18 according to the catalogue by Moll et al. 1982) only present in certain epithelial 
tissues or epithelial cell cultures. No reaction is seen with non-epithelial tissue samples or with 
other cytokeratin polypeptides (Fig. 1A). 
(4) The monoclonal antibody CK 18-2 raised against human mesothelial cells and also directed 
against cytokeratin 18. This antibody gives a similar staining pattern to RGE53 when tested on 
human tissues. In immunoblotting assays this antibody only recognizes a 45xl03A/
r
 cytokeratin 
polypeptide and no other cytokeratins, nor does it react with non-epithelial cytoskeletal proteins 
(Fig. IB). 
(5) The monoclonal antibody RKSE60, directed against human skin keratins and specific for 
keratinizing stratified squamous cells. No reaction is found with columnar epithelial cells, non-
keratinizing squamous cells or non-epithelial cells (Ramaekers et al. 1983α). 
(6) The monoclonal antibodies PKK1 and PKK2 (Holthöfer et al. 1983, 1984), kindly pro-
vided by Dr I. Virtanen (Department of Pathology, University of Helsinki, Finland), were 
obtained after immunization of mice with cytoskeletal polypeptides from a pig kidney epithelial cell 
line (LLC-PK). PKKI antibodies do not react with epidermal cells, but strongly stain all glandular 
and simple epithelial cells in human tissues. In immunoblotting assays PKKI reacts with several 
cytokeratin polypeptides, including cytokeratins 8 and 18. PKK2 antibodies bind to basal cells of 
the epidermis, myoepithelial cells, bile-duct epithelial cells of the liver, kidney collecting duct 
epithelial cells, as well as various cultured epithelial cells. In immunoblotting experiments this 
antibody recognizes cytokeratins 17 and 19, but does not seem to react with cytokeratins 8 and 18 
(Dr I. Virtanen, personal communication). PKKI and PKK2 do not react with non-epithelial 
tissue. 
(7) The monoclonal antibodies AE1, AE2 and AE3 (Cooper et al. 1985; Eichner et al. 1984; 
Woodcock-Mitchell et al. 1982) were kindly provided by Dr T.-T. Sun (Department of 
Dermatology, New York University Medical Centre) and were obtained after immunization of 
mice with human epidermal keratins. The AE1 antibody reacts with cytokeratins 10, 14/15, 16 and 
19 (Cooper et al. 1985). In immunofluorescence the AE2 antibody stains the suprabasal cell layers 
in the epidermis, but is negative in other epithelia (e.g. oesophagus, urinary bladder or pancreas). 
AE3 uniformly stains all epithelia tested and reacts with cytokeratins 1 to 8 (Cooper et al. 1985). 
Thus, the cytokeratins recognized by AE1 are the more acidic polypeptides (type I cytokeratins) 
Θ2 
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within this protein family, while those recognized by AE3 represent the more basic polypeptides 
(type 11 cytokeratins). Using the three different antibodies no reaction was found with fibroblasts, 
muscle cells, fat cells, neural tissues, endothelial cells and blood cells. 
(8) The monoclonal antibodies LE41, LE61 and LE65 were obtained after injection of mice 
with cytoskcleton preparations of cultured PtKl cells (Lane, 1982). The monoclonal antibody 
LE41 is monospecific for cytokeratin 8, while LE61 and LE65 are both monospecific for 
cytokeratin 18.1n frozen sections, LE61 and LE65 give tissue-staining patterns comparable with 
B C D 
vm 
1 2 3 4 5 1 2 3 4 5 1 2 3 4 1 2 3 4 
Fig. I. Demonstration of antibody specificity by immunoblotting tests. A,B. Cytokeratin 
antibodies RGES3 (A) and CK18-2 (B) tested on proteins from callus keratins (lane 1), 
cytoskeletons from LLCMK-2 cells (lane 2), bovine liver cell cultures (lane 3), human 
neurofilament proteins (lane 4) and a preparation from uterine smooth muscle (lane 5). 
Note the strong reaction of these antibodies with cytokeratin 18 (45х103Л/
І
) in lanes 2 
and 3. C. The monoclonal antibody mVIM tested on a cytoskeletal extract from bovine 
lens (lane 1), callus keratins (lane 2), muscle desmin (lane 3) and a cytoskeletal 
preparation from BHK-21 cell cultures (lane 4). A strong reaction at the level of vimentin 
(STXlO'jl/,) and its degradation products can be observed in the lens vimentin extract 
(lane 1). The negative reaction in BHK-21 cell extracts (known to contain vimentin) may 
be due to species specificity of the antibody. D. The neurofilament antibody RT97 tested 
on protein extracts from the lung squamous cell carcinoma cell line MR32 (lane 1), callus 
keratins (lane 2), a neurofilament preparation from human brain (lane 3) and bovine lens 
vimentin (lane 4). Note the reaction of RT97 with the neurofilament extract at the 
ZOOXlO'M, level (top), and a weaker reaction with the 160ХІ03Л/
Г
 neurofilament 
polypeptide (lane 3). 
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biochemical data on the distribution of cytokeratin 18, while LE41 sees only some of the tissues 
known to contain cytokeratin 8, presumably recognizing a more variable aspect of the protein's 
conformation No reaction is seen with these three antibodies in any stratified squamous epitheha 
The antibodies LE41, LE61 and LF.65 do not react with non epithelial cells 
(9) Τ he monoclonal antibodies LP1K, LP2K, LP3K and LPSK were raised against detergent-
insoluble material from simian virus 40 (SV40) transformed human kcratmocytes LP2K is 
monospecific for cytokeratin 19, and stains most simple epitheha and basal cells in stratified 
squamous epitheha that are not keratinizing (Lane & Perkis, unpublished data) LP1К recognizes 
many of the basic, type II cytokeratins, and stains simple epitheha but not epidermis in unfixed 
frozen sections LP3K and LPS К also recognize predominantly simple epitheha, and react 
principally with cytokeratin 8 
(10) The monoclonal antibody LP34 recognizes all human epitheha tested by immuno-
peroxidase on unfixed frozen sections, and by immunoblotting binds to several cytokeratin 
polypeptides of both type I (acidic) and type II (basic) groups It was raised by immunizing mice 
with human stratum corneum material (Lane et al 1985) 
B. Antibodies directed against vimentin 
(1) A polyclonal antibod} (pVIM) to bovine lens vimentin Purification and characterization of 
the polyclonal rabbit antibody have been described in detail (Ramaekers et al 1983b) 
(2) A monoclonal antibody (mVIM) directed against bovine lens vimentin, purchased from 
Euro-Diagnostics В V (Apeldoorn, The Netherlands) This antibody only stains tissues of 
mesenchymal origin, such as fibroblasts, endothelial cells, some blood vessel smooth muscle cells, 
glomeruli in the kidney, etc , but does not stain epithelial tissues In cultured bovine lens cells and 
IleLa cells the monoclonal antibody shows a filamentous staining pattern, identical to the pattern 
obtained with polyclonal antibody to vimentin In immunoblotting assays this monoclonal 
antibody gives a specific positive reaction with the vimentm band in cytoskeletal extracts from a 
human leiomyosarcoma, bovine lens (Fig 1С), and LLCMK-2 cultures 
(3) A monoclonal antibody (RV201) to bovine lens vimentin, used for immunoblotting studies 
only 
C. Л panel of antibodies directed against the neurofilament proteins 
(1) Two monoclonal antibodies BF10 and RT97 directed against different neurofilament 
polypeptides (Anderton et al 1982), were kindly provided by Dr Brian Anderton (St Georges 
Hospital Medical School, London) In immunoblotting assays BF10 was shown to react only with 
the 160x10 Λ/
Γ
 neurofilament protein, while RT97 reacted mainly with the 200x10 M, protein 
(Fig ID) Both antibodies were shown to react exclusively with neural tissues 
(2) Three polyclonal antibodies raised in rabbits after immunization with purified neuro­
filament extracts, each raised against one of the three different neurofilament polypeptides as 
described by Nakazato et al (1984) The antibody against the 68x 103M, polypeptide shows no 
cross-reactivity with the other ΝΓ polypeptides, while the antibodies directed against the 
IfiOxlO'A/r polypeptide and the 200х103Л/, polypeptide do exhibit some cross-reactivity with 
both the 200 and the 160x10^1/, proteins, respectively No staining reaction is seen with other 
than neural tissues The antibodies were kindly provided by Dr Nakazato (Maebashi, Japan) 
D . Antibodies dtiected against desmin 
(1) A rabbit antibody to chicken gizzard muscle desmin Preparation and specificity of this 
antibody have been described in detail elsewhere (Ramaekers et al 1983c) 
(2) A monoclonal antibody to chicken gizzard desmin (RD301), which showed a staining 
pattern in human, rat and chicken tissues virtually identical to that of the polyclonal desmin 
antibody In BIIK-21 cells this antibody stains a filamentous network, while cultured bovine lens 
cells, fibroblasts, IleLa cells and several other cell lines, known to contain cytokeratin and, or, 
\ imentin IF but no desmin, were negative In immunoblotting assays this antibody could be shown 
to react exclusively with the desmin protein band in cytoskeletal preparations from BIIK-21 cells or 
from a human leiomyosarcoma 
E. A rabbit antibody to glial fibrillary acidic protein (GFAP) from human spinal 
cord, as described (Ramaekers et al 1983Ъ) 
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F Other antibodies 
The mouse monoclonal antibody MOC 1 was purchased from Euro-Diagnostics В V 
(Apeldoorn, The Netherlands) and has been described as a marker for neuroendocrine differen­
tiation (de Leij et al l9S5a) 
As second antibodies in the indirect immunofluorescence technique either fluorescein isothio-
cyanate(Fn C)-conjugated goat anti rabbit immunoglobulin G (IgG) (1 25 (v/v), Nordic, 
Tilburg, The Netherlands) or FITC-conjugaled rabbit anti mouse IgG (1 25, Nordic, Tilburg, 
I he Netherlands) were used In control experiments phosphate buffered saline (PBS) was used 
instead of the primary antibody 
Immunofluorescence and tmmunoperoxidase techniques 
Indirect immunofluorescence Cell lines NCI-H23 and NCI H125 were grown on glass cover-
slips (ISmmX 18mm) in plastic Petri dishes The other cell lines, which grow as loose or tight-
floating aggregates, were spun down onto glass slides using a Cytospin centrifuge (Shandon 
Southern, 500 rev mm - 1 for 10 mm) 
In order to trace and prevent possible fixation artefacts we have tested different fixation times 
with methanol and assayed the binding capacity of monoclonal cytokeratin antibodies under these 
conditions Overnight fixation in methanol (—20°C) resulted in an almost complete loss of 
cytokeratin filament staining reaction in all cells and cell lines, when incubated with the monoclonal 
antibody RGE53, PKK1 or PKK2 Reducing fixation time to 20mm resulted in a weak fila­
mentous reaction of the adenocarcinoma cell lines and in a weak to negative reaction in the other 
cell lines To retain a good preservation of the cell shape and to prevent possible denaturation of 
cvtokeratins and other IFP upon fixation cells were routinely fixed by dipping in methanol for 5 s 
(—20°C) and acetone (3 times, 5 s), air dried and thereafter incubated with the primary antibody 
for 30-45 mm at room temperature 
After repeated washing in PBS the appropriate FITC-conjugated antiscra were applied to the 
cells After incubation for 30-45 mm the cells were washed again in PBS, and mounted in Gclvatol 
(Monsanto, USA) containing 1,4 diazobicyclo [2,2,2,] octane (DABCO, Janssen Pharmaceutica, 
Beerse, Belgium) as described before (Langanger et al 1983) Slides were viewed with a Leitz 
Dialux 20EB microscope equipped with epifluorescent illumination Pictures were taken using a 
400 ASA Tn-X film (Kodak) with an automatic camera 
Immunopeivxtdase technique In the indirect immunoperoxidase technique fixation and incu­
bation with the primary antibodies were performed in the same manner as described above for 
immunofluorescence 
Swine anti rabbit conjugated to peroxidase (DAKOpatts, Denmark) diluted 1 25 (v/v) in PBS 
containing 10% normal goat serum, or rabbit anti mouse conjugated to peroxidase (DAKOpatts, 
Denmark) diluted 1 25 (v/v) in PBS with 5 % human AB serum were used in the second step, and 
incubated for 30-45 mm 
After washing in PBS, peroxidase activity was detected with 3-amino-9-ethylcarbazole (AEC, 
Aldrich Chem Comp , USA), 40mg of AEC was dissolved in 10ml N./V-dimethylformamide 
(Merck, Darmstadt, FRG) and added to 190ml of sodium acetate buffer (0 05м, pH4 85) 
Hydrogen peroxide was added to a final concentration of 0 01 % (v/v) After incubation for 10 mm 
cells were rinsed with tap water, counterstained with haematoxyhn and mounted with Aquamount 
(Gurr, BDH chemicals Ltd, Poole, UK) 
Gel electwphorests and tmmunoblottmg assays 
Cells were harvested from 75 cm2 culture flasks, spun down using a MSE Minor centrifuge at 
1000 rev mm - 1 for 5 mm, washed once with PBS and stored at —20oC until use 
Cytoskcleton preparations were made essentially as follows after pelleting, the cells were 
rcsuspended in PBS containing 1% Triton X 100 (BDM Chemicals, Poole, UK) and 1 тм-
phenylmethylsulphonyl fluoride (PMSF, Merck, Darmstadt, FRG) and extracted for lOmin at 
0°C After centrifugation (5000^ for 10 mm) and washing in PBS the cytoskeletal preparation was 
dissolved by boiling during 5 min in sodium dodecyl sulphate (SDS) sample buffer (Laemmli, 
1970) 
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One-dimensional gel electrophnrcsis was performed in 10% Polyacrylamide slab gels containing 
0 1 % SDS, as described by Laemmh (1970). One strip of the gels was stained with Coomassie 
Brillant Dlue R250 (Gurr, Hopkin and Williams, Chadwell Heath, Essex, UK; 30min, 60oC), 
while the remaining part was used for immunoblottmg studies. 
Two-dimensional gel electrophoresis was performed essentially as described by O'Farrcll (1975). 
In the first dimension isoelectric focusing (IEF) was performed in 4% Polyacrylamide (Biorad, 
California, USA) rod gels containing 2 % amphohncs, pH 3 5-10 (LKB, Bromma, Sweden). 
For the second dimension the rod gels were applied directly onto the stacking gel of SDS-
polvacrylamidc gels and covered with a 1 % agarose solution in running buffer. 
For immunoblotting experiments the electrophoretically separated polypeptides were trans­
ferred to a nitrocellulose sheet (Schleicher and Schuil Membrane Filters, ΒΛ 85, Dassel, FRG) by 
meringhi blollingat 250 m A using an electrophoresis buffer containing 25 mM-Tris · I ICI, 192mM-
gljcinc and 20% methanol (pll 83), csscntiallv as described by Towbine/ al. (1979). The sheets 
were then exposed lo the following incubation steps at room temperature and under gentle shaking: 
(a) Preincubation (3h) with a solution containing 350mM-NaCl, 0-3% gelatin, lOmM-Tris· HCl 
(ρΙΙ7·6) and 0 5mM-PMSF. (b) Overnight incubation with the primary antibody either as 
undiluted culture supernatant or diluted in a buffer containing 150mM-NaCl, 0-3% gelatin, 
10 пім-Тпч • HCl (pH 7-6), 0· 1 тМ-PMSF, 1 % Triton X-100, 0-5 % sodium deoxycholate (Merck, 
Darmstadt, FRG) and 01 % SDS. Dilutions of the antibodies used for immunoblotting were as 
follows: RCK102, RGE53, CK18-2 and RV201 were used аз undiluted culture supernatant; 
mVIM stock solution was diluted 1:20; RT97 cultunng supernatant was diluted 1:20; anti-
68xl0M/
r
NF antibody was diluted 1:4000; anti-l60x 103M
r
NF antibody was diluted 1:6000; 
and anli-200xl03 Л/, antibody was diluted 1:4000. (c) Three washing steps in PBS containing 
Ü'5% Triton, for lOmin each, (d) Incubation for 60min with rabbit anti-mouse peroxidase 
(DAKOpatts, Denmark) or with goat anti-rabbit peroxidase (DAKOpatts, Denmark) both diluted 
1'2()() in PBS containing 0 5% Triton and 0-3% gelatin, (e) Three washing steps in PBS 
containing 0-5 % Triton, 10 mm each, (f) Detection of the peroxidase activity on the immunoblot 
using 4-chloro-l-naphthol (Merck, Darmstadt, FRG) asa substrate; 50 mg of 4-chloro-l-naphthol 
«as dissolved in 5 ml 96% ethanol, added to 95 ml PBS and stirred for 5 mm. After nitration, 
hydrogen peroxide was added to the filtrate to a final concentration of 006%. The peroxidase 
reaction was developed for 10-30 mm. (g) Rinsing of the blots with tap water for 30 mm and drying 
between sheets of filter paper. 
RESULTS 
Chaiaclerization of the cell lines 
In addition to the characteristics summarized in Table 1, the cell lines were 
investigated for the presence of the MOC-1 antigen, a cell surface antigen specific 
for SCLC and cells of neural and neuroendocrine nature. Using the indirect 
immunofluorescence technique, the MOC-1 antigen could be demonstrated to be 
present at the cell membrane in classic and variant cell lines, but not in the 
adenocarcinoma cell lines (Table 1, Fig. 2A,B). 
Itnmunojhtotescence studies with a panel of cy loket aim antibodies (Table 2, Fig. 3) 
According to their different reaction profiles in human epithelial tissues the 
monoclonal and polyclonal cytokeratin antibodies can be subdivided into five groups, 
each with a distinct pattern of staining reactions. 
(1) A group of antibodies with a broad cross-reactivity recognizing epidermal as 
well as non-epidermal epithelial cells. In general terms, these antibodies do not 
discriminate between any of the epithelial tissues. This group includes the mono-
clonal antibodies RCK102, AE1, PKKl , LP34 and the polyclonal cytokeratin 
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antibody (pKer). The classic SCLC as well as the adenocarcinoma cell lines reacted 
strongly with these antibodies (Vig. ЗА.С) while no reaction was seen in variant 
SCLC celllines (Fig. 3B). 
(2) A group of antibodies recognizing stratified squamous (keratinizing) epithelia 
only, including the monoclonal antibodies RKSE60 and AE2. RKSE60 did not react 
with any of the cell lines examined, while AE2 reacted weakly with some cells in the 
adenocarcinoma cell lines. 
(3) A group of antisera recognizing stratified squamous epithelia, but also other 
epithelia. This group includes the monoclonal antibodies PKK2 and AE3. AE3 
showed a weak reaction with the classic SCLC and a strong reaction with the 
adenocarcinoma cell lines, while PKK2 reacted positive with the classic SCLC cell 
lines and with the adenocarcinoma cell line NCI-H12S (Fig. 3D,E). No reaction was 
seen with PKK2 in NCI-H23 (not shown). 
(4) A group of antibodies reacting with simple epithelia and not with squamous 
epithelia, recognizing only cytokeratin 18 by immunoblotting analysis. This group 
includes the monoclonal antibodies RGE53, CK18-2, LE61 and LE65. These 
antibodies show a positive reaction with most classic SCLC and a strongly positive 
filamentous staining reaction with the adenocarcioma cell lines (Fig. 3F,H), but no 
significant positive reaction with the variant SCLC cell lines (Fig. 3G). 
(5) A group of antibodies recognizing cytokeratin 8 as their major or exclusive 
target, i.e. the monoclonal antibodies LE41, LP1K, LP3K and LP5K. These stain 
the classic SCLC cell lines albeit more weakly than the cytokeratin 18 antibodies 
(Fig. 31), do not stain the variant SCLC cell lines (not shown) and stain adeno­
carcinoma cell lines strongly (Fig. 3J). 
(6) An antibody to cytokeratin 19 (LP2K) whose tissue distribution appears to be 
distinct from the other cytokeratins since it occurs in most simple and in basal cells of 
stratified squamous epithelia (Lane et al. 1985). LP2K stained the adenocarcinoma 
cell line NCI-H125 strongly, the adenocarcinoma cell line NCI-H23 in part of the 
Fig. 2. Reaction pattern of MOC-1, a membrane surface antigen monoclonal antibody, 
specific for neuroendocrine cells and neural dérivâtes, with a classic (NCI-H69; A, X400) 
and a variant (NCI-H82; В, X400) SCLC cell line in immunofluorescence. Note the 
characteristic staining pattern of the cell membranes with this antibody. 
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Table 2. Intermediate filament expresston in human lung cancer cell lines as 
detected by immunocytochenncal techniques 
Cytokeratins 
RCK102 
AE1 
PKK1 
LP34 
pKer 
RKSE60 
ΑΠ2 
AE3 
PKK2 
RGES3 
CK18-2 
LE61 
LE6S 
I.E41 
LP1K 
LP3K 
LP5K 
LP2K 
Neurofil 
RT97 
BF10 
p68kD 
pl60kD 
p200kD 
Vimentin 
pVim 
mVim 
Desmin 
pDcs 
RD301 
GFAP 
Adenocarcinoma 
NCI 
H-23 
+ 
Some с 
+ 
+ 
+ 
-
Some с 
+ 
-
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
-
-
-
— 
-
+ + 
+ + 
— 
-
— 
NCI 
H-125 
+ + 
+ + 
+ + 
+ + 
+ + 
— 
Some с 
+ 
+ + 
+ + 
+ + 
+ + 
+ + 
+ + 
+ + 
+ + 
+ + 
+ + 
-
-
-
— 
-
+ 
+ 
— 
-
— 
CI 
NCI 
H-69 
+ 
+ 
+ + 
+ 
+ + 
-
-
+ 
+ 
+ 
+ 
+ 
+ 
-
Some c. 
+ 
+ 
Some с 
-
-
-
— 
-
-
-
— 
-
— 
lassie SCLC 
NCI 
11-128 
+ 
+ + 
+ 
Some с 
+ + 
-
-
-
+ 
+ + 
+ + 
+ 
Some c. 
-
-
Some c. 
-
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cells, and the classic SCLC cell lines variably, while the variant SCLC cell lines were 
all negative (not shown). 
Immunofluorescence studies with a panel of neurofilament antibodies (Table 2, 
Fig. 4) 
The adenocarcinoma and classic SCLC cell lines do not show a significant reaction 
with any of the monoclonal or polyclonal antibodies to neurofilaments. A similar 
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observation is made with the variant SCLC cell line NCI-N417. However, the 
variant SCLC cell line NCI-HS24 shows clearly positive staining reaction in a 
number of cells with the monoclonal antibody BF10 (Fig. 4A), while some cells of 
NCI-H82 showed a weak reaction with this antibody (not shown). Most cells of 
NCI-H82 show a staining reaction with RT97 (Fig. 4B), although background 
staining is relatively high; no reaction is seen in NCI-H524 with this antibody (not 
shown). 
Using the polyclonal neurofilament antibodies a strong filamentous staining re­
action is observed with the anti-68x 103M
r
 and the anti-160x 103Λί
Γ
 antibody in 
virtually all cells of the cell lines NCI-H82 and NCI-HS24 (Fig. 4C,D,F ) G). Using 
the polyclonal antibody to the 200xlO3A/
r
 neurofilament protein a positive reaction 
is seen in NCI-H82 (Fig 4E). In NCI-HS24 (Fig. 4H) a very weak to negative 
staining reaction is seen. Taking into account the relatively high background of this 
antiserum one might consider this to be a negative reaction. 
Other intermedíate filament antibodies (Table 2, Fig. 5) 
The classic SCLC cell lines exhibited a very weak to negative reaction with the 
vimentin antibodies (Fig. SA). In the variant SCLC cell lines only a fraction of the 
cells gave a positive reaction for vimentin (Fig SB). Both adenocarcinoma cell lines 
are positive for the antibodies to vimentin, with a much stronger positive reaction in 
NCI-H23 (Fig SC) than in NCI-H125. No difference was observed between the 
immunofluorescence staining patterns of the polyclonal and the monoclonal anti-
bodies to vimentin In general, no significant reaction can be found in cells growing 
in floating tight aggregates, while few cells seem to express vimentin when growing in 
floating loose clusters. Cells growing as a monolayer or attached to the bottom of the 
Petri dish exhibit a stronger vimentin staining with more pronounced filamentous 
arrangements. No reaction was found in any of the cell lines tested with the 
antibodies to desmin or GFAP. 
The results obtained by the indirect immunofluorescence technique with the 
antibodies described above could be confirmed using the peroxidase technique 
(results not shown). In some cases, however, some differences in intensity between 
the two methods were noticed. For example, the intensity of the staining reaction 
with monoclonal antibody CK 18-2 was clearly stronger when assayed by the per-
oxidase technique than by the immunofluorescence technique. 
Gel electmphoietic identification of IF polypeptides 
The results of the one-dimensional gel electrophoretic separations of cytoskeletal 
proteins from lung cancer cell lines are shown in Fig. 6. In all cell lines the 
microfilament protein actin is demonstrable (denoted as a; 42X 103Λ/
Γ
), while in cell 
line NCI-H23 a distinct protein band at the vimentin position can be seen (denoted 
as 7'; S7xl03iV/
r
; Fig 6, lane B,E), which cannot be seen in the other adeno­
carcinoma cell line NCI-H125 (Fig. 6, lane C) or in the classic SCLC cell line 
patterns (compare Fig. 6, lanes E,F). In the variant cell lines only a very faint 
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protein band migrating at the position of vimentin is observed in the one-dimensional 
gels (not shown). 
In two-dimensional gel electrophoretic patterns all three classic SCLC cell lines 
can be shown to contain proteins migrating at positions of cytokeratins 7, 8, 18 and 
19 albeit in minor amounts (Fig. 7A,B,C). In the three variant SCLC cell lines no 
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cvtokeratms could be demonstrated using this technique (Fig. YD.E.F), neither 
after silver staining procedures nor after heavily overloading the gels (not shown). 
The adenocarcinoma cell line NCI-H23 could be shown to contain at least cyto-
keratins 7, 8 and 18, next to vimentin with its characteristic degradation products 
(Fig. 7H). The adenocarcinoma cell line NCI-H125 contains also cytokeratin 19 
next to cytokeratins 7, 8 and 18. Vimentin is present only in a minute amount in this 
cell line (Fig. 7G). 
Both classic and variant SCLC cell lines contain two characteristic protein spots 
migrating close to vimentin in two-dimensional gels (ρΗ5·3, 55-57 (Xl0 3 )M
r
) . 
Comigration of cytoskeletal preparations from NCI-H23 and NCI-H449 showed 
that the two protein spots of the classic SCLC cell line NCI-H449 (55-57 (X 10J)Af
r
) 
migrate to the same position as vimentin (Fig. 71). Immunoblotting experiments 
(see below) using both one- and two-dimensional gels, however, failed to reveal 
significant amounts of vimentin in cytoskeletal preparations of these cells, indicating 
that these protein spots are not vimentin. Another indication is that no typical 
vimentin breakdown products are seen (compare Fig. 7 D - F with H). 
Immunoblotting experiments 
The results obtained with the immunocytochemical and gel electrophoretic tech­
niques could be confirmed using one- and two-dimensional immunoblotting. The 
presence of cytokeratin 18 could clearly be demonstrated in one-dimensional blots of 
the adenocarcinoma cell line NCI-H125 using the monoclonal antibodies RGE53 
and CK18-2 (Fig. 8A, lane 1). In the other adenocarcinoma cell line NCI-H23 and 
in the classic SCLC cell lines this protein could only be detected when heavily 
overloaded gels were used, indicating that cytokeratin 18 is present in only small 
amounts in these cell lines (Fig. 8A, lanes 2-5). In all cases the variant SCLC cell 
lines were negative in immunoblotting with the cytokeratin antibodies, and when 
heavily overloaded gels were used. 
In immunoblotting assays with the monoclonal antibodies to vimentin (RV201 and 
mVIM) only the adenocarcinoma cell line NCI-H23 exhibited a strong staining 
Fig. 3. Indirect inimunoiluorescence staining patterns of classic SCLC, variant SCLC 
and andenocarcinoma cell lines incubated with various antibodies to cytokeratins. 
Л.В.С. Reaction pattern of antibodies recognizing all types of epithelia. Note the positive 
reaction of the classic SCLC cell line NCI-H449 with PKK1 (Л, X350), the absence of 
staining in the variant SCLC cell line NCI-H524 with pKer (Η, X350) and the strong 
filamentous staining pattern in the adenocarcinoma cell line NCI-II23 with the pKer 
antibody (C, X27S). D,E. Reaction patterns with antibodies directed against stratified 
squamous epithelia. Note the weak reaction of the classic SCLC cell line NCI-H449 with 
PKK2 (D, X375) and the strong filamentous staining of the adenocarcinoma cell line 
NCI-H125 also with VKK2(E, X45Ü). F,G,H. Reaction patterns of anlibodies directed 
against cvtokeratin 18. Note the strong reaction of RGE53 with the classic SCLC cell line 
NCI-1I449 (F, X2S0), the absence of filament staining in the variant SCLC cell line 
NCI-N417 with RGES3 (G, x250), and the very strong reaction of the adenocarcinoma 
cell line NCI-IUZS wilh RGES3 (И, X200). I,J. Reaction pattern of antibodies with 
cjtokcratm 8 as their main antigen. Noie the positive reaction of LP5K with ihe classic 
SCLC cell hue NCI-H69 (I, X300) and the strong filamentous staining pattern of the 
adenocarcinoma cell line NCI-H125 also with LP5K (J, X2S0). 
91 
J. L. V. Broers and others 
reaction (Fig. 8B, lane 1, RV 2 0 1 ; lane 2 m V I M ) while in the other cell lines the 
a m o u n t s of vimentin were apparently too low to be detected (Fig. 8B, lanes 3-6) . 
Using the polyclonal antibodies to the three neurofilament polypeptides both the 
6 8 x l 0 3 A /
r
 neurofilament protein and the ІбОхІО^Л/,. neurofilament polypeptide 
could be demonstrated in the variant S C L C cell lines N C I - H 8 2 and N C I - H 5 2 4 
Fig. 4. Indirect immunofluorescence staining patterns of monoclonal and polyclonal 
antibodies to neurofilament proteins in variant SCLC cell lines. Λ,Β. Reaction pattern 
with the monoclonal antibody BFIO in NCI-HS24 and RT97 in NC1-H82, respectively. 
Note the strong positive reaction in some cells of NCI-HS24 with BF10 (A, X240) and 
the positive reaction with RT97 in NCI-H82 (В, X240), which does, however, perform a 
higher background staining than BF10. C,F. Reaction pattern of the polyclonal anti-
бЗхЮ'Л/, neurofilament antibody in NCI-H82 (C, X240) and NCI-H524 (F, X240). 
D,G. Reaction pattern of the polyclonal anti-160x 103Л/
Г
 neurofilament antibody in 
NCI-H82(D, x240)andNCI-HS24(G, X240). E,H. Reaction pattern of the polyclonal 
аті-200х103Л/
г
 neurofilament antibody with NCI-H82 (E, X240) and NCI-HS24 
(H, X300). Note the strong specific staining in NCI-H82 and the absence of a 
filamentous staining pattern in NCI-HS24, although some diffuse (background) staining 
is observed. 
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Fig. 5. Indirect immunofluorescence staining reaction of the vimentin antibody pVIM 
with the classic SCLC cell line NCI-H449 (A, X225), the variant SCLC cell line NCI-
H524 (B, X425) and the adenocarcinoma cell line NCI-H23 (C, x27S). Note the absence 
of filamentous staining in the classic SCLC cell line, the presence of some vimentin 
filaments in the variant SCLC cell line and the well-developed filament pattern in the 
adenocarcinoma cell line. 
A B C 
Mr 
x10 
D E F 
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f i ; 
. 
Fig. 6. One-dimensional SDS-polyacrylamide gel electrophoretic patterns of cytoskel-
etal preparations from the two adenocarcinoma cell lines NCI-H23 (lanes B,E) and NCI-
И125 (lane C), and from the classic SCLC cell line NCI-HI28 (lane F). Lanes A,D 
contain marker proteins as indicated. V and a indicate the positions of vimentin and actin, 
respectively. Note the presence of large amounts of vimentin in NCI-H23 and the 
absence of vimentin bands in NCI-H12S and NCI-H128. 
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(Fig. 8C,D). Two-dimensional immunoblolting experiments with the neurofil­
ament antibodies anti-68x 101Λ/
Γ
 and anti-160x 103Л/
Г
 showed the acidic nature of 
these proteins (Fig. 9А,Щ. No reaction could be seen with the neurofilament 
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Fig. 7. Details of two-dimensional gel clcctrophoretic patterns of cytoskeletal prep­
arations from the classic SCLC cell lines (A,B,C), the variant S C L C cell lines (D.E,!·'') 
ami the adenocarcinoma cell lines (G,H). The different cytokeratin polypeptides are 
indicated bv italic numerals corresponding to the cytokeratin nomenclature as proposed 
by M o l i c i ni (1982). ν and a indicate vimentm and actin, respectively, while the bracket 
embraces the typical degradation products of vimentm. I. Comigration of NCI-H23 and 
NCI-H449 cytoskeletal preparations. 
94 
Intermediate filaments in SCLC cell lines 
antibodies described above in either one- or two-dimensional immunoblotting with 
other than the variant SCLC cell lines (not shown). 
DISCUSSION 
In this study we have examined the IFPs in classic and variant SCLC cell lines 
using immuno(cyto)chemical and gel electrophoretic techniques. The results show 
A B СП 
.m 
ì["^y,~.i 
1 2 3 4 5 I 2 3 4 5 6 1 2 3 1 2 3 
Fig 8 One dimensional immunoblotting data with cytoskeletal extracts from lung 
cancer cell lines using different intermediate filament antibodies A Monoclonal antibody 
CK18-2 reacting strongly with cytokeratm 18 from adenocarcinoma cell line NCI 11125 
(lane 1), but weaker with the adenocarcinoma cell line NCI H23 (lane 2) and the three 
classic SCLC cell lines (NCI 1169, lane 3, NCI H128, lane 4, NCI-II449, lane 5) 
D Monoclonal vimentin antibody RV201 with the adenocarcinoma cell line NCI 1123 
(lane I), and monoclonal antibody m VIM with NCI II23 (lane 2), the adenocarcinoma 
cell line NCI-H12S (lane 4), NCI 11128 (lane 5) and NCI H449 (Lane 6) Note the 
posili\ e reaction of R V201 and m VΙM with vimentin and Us typical degradation products 
in NCI II23 (lanes 1, 2) No reaction is found in the other adenocarcinoma cell line NCI-
II125 (lane 3), or m the classic SCLC cell lines (lanes 4-6) С Polyclonal anti-68x 103Л/
Г 
neurofilament protein with the variant SCLC cell lines NCI-N417 (lane 1), NCI-H82 
(lane 2) and NCI-II524 (lane 3) Note the reaction at the 68x 103Л/
Г
 level in lanes 2 and 3 
D Polyclonal апіі-ІбОхІС^М, neurofilament protein with the three variant SCLC cell 
lines NCI-N417 (lane 1), NCI-H82 (lane 2) and NCI-H524 (lane 3) Note the strong 
reaction at the 160x 103MT level (top) 
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В 
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Fig 9 Two-dimensional immunoblotting of cytoqkeletal preparations from NCI-II82 
(A) and NCI 11524 (B) will) the polyclonal neurofilament antibodies against the 68 and 
the 160xl03;W
r
 polypeptides incubated subsequently on the same immunoblots Note 
the positive staining reaction with spots at the 68 and 160xl03A/
r
 levels 
that these cell types differ in IFP content, insofar as classic SCLC contain 
cytokeratins and variant SCLC contain neurofilaments and, or, vimentm. 
Small cell lung cancer is an aggressive type of lung tumour with a bad prognosis 
(5-10% survival rates; Minna et al 1982) due to early and widespread metastasis 
and rapid progession of the disease. It occurs in about 20-25 % of all cases of primary 
lung cancer (Minna et al 1982). Unlike most other forms of lung cancer, SCLC is at 
first sensitive to chemotherapy and, or, radiotherapy, in some cases resulting in an 
almost complete response. Unfortunately, during therapy most tumours become 
resistant to further treatment and patients die within 8-10 months after discovery of 
the disease Amongst the patients with SCLC those with a 'mixed' SC/LC tumour 
have a lower response rate and a shorter survival period upon cytotoxic therapy 
(Hirsch et al 1983; Radice et al 1982; Vollmer eí al. 1985). It is striking to notice 
that tins mixed type of SCLC, which occurs in 6-15 % of all SCLC at first diagnosis 
(Gazdar et al 1981 ; Hirsch et al 1983; Radice et al. 1982), is seen more frequently 
(up to 35%) after treatment with combined chemotherapy (Abeloff étal. 1979; 
Gazdar et al. 1981). Therefore, early histopalhological subtyping of classic SCLC 
and variant SCLC (the mixed SC/LC carcinoma) is of prognostic significance. 
The origin of classic and variant SCLC is yet unclear. Since Bensch et al. (1968) 
demonstrated the presence of neurosecretory granules in oat-cell carcinoma and 
suggested a neuroendocrine origin for this type of tumour, many authors have 
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demonstrated other neuroendocrine characteristics in these neoplasms (for a review, 
see Gould et al 1983). On the other hand, however, other authors have suggested an 
epithelial origin for SCLC (Gazdareta/. 1981; McDowell & Trump, 1983; Sidhu, 
1979). Even the derivation of SCLC from haemopoietic stem cells has recently been 
proposed (Ruff & Pert, 1984) 
Intermediate filaments consist of tissue-specific proteins (Osborn & Weber, 1982, 
1983), which can be used to study the origin of cells and tissues. In general, 
neoplasms derived from certain tissues retain their IF characteristics, e.g. car­
cinomas express cytokeratins, sarcomas express vimentin or desmin, malignant 
gliomas contain glial fibrillary acidic protein (GFAP) and tumours derived from 
neural tissues can express neurofilaments. Conflicting results have been obtained 
using antiscra to IFP on solid SCLC. Several authors have been able to demonstrate 
the presence of cytokeratins in SCLC, albeit in some instances in only a minor 
proportion of the cases examined (Altmannsbcrger et al 1984; Bernal et al. 1983; 
Blobel et al 1985; Broers et al. 1985я,о; Gusterson et al. 1982; van Muijen et al. 
1984; Schlegel et al 1980) while others (Lehto et al. 1983, 1984; Nagle et al. 1983) 
could not demonstrate cytokeratins at all. Lehto et al. (1983, 1984) have shown a 
positive staining reaction in SCLC and carcinoids with a neurofilament antiserum 
but not with cytokeratin antisera Bergh et al (1984) have demonstrated only 
neurofilaments and not cytokeratins in cultured SCLC cell lines. Banks-Schlegel 
et al (1985) have suggested that SCLC cell lines contain both cytokeratins and 
neurofilaments These apparent discrepancies in the literature may be explained by 
our recent findings (Broers et al 1985α), and those described here. The main reason 
that \\c have used such a large panel of monoclonal and polyclonal antibodies to IFP 
on well-characterized cell lines was to exclude false negative or false positive 
reactions False negative results with cytokeratin antibodies may occur as a result of 
lack of cross-reactivity of a certain antibody with some specific cytokeratin poly­
peptides. It is well known that some antisera to skin keratins do not cross-react with 
epithelial tissues of certain internal organs, although these tissues are known to 
contain cytokeratins as detected by biochemical methods (Krepier et al. 1980). 
Furthermore, antigenic determinants recognized by specific monoclonal antibodies 
may be masked under certain conditions {Franke et al. 1983). False negative results 
may also occur as a result of tissue or cell-fixation. For example, the negative results 
of Bergli et al (1984) in several methanol-fixed SCLC cell lines with antibodies 
PKK1 and PKK.2 can be explained by our findings that a considerable decrease or a 
total loss of cytokeratin reactivity in the classic SCLC cell lines occurs when these 
cells are treated with methanol for longer than a few minutes (see Materials and 
Methods) Fixation procedures should therefore be tested extensively before draw­
ing any conclusions with respect to negative reaction patterns with monoclonal 
antibodies. This is especially true for cells that contain low amounts only of a certain 
antigen As can be concluded from our immunoblolting experiments and two-
dimensional gel electrophorctic data, the concentration of cytokeratins in the classic 
SCLC cell lines is low Therefore, false negative results with these cell lines in 
immunofluorescence and immunoblolting assays are likely to occur. 
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We conclude from our studies with the large panel of antibodies to cytokeratins 
that the negative results with the variant SCLC cell lines in both immunoperoxidase 
and immunofluorescence indicate the complete absence of cytokeratins in these cell 
lines. Furthermore, this conclusion is supported by our two-dimensional gel electro-
phoretic data and our immunoblotting experiments. 
The cytokeratin polypeptide patterns detected biochemically in the classic SCLC 
cell lines correspond relatively well to the cytokeratins found in solid SCLC by 
Blobel et al. (1985). As well as cytokeratins 7, 8 and 18 varying amounts of 
cytokeratin 19 are found. The presence of cytokeratins 8, 18 and 19 is also con­
firmed by the immunocytochemistry with monospecific antibodies. Discrepancies, 
such as that observed with LP2K (an antibody specifically directed against cyto­
keratin 19) staining NCI-H23 in some cells, while cytokeratin 19 was not de­
tected on two-dimensional gels, indicate the greater discriminating powers of 
immunocytochemistry. 
The positive reaction of some, but not all, variant SCLC cell lines with the N F 
antibodies points to a relation between at least some of the variant SCLC and neural 
cells. Whether this is caused by a neural origin or a neural differentiation is not clear. 
The fact that not all three N F proteins seem to be expressed in all NF-positive 
variant SCLC cell lines is an interesting phenomenon that deserves further eluci­
dation. Also in the case of neurofilaments one should keep in mind that false negative 
results may occur because of masking, fixation and lack of cross-reactivity. The 
finding that monoclonal antibodies to neurofilaments react weaker and with less-
variant SCLC cells than the polyclonal neurofilament antibodies may be explained 
by the fact, described by Goldstein et al. (1983) and Sternberger & Sternberger 
(1983), that such monoclonal antibodies may recognize specifically phosphorylated 
neurofilament proteins. Future studies will have to show whether or not neuro­
endocrine tumours, including variant SCLC and Merkel cell tumours (Gould et al. 
1985; van Muijen et al. 1985), regulate their NF protein expression in a different 
way from neural tissues. The fact that both classic and variant SCLC cell lines 
express the MOC-1 antigen, a membrane marker also present in neural tissues, 
suggests a close relationship between these cell types, at least with respect to cell 
surface proteins. Furthermore, the fact that neurone-specific enolase and the MOC-1 
antigen are found in classic SCLC cell lines illustrates that co-expression of epithelial 
markers (cytokeratins) and neural markers may occur (see also Blobel et al. 1985). 
The suggestion that SCLC might be derived from stem cells of the haemopoietic 
system (Ruff & Pert, 1984) cannot be supported by our results. We have shown 
SCLC cell lines to contain cytokeratins or neurofilaments, intermediate filaments 
that do not occur in human cells of haemopoietic origin. The significance of the 
presence of vimenlin in variant cell lines has been discussed before (Broers el al. 
1985я). Taking together the suggestion that variant SCLC might originate from 
classic SCLC (Carney et al. 1985) with the fact that some variant SCLC cell lines 
have been found to be NF-negative and cytokeratin-negative, and the recent findings 
that solid SCLCs contain cytokeratins and not neurofilaments in most cases (Blobel 
et al. 1985; Broers et al. 1985α; van Muijen et al. 1984) strongly suggests that NF-
Intermediate filaments in SCLC ceil lines 
containing SCLC cells originate from cytokeratin-containing SCLC cells possibly 
via an undifferentiated cell type containing no intermediate filaments or via a cell 
tvpe containing both cytokeratins and neurofilaments. The hypothetical model that 
we propose for the interrelationship between these lung cancers starts with a stem cell 
that contains cytokeratin IF only. Such a cell would be multipotential, so that it 
could differentiate into neuroendocrine as well as into true epithelial progenitor cells. 
The neuroendocrine progenitor cell may then give rise to classic SCLC and 
carcinoids, while the epithelial progenitor cells may give rise to pulmonary adeno­
carcinomas and squamous cell carcinomas. Such a capacity of multidirectional 
differentiation may also explain the emerging body of evidence that lung cancers 
cover a spectrum of differentiated stages that are interchangeable and subject to 
various environmental influences, including therapy (Abeloff et al. 1979). 
In summary, the results described here provide further proof for the presence of 
cytokeratins in classic SCLC cell lines, suggesting an epithelial character for these 
cells, the absence of cytokeratins m all variant SCLC cell lines and the presence of 
neurofilaments in some variant SCLC cell lines, suggesting a neural character for 
these cells. The distinction between these two types of neuroendocrine cells within 
solid SCLC using intermediate filament antibodies may become of clinicopatho-
logical significance in view of the differences in prognosis and treatment of classic and 
variant SCLC. 
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Note added tn proof 
Recently we have developed a monoclonal antibody directed against cytokcratin 7 (RCK105). 
Tins antibody docs not react «uh the classic SCLC cell lines, although in two-dimensional gels a 
protein spot migrating at the M, and isoelectric pi I level of cytokcratin 7 could be demonstrated 
(sec Fig 7A-C) The adenocarcinoma cell lines, on the other hand, give a strong filamentous 
staining pattern with this antibody Future studies will have to elucidate the molecular basis of this 
discrepane) between immunocytochemistry and the gel electrophoretic analyses. 
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SUMMARY 
The usefulness of cell lines in the study and prediction of the 
clinical behaviour of lung cancer is still a matter of debate. However, 
lung tumour cell cultures have been of value in investigations concerning 
molecular and cell biological aspects of these neoplasms. Especially in 
the examination of characteristics specific for the main types of 
differentiation (squamous cell carcinoma, adenocarcinoma, small cell 
carcinoma), in vitro studies have been most important. 
Twenty eight lung cancer cell lines were cultured for up to four 
years, and were examined at regular intervals for their intermediate 
filament protein (IFF) expression patterns using a panel of cytokeratin 
(CK) and neurofilament (NF) antibodies. These studies showed that the 
classic type of small cell lung cancer (SCLC) cell lines contain CKs 8, 18, 
and occasionally CK 19, while the variant-type SCLC cell lines generally 
express no CKs but can contain NFs. Non-SCLC cell lines, such as squamous 
cell carcinoma and adenocarcinoma cell lines contain CKs 7 (in most cases), 
8, 18 and 19. In one variant SCLC cell line and in one adenocarcinoma cell 
line CKs 4, 10 and 13, characteristic of squamous cell differentiation, 
vere found. Although most cell lines have remained stable with respect to 
growth characteristics and IFP expression patterns, five lung cancer 
cultures exhibited a transition from one cell type to another, paralleled 
by changes in IFP expression. Progressions from classic to variant SCLC 
cell lines have been observed, next to conversions from variant SCLC to 
cell lines re-expressing cytokeratins. In some cases this resulted in a 
coexpression of CKs and NFs within a cell line and even within individual 
tumour cells. These results strongly support the earlier finding that CK 
expression in SCLC cell lines is a reliable marker for the classic type of 
differentiation, while the absence of CKs and the presence of NFs marks the 
variant type of differentiation. Our results are discussed in view of 
previous histological findings. 
INTRODUCTION 
Intermediate filament proteins (IFPs) are cytoskeletal components, 
which are expressed in a more or less tissue-specific fashion and are, in 
most cases, retained during neoplasia (Osborn & Weber, 1983; Ramaekers et 
al. 1983a, 1987c). In general, only one type of intermediate filament 
protein is expressed in a certain tissue or tumour. For instance, 
epithelial cells and carcinomas normally express only IFPs of the 
cytokeratin (CK) type (e.g., Ramaekers et al. 1983b), while neuronal cells 
and some neuronal tumours express only neurofilament (NF) proteins 
(Altmannsberger et al. 1984). In normal tissues, vimentin is in general 
found only in mesenchymal tissues. 
However, in the last few years a growing number of cases has been 
reported, in which a coexpression of two or even three types of IFPs within 
the same type of (tumour) cells was demonstrated. Most frequently, if 
coexpression occurs, vimentin is one of the IFPs present. Expression of 
vimentin next to CK has been found in some normal epithelial cells, such as 
human mesothelium and epithelia from ovarium, amnion, endometrium, thyroid 
gland and foetal kidney (Moll et al. 1983; Holthöfer et al. 1984; LaRocca 
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Si Rheinwald, 1984; Rheinwald et al. 1984; Czernobilsky et al. 1985; 
Regauer et al. 1985; Achtstätter et al. 1986). Also, in some types of 
primary carcinomas coexpression of CKs and vlmentin is seen (Caselitz et 
al. 1981, 1984; Herman et al. 1983; Churg 1985; Blobel et al. 1985b; 
Gould, 1985; Jasani et al. 1985; Upton et al. 1986), and this 
coexpression may also be seen in metastatic carcinoma cells in body cavity 
fluids (Ramaekers et al. 1983c). In carcinoma-derived cell lines the 
presence of vimentin is a rule rather than an exception (cf. Franke et al. 
1979; Broers et al. 1985). Vimentin is expressed next to desmin in muscle 
cell tumours (Molenaar et al. 1985). 
More recently, coexpression of other types of intermediate filaments 
has been reported. For instance, Brown et al. (1987), Norton et al. 
(1987), van Muljen et al. (1987) and Ramaekers et al. (1988) reported on 
the coexpression of CKs and desmin in human foetal and adult muscle tissue, 
and in smooth muscle tumours. Kasper et al. (1986) shoved the coexistence 
of CK, vimentin and NF protein in human choroid plexus, while Budka (1986) 
demonstrated a triple expression of glial fibrillary acidic protein, 
vimentin and CKs in papillary meningioma and renal carcinoma. Gatter et 
al. (1986) showed a double and triple expression of different IFF in many 
lung carcinomas. Coexpression of CKs and NFs seems to be characteristic of 
some neuroendocrine tumours, such as neuroendocrine skin carcinomas (Merkel 
cell tumours; van Muijen et al. 1985; Gould et al. 1985; Moll et al. 
1986) in parathyroid tumours (Miettinen et al. 1985), in lung carcinoids 
(Lehto et al. 1985; Blobel et al. 1985a; Broers et al. 1987; Ramaekers 
et al. 1987b), in some small cell lung cancers (SCLCs; Gatter et al. 
1986; Broers et al. 1987) and (poorly differentiated) squamous cell 
carcinomas (SQCs) of the lung (van Muijen et al. 1984; Broers et al. 
1987). Also in a celi culture of a large cell carcinoma of the lung (Bergh 
et al. 1984), in a neuroendocrine skin carcinoma cell line (Rosen et al. 
1987), in the neuroendocrine rat cell line PC12 (Franke et al. 1986) and 
in some SCLC cell lines (Bernal et al. 1983; Banks-Schlegel et al. 1985; 
Gupta et al. 1986) coexpression of CKs and NFs has been reported. 
The three major types of lung cancer comprise SCLC, adenocarcinoma 
(AC) and SQC (W.H.O. 1982). In addition, according to the latest IASLC 
classification, SCLC can be subdivided into classic SCLC, variant SCLC and 
combined SCLC (Yesner, 1985). It is now generally accepted that lung 
cancer is an extremely heterogeneous type of malignancy. On the basis of 
detailed histological (Roggli et al. 1985), immunohistochemical (Hammar et 
al. 1985; Dunnill & Gatter, 1986; Broers et al. 1987, 1988) and 
electron-microscopic (McDowell & Trump, 1981; Trump et al. 1982; Dingeraans 
& Mooi 1984; Mooi et al. 1988) studies, more than one type of 
differentiation can be detected in the majority of lung cancers. 
Occasionally more than one type of differentiation can be detected in cell 
lines, for example in the so-called multipotent lung tumour cell cultures 
(Carney et al. 1984; de Leij et al. 1985). Cloned cells of these cell 
lines are apparently able to differentiate again into the three major types 
of lung cancer within the same culture. In addition, sometimes a 
conversion of one cell type to another has been noticed. For example, 
progressions of classic SCLC cell lines into the variant type of SCLC cell 
line have been described (Bepler et al. 1987b, Carney et al. 1984, 
1985a,b; Gazdar et al. 1981, 1985; Graziano et al. 1987). Bepler et al. 
(1987c, 1988a) described a transitional type of SCLC with features between 
the classic and variant types. 
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Previous investigations in our laboratory on the intermediate filament 
expression of classic and variant SCLC cell lines have demonstrated the 
occurrence of CKs only in classic SCLC cell lines, while in variant SCLC 
cell lines no IFPs or only NFs could be demonstrated (Broers et al. 1985, 
1986). In recent years, cell lines in which a morphological change from 
one cell type to another could be seen were examined for their IFF 
expression patterns. 
Since different CK polypeptides are expresssed in different types of 
lung cancer (cf. Blobel et al. 198A, 1985a; Broers et al. 1988), we paid 
special attention to the CK polypeptide expression of these cell lines. 
Using a panel of monoclonal CK antibodies, most of which are specific for 
one CK polypeptide, it is possible to detect SQC differentiation, AC 
differentiation and SCLC differentiation at the cellular level (Broers et 
al. 1988). 
In this paper we describe spontaneous changes in intermediate filament 
patterns that can occur in lung cancer cell lines, especially in SCLC cell 
lines. In part, these alterations follow the phenotypic changes in the 
tumour cells, and may be correlated with recent data obtained with lung 
tumour tissues. 
MATERIALS AND METHODS 
CELL LINES. 
Establishment and characterization of the cell lines used in this 
study have been described (Carney et al. 1985a,b; de Leij et al. 1985; 
Gazdar et al. 1985; Bepler et al. 1987a,b, 1988b) or will be described 
elsewhere. In all, 19 SCLC cell lines were Investigated (NCI-H69, 
NCI-H128, NCI-H4A9, NCI-N417, NCI-H524 and NCI-H82; GLC1-M13, GLC-1, GLC-2, 
GLC-3, and GLC-5; SCLC-16HC, SCLC-16HV, SCLC-21H, SCLC-22H, SCLC-24H and 
SCLC-86M1; NL-SCLC2 and NL-SCLC3). Next to these, one LCLC cell line 
(LCLC-103H), six AC cell lines, (NCI-H23, NCI-H125, GLC-A1, GLC-A2, GLC-A3, 
NL-AC1) and two epithelial cell lines derived from SQCs (EPLC-32M1 and 
EPLC-65M2) were used. 
All cell lines were maintained in a humidified incubator at 370C in 5% 
C02 and were grown in Roswell Park Memorial Institute Medium 16A0 
(RPMI-1640, Flow, Irvine, UK) containing Hepes, supplemented with 15X 
newborn calf serum (Flow). At regular intervals cells were passaged by 
splitting cells 1:2 to 1:3. If cells tended to attach to the culture 
flasks, the adhering cells were selected by removing the floating cells. 
As a result sublines NCI-N417-A1, NCI-NA17-A2, NCI-H524-A and NCI-H82-A 
were obtained. 
INDIRECT IMMUNOFLUORESCENCE TECHNIQUE. 
The procedures for the application of the indirect immunofluorescence 
technique have been described (Broers et al. 1986). In brief, floating 
cells were placed on glass slides using a Cytospin centrifuge (500 revs 
min-1 for 10 min; Shandon Southern Instruments, Astmoor, Cheshire, UK), 
while cells growing attached to the culture flasks were treated with 0.05% 
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trypsin/0.02X EDTA in 0.05 M phosphate buffered saline (PBS) pH 7.4, and 
allowed to grow on glass coverslips for 1-2 days. In the first step, cells 
were incubated with the primary antibody (see below) for 30-45 min. 
As second antibody either fluorescein isothiocyanate (FITC)-conjugated 
rabbit anti-mouse IgG (1:25, Nordic, Tilburg, The Netherlands) or 
FITC-conjugated goat anti-rabbit IgG (1:25, Nordic) was applied to the 
cells for 30-45 min. 
In the double-label immunofluorescence technique a mixture of two 
primary antibodies (one raised in mouse and one in rabbit) was applied in 
the first step. Cells were Incubated for 30-45 min and, after washing with 
PBS, a mixture of FITC-conjugated goat anti-rabbit IgG and Texas 
Red-conjugated sheep F(ab')2 anti mouse IgG (Amersham, Little Chalfont, 
Bucks, UK)) with final dilutions of 1:25 and 1:50, respectively, was added. 
Cells were incubated for 30-45 min, and washed again. DNA was then stained 
by incubating the cells for 15 min with Hoechst 33258 (0.1 ug-ml-1 in 22 
mM-citric acid, 56 mM-disodium hydrogen phosphate). After washing with PBS 
the cells were mounted as described above. Pictures were taken with an 
automatic camera as described above, with either a 400 ASA Tri-X film 
(Kodak) or with a 400 ASA Ektachrome film (Kodak) for triple exposures at 
three different wavelengths. Overlap between the FITC and Texas Red 
fluorescence at the respective wavelengths was checked using preparations 
labelled with a single second antibody. Incubations with the second 
antibodies alone were used as negative controls. 
ANTIBODIES. 
Specificity and references of the primary antibodies used in this 
study are summarized in Table 1. The following primary antibodies were 
used. 
A) Mouse monoclonal CK antibodies (undiluted). 
1. RCK102 is a broadly cross-reacting CK antibody of the IgGl subclass, 
which recognizes CKs 5 and 8, and as a result stains virtually all 
epithelial tissues (Ramaekers et al. 1987a). 
2. RCK105 (IgGl; Ramaekers et al. 1987a) reacts only with CK 7 in 
immunoblotting and stains a subgroup of glandular epithelia and their 
tumours, next to transitional bladder epithelium and bladder carcinomas. 
3. RGE53 (IgGl; Ramaekers et al. 1983d, 1985) and RCK106 (IgGl; Ramaekers 
et al. 1987a) are monospecific for CK 18 in immunoblotting. In general 
these two antibodies recognize columnar epithelial cells from digestive, 
respiratory, and urogenital tracts, endocrine and exocrine tissues and 
mesothelial cells, as well as their tumours. Generally, no reaction is 
found in squamous epithelia or SQCs. 
4. LP2K (Lane et al. 1985) and BA17 (IgGl; Bartek et al. 1986a,b) stain 
most simple epithelia and basal cells in stratified squamous epithelia that 
are not keratinizing. Both antibodies recognize only CK 19 in 
immunoblotting assays. 
5. RKSE60 (IgGl; Leigh et al. 1985; Puts et al. 1985) reacts only with 
keratinizing epithelial cells, and recognizes CK 10 in immunoblotting. 
6. 6B10 (IgGl; van Muijen et al. 1986) reacts with non-corni fying squamous 
epithelium and with certain ciliated pseudostratified epithelia such as 
cylindrical epithelium of bronchi, and recognizes only CK 4 in 
immunoblotting. 
7. Antibodies 1C7 (IgG2a; van Muijen et al. 1986) and 2D7 (IgG2b; van 
Muijen et al. 1986) react both with non-cornifying squamous epithelia. 
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Table 1: Specificity of antibodies used in this study. 
Antibody 
RCK102 
al. 
ROCÍOS 
al. 
RGE53 
al. 
RCK106 
al. 
LP2K 
1985 
BA17 
RKSE60 
1985; 
1985 
6B10 
al. 
1C7 
al. 
2D7 
al. 
MNF 
1984 
pNF68 
pNF160 
pNF200 
Mouse Ig 
subclass 
(dilution 
for immunofl 
IgGl 
(undil.) 
IgGl 
(undil.) 
IgGl 
(undil.) 
IgGl 
(undil.) 
(undil.) 
IgGl 
(undil.) 
IgGl 
(undil.) 
IgGl 
(undil.) 
IgG2a 
(undil.) 
IgG2b 
(undil.) 
IgGl 
(1:5) 
rabbit 
(1:400) 
rabbit 
(1:600) 
rabbit 
(1:400) 
Antigen 
recognized 
·) 
Cytoker. 
Cytoker. 
Cytoker. 
Cytoker. 
Cytoker. 
Cytoker. 
Cytoker. 
Cytoker. 
Cytoker. 
Cytoker. 
5+8 
7 
18 
18 
19 
19 
10 
4 
13 
13 
NF 68, 200kD 
NF 68 kD 
NF 160 kD 
NF 200 kD 
Tissue specificity 
Nearly all 
epithelial tissues 
Some glandular 
epithelia 
Glandular epithelia, 
not with squamous 
cell epithelia 
Glandular epithelia, 
not with squamous 
cell epithelia 
Most simple epithelia 
Most simple epithelia 
Keratinizing 
epithelial cells 
Non-cornifying 
squamous epithelia, 
pseudostratified 
epithelia 
Non-cornifying 
squamous epithelia 
Non-cornifying 
squamous epithelia 
Neuronal tissues 
Neuronal tissues 
Neuronal tissues 
Neuronal tissues 
Reference 
Ramaekers et 
19B7a 
Ramaekers et 
1987a 
Ramaekers et 
1983d, 1985 
Ramaekers et 
1987a 
Lane et al. 
Bartek et al. 
1986a,b; 
Leigh et al. 
Puts et al. 
van Muijen et 
1986 
van Muijen et 
1986 
van Muijen et 
1986 
Klück et al. 
Nakazato et al. 
1984 
Nakazato et al. 
1984 
Nakazato et al. 
1984. 
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These antibodies recognize only CK 13 in immunoblotting studies. 
B) NF antibodies 
1. The mouse monoclonal antibody MNF (IgGl, diluted 1:5 in PBS), is 
reactive with the 68 kD and 200 k.D NF subunits and stains neuronal tissues 
and tumours (Klück. et al. 1984). 
2. The polyclonal rabbit NF antibodies pNF68 (diluted 1:400), pNF160 
(diluted 1:600) and pNF200 (diluted 1:400) are specific for the three NF 
subunits of 68kD, 160kD and 200kD, respectively (Nakazato et al. 1984), 
and react in neuronal tissues. 
C) Vimentin antibodies. 
1. The mononclonal antibody RV202 (IgGl; Ramaekers et al. 1987a) reacts 
with mesenchymal cells. 
2. The polyclonal antibody pVIM prepared against bovine lens vimentin 
(Ramaekers et al. 1983a) also reacts with mesenchymal cells. 
Antibodies RCK102, RCK105, RGE53, RKSE60, MNF, 6B10, 1C7, 2D7, and pVIM are 
available from Euro-Diagnostics B.V. (Apeldoorn, The Netherlands). 
GEL ELECTROPHORESIS AND IMMUN0BLOTTING. 
For gel electrophoresis and immunoblotting experiments the same 
procedures were followed as described (Broers et al. 1986, 1988). For 
immunoblotting the following antibodies were used: RCK102 (undiluted 
supernatant), RCK105 (undiluted supernatant), RCK106 (undiluted 
supernatant), LP2К (diluted 1:10) and pNF68 (diluted 1:5000). 
FLOW CYTOMETRY. 
The preparation of cell samples for flow cytometric analyses has been 
described (Ramaekers et al. 1986). Briefly, cells were centrifuged at 
room temperature (5 min., x500g), and the supernatant was discarded, but 
fluid sticking to the wall of the tubes was allowed to cover the pellet. 
Cells were resuspended in this fluid by vigorously vortexing, cold (-200C) 
70% ethanol was added, and the cells were kept in this solution until 
staining. The final cell concentration was about 1 million cells per ml of 
70% ethanol. Approximately 1 million cells were taken from this suspension 
and stained for DNA with propidium iodide according to Feitz et al. 
(1985), and for CKs using the antibody RCK102 as described (Ramaekers et 
al. 1986). 
Cell analysis was performed using a Cytofluorograph 50H (Ortho 
Instruments, Westwood, Ma, USA). Propidium iodide was excited at 488 nm 
and fluorescence was measured using a 630 nm longpass filter. For 
determination of the DNA index chicken red blood cells served as an 
internal standard and human lymphocytes as an external standard (Jakobsen, 
1983). 
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RESULTS 
EXPRESSION OF CYTOKERATINS, NEUROFILAMENTS, AND VIMENTIN. 
The expression patterns of CKs, NFs and vimentin in lung carcinoma 
cell lines as detected by the indirect immunofluorescence technique are 
shown in Table 2. The CK expression patterns are depicted in Fig. 1. 
Within the SCLC cell lines a subdivision can be made between the classic 
SCLC cell lines, which contain CKs but not vimentin or neurofilaments, 
transitional SCLC cell lines with a variable CK expression pattern and the 
expression of vimentin, and the variant SCLC cell lines, which in general 
do not contain CKs but contain vimentin and have a variable expression of 
neurofilaments. In all classic SCLC cell and in most transitional SCLC 
cell lines a positive staining reaction was observed with the broadly 
cross-reacting RCK102 antibody (CK. 5+8; Fig. 1A,B,C). Also in the large 
cell lung cancer (LCLC), the AC (Fig. ID) and the SQC cell lines a strong 
staining reaction was seen with this antibody. Antibodies to stratified 
squamous cell epithelia, reacting with CK 4, 10 or 13, were reactive with 
two cell lines. One of these cell lines (GLC-3) was derived from a SCLC, 
which at the electron-microscopic level showed next to SCLC also AC 
differentiation, while the CK expression patterns indicate squamous cell 
differentiation. The other cell line (GLC-A2) was derived from an AC of 
the lung. The expression of CKs A, 10 and 13 in this cell line clearly 
shows squamous cell differentiation, next to AC differentiation (a positive 
reaction with the CK 7 antibody). The classic SCLC cell lines reacted in 
general in most cells with the antibodies to CK 19 (Fig. 1E,G), while the 
transitional SCLC cell lines reacted only in part of the cells or not at 
all (Fig. IF) with these antibodies. In non-SCLC cell lines a reaction 
pattern varying from only a weak reaction in some cells to a very strong 
reaction in all cells (Fig. IH) was seen with the CK 19 antibodies. The 
monoclonal antibodies to CK 18 reacted with all classic (Fig. II,K), three 
out of four transitional (Fig 1J) and three variant SCLC cell lines, and a 
strong reaction with all non-SCLC cell lines could be observed (Fig. IL). 
The antibody to CK 7 reacted with only one out of 19 SCLC cell lines in 
some of the tumour cells (Fig. ΙΜ,Ν,Ο), while in contrast all but one of 
the non-SCLC cell lines were positive with this antibody (Fig. IP). 
Neurofilaments were present in seven out of ten variant SCLC cell 
lines. A filamentous staining reaction was not seen in the other types of 
SCLC cell lines with the NF antibodies. In only one out of nine non-SCLC 
cell lines was a reaction seen with the NF antibodies. 
Vimentin was expressed in variable amounts, ranging from no reaction 
in the classic SCLC cell lines (see also Broers et al. 1985, 1986) to a 
strong filamentous staining reacting in adherent growing cells of most AC 
cell lines. 
Our immunofluorescence findings on the CK expression in lung cancer 
cell lines were confirmed using the immunoblotting technique. Fig. 2 
shows the results of one-dimensional immunoblotting assays of an AC cell 
line (A) and two classic SCLC cell lines (B). For comparison, the same 
nitrocellulose blots were subsequently incubated with different CK 
antibodies. Using LP2K, the presence of CK 19 could be demonstrated in the 
AC cell line (A, lane 1) and in one classic SCLC cell line (B, lane 2). 
CKs 8 and 18 were present in all three cell lines as detected by antibodies 
RCK102 and RCK106, respectively (A, lane 2; B, lanes 3,4). Application of 
111 
+ 
+/-
+/-
++ 
V-
+ 
++ 
+ 
+/-
+/-
+/-
+ 
Table 2: Reaction patterns of lung carcinoma cell lines with antibodies to intermediate filaments. 
RCK102 RCKIOS RGES3/ LP2K/ 6B10 1C7/ RKSE60 MNF pNF68 £*IF160 pNF200 KV202 pVim 
RCK106 BA17 2D7 
Cell line (5+Θ)* (7) (18) (19) (4) (13) (10) 
SCLC 
Classic 
NCI-H128 + + - ++ + _ _ _ _ _ _ _ _ _ 
NCI-H449 + +/-
NCI-H69 + 
GLC1-M13 + 
NL-SCLC2 ++ 
Transitional 
SCLC-16HC +/-
SCLC-22H -H-
SCLC-24H -H-
SCLC-86M1 - - _ _ _ _ _ 
Variant 
NCI-N417 - - -
NCI-H524 - - -
NCI-H82 - - _ _ _ _ _ 
GLC-1 - - _ _ _ _ _ 
GLC-2 - - _ _ _ _ _ 
GLC-3 +/- - +/- +/- 5 а ш е c· sene с. some с. 
GLC-5 some с. - seme с. - - -
NL-SCLC3pl0 - _ _ _ _ _ 
SCLC-21H +/- - + / - - - - -
SCLC-ІбЕІ - - _ _ _ _ _ 
Large Cell 
LCLC-103H ++ - •/- +/- _ - _ - _ _ + + 
Squamous Cell 
EPLC-32m ++ +/- ++ +/- _ _ _ _ _ _ + + 
EPLC-65M2 ++ ++ ++ +/- _ - - - _ _ + + 
Adenocarc. 
NCI-H23 +/- some c. +/- - - - - - - - - + + + + 
NCI-H125 + + + + + + + + _ - _ _ _ - _ + + 
NL-AC1 + + + + + + + + - - - - - - - + + + + 
GLC-Al +/- some с +/- +/- - - - +/- +/- •/- +/- + + 
GLC-A2 ++ ++ +/- ++ +/- +/- +/- - - - - + + 
GLC-A3 + + - H - + + + + - - - - - - - + + 
-
-
-
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-
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-
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Table 3: Reaction pattern of cell lines exhibiting transitions in intermediate filament expression patterns. 
RCK102 RCK105 HGE53/ LP2K/ 6B10 1C7/ RKSE60 MNF EÍJF68 fiJF160 pNF200 RV202 pVim 
RCK106 BA17 207 
Cell line (5+8)* (7) (18) (19) (4) (13) (10) 
GLC-1 
GLC-l-m.3 
SCLC-16HC 
SCLC-16HV 
NCI-H524 
NCI-H524-A 
NCI-H82 
NCI-H82-A 
V-
NCI-N417 
NCI-N417-A1 ++ 
NCI-N417-A2 
NL-SCLC3pl 
NL-SCLC3plO 
+/-
+ / -
+ / -
dot-like 
+/-
+/-
_ 
+/ -
+ / -
+ / -
+ / -
-
++ 
+/ -
dot-lik 
+/-
+ / -
+ / -
++ 
+ / -
++ 
+ / -
e 
+/-
+ / -
+ / -
++ 
+/-
++ 
+/-
+ / -
+ / -
+ / -
-
++ 
+/ -
+ / -
+ / -
+ / -
++ 
+ / -
+ / -
+ / -
+ / -
+ / -
+ 
+/-
+/-
+/-
++ 
+ / • 
+/-
+/-
+/-
+/-
+ 
++ » strong reactivity in all cells 
+ » reactivity in more than 90% of all cells 
+/- - reactivity in part of the cells (10-90%) 
some с - reactivity in less than 10% of all cells 
dot-like • a dot-like reaction in a small part of the cells 
« no reaction in any cells 
*(5+8) - CK polypeptide(s) recognized according to the catalog of Moll et al. (1982) 
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FIGURE 1 
Expression of cytokeratins (CKs) In classic small cell lung cancer (SCLC) 
cell line GLC1-M13 (Α,Ε,Ι, M), transitional SCLC cell line SCLC-2AH (B, F, 
J, N), classic SCLC cell line NCI-H449 (C, G, K, 0), and in adenocarcinoma 
(AC) cell line NCI-H125 (D, H, L, P) as monitored by (chain-specific) 
monoclonal antibodies in the indirect immunofluorescence technique. A 
strong filamentous reaction pattern is seen with the broadly cross-reacting 
antibody RCK102 in all classic and most transitional SCLC cell lines (A, 
x460; B, x400; C, x460), and in all AC cell lines (D, x300). A variable 
reaction pattern is seen in SCLC cell lines using LP2K, specific for CK 19, 
showing a clearly filamentous staining reaction in the classic SCLC cell 
lines (E, x360; G, x410), while no reaction is seen in the transitional 
SCLC cell line (F, x460). A strong reaction is seen with LP2K in the AC 
cell line (H, x300). All CK positive SCLC cell lines contained CK 18 as 
demonstrated with RCK106 (I, x460; J, x410; K, x460), while also the AC 
cell line showed a strong reaction with this antibody (L, x300). In SCLC 
cell lines no reaction was seen with the CK 7 antibody RCK105 (M, x460; N, 
x410), except for cell line NCI-H449, in which part of the cells showed a 
positive reaction (0, x460). Most cells of the AC cell line showed a 
strong staining reaction with RCK 105 (P, x300). 
the CK 18 antibody RCK106 alone showed the presence of large amounts of CK 
18 in the AC cell line (A, lane 3) as compared to a weak reaction in the 
two SCLC cell lines (B, lanes 5 and 6). When applying the CK 7 antibody on 
these blots, an additional band vas seen In the AC cell line (A, lane 4) 
but not in the SCLC cell lines (B, lanes 7,8). Probably owing to breakdown 
of CK polypeptides, a phenomenon often occurring as a result of (limited) 
proteolysis by an endogenous protease (see also Schiller & Franke, 1983), 
additional bands can be seen, which are denoted by arrows. In 
immunoblotting studies of variant SCLC cell lines no CKs could be 
demonstrated (results not shown). 
C0EXPRESSI0N OF CYTOKERATINS AND NEUROFILAMENTS 
Cell line GLC-A1 was derived from an AC of the lung. In contrast to 
other AC cell lines (see Table 2), very few of its cells react with the CK 
7 antibody, and many cells do not seem to contain any CKs at all. Fig. ЗА 
shows that some cells of GLC-A1 react with RCK102, while others do not. In 
addition, an expression of NF proteins can be seen in part of the tumour 
cells (Fig. 3B). Quantification of labelled cells showed a reaction with 
RCK102 in about 7% of all cells, and a reaction with the pNF160 antibody in 
about 30%. Approximately 5% of all cells showed a coexpression of CKs and 
NFs, i.e. reacting with RCK102 and with pNF160 in the same cells. Double 
immunofluorescence staining showed that some cells clearly coexpress CKs 
and NFs, (compare Fig. 3C and D, E and F), while other cells express only 
NFs and no CKs (Fig. 3C, D). Staining of cell nuclei in the 
immunolabelled preparations (Fig. 3G) showed that most cells in the GLC-A1 
culture do not express IFPs of the CK or NF type. 
GLC-5 was initiated from a lymph node metastasis of a SCLC expressing 
NFs next to CKs (de Leij et al. 1986). In early passages of this cell 
line only NFs were found, while in later passages a coexpression of CKs and 
NFs was seen again. Subcloning of GLC-5 did not result in a separation of 
CK or NF positive cells, but after some time each cloned population 
contained cells positive for NFs and few cells positive for CKs. Cells 
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FIGURE 2 
One-dimensional Immunoblotting assays using different chain-specific CK 
antibodies on cytoskeleton preparations from an AC cell line (NCI-H125¡ A), 
and from the two classic SCLC cell lines NL-SCLC2 (B, lanes 1, 3, 5, 7) and 
NCI-H69 (B, lanes 2, 4, 6, 8). On the basis of Coomassie Brillant Blue 
staining patterns, comparable amounts of cytoskeletal proteins from each 
sample were applied. Immunoblotting with the antibody LP2K gave a band at 
the CK 19 level in the AC cell line (A, lane 1), and in the SCLC cell line 
NCI-H69 (B, lane 2), Subsequent incubation of the same immunoblots with a 
CK 18 antibody RCK106 and with RCK102, recognizing CKs 5 and 8, resulted in 
the appearance of bands at the level of CKs 18 and 8, respectively, in the 
AC cell line (A, lane 2), whereas in the SCLC cell lines a relatively 
strong band was detected in both cell lines at the CK 8 level. A much 
weaker reaction was seen at the CK 18 level (B, lanes 3 and 4). Incubation 
with RCK106 alone resulted in a strong reaction in the AC cell line (A, 
lane 3) and a weak, but evident reaction in the two SCLC cell lines at the 
CK 18 level (B, lanes 5 and 6). A subsequent incubation of these 
immunoblots with the antibody RCK105 gave an additional band at the CK 7 
level in the AC cell line (A, lane A), but not in the classic SCLC cell 
lines (B, lanes 7 and 8). Note the prominent bands in the AC cell line 
(denoted by arrows) representing breakdown products of CKs 18 and 19. 
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expressing CKs had the morphological appearance of classic SCLC cells, i.e. 
growing in very tight clusters of floating cells, while most of the cells 
expressing NFs grew as loose clusters, which tended to attach to the 
surface of culturing flasks. 
TRANSITIONS OF IFF PATTERNS WITHIN SCLC CELL LINES 
Subcloning of the variant SCLC cell line GLC-1 resulted in cell line 
GLC1-M13, having biochemically classic SCLC properties (de Leij et al. 
1985) and expressing CKs in nearly all tumour cells (Fig. 1). The variant 
SCLC cell line GLC-1, however, does not express any CKs (Broers et al. 
1985; de Leij et al. 1985; Tables 2, 3). 
One of the SCLC cell lines, i.e. SCLC-16H, was initially 
characterized as a classic SCLC cell line (Bepler et al. 1987a,b) and 
later reclassified as transitional SCLC cell line (Bepler et al. 1988a). 
After about one year of culturing (approximately 65 passages) this cell 
line had lost its transitional SCLC morphology and expression of L-Dopa 
decarboxylase activity (Bepler et al. 1987b). An early passage of this 
cell line (SCLC-16HCp39, Table 3), with typical transitional SCLC 
properties, showed the expression of CKs in most cells (Fig. 4A) and the 
absence of NFs (Fig. AB). Some cells, however, showed a dot-like reaction 
pattern with the pNF68 antibody (Fig. 4C). A late passage of this cell 
line (SCLC-16HVp93), which was biochemically characterized as a variant 
SCLC cell line (Bepler et al. 1987b) did not express any CKs (Fig. AD), 
but showed the presence of NFs in about 10% of the cells (Fig. AE). 
Cell line NCI-NA17 did not seem to express CKs or NFs when introduced 
in our laboratory (Fig. 5A,B; see also Broers et al. 1985, 1986). 
However, when grown for more than 6 months in the same culture flask with 
regular changes of the culture medium, a subset of cells arose 
(NCI-N417-A1), that grew firmly attached to the plastic. These cells 
appeared to express CKs (Fig. 5D,E), while some of the remaining floating 
cells of NCI-NA17 showed a dot-like reaction with the CK 18 antibody RCK106 
(Fig. 5C), but not with other CK antibodies. After several passages the 
formerly adhering cells were no longer attached, and the CK-positive subset 
of cells was lost. After another 6 months again some cells attached to the 
surface of the culture flasks (NCI-N417-A2). Both the floating and the 
attached cells now revealed a positive staining reaction with NF antibodies 
in about 10% of all cells (Fig. SF.G). 
A comparable switch in IFF expression was noticed in cell line 
NL-SCLC3. In frozen sections of the SCLC from which this cell line was 
derived, no CKs or NFs could be detected in the tumour cells. The same 
holds true for the cell line up to passage 7. However, at passage 10 a 
small subset of cells was found, that expressed NF proteins. With each 
subsequent passage the percentage of cells positive for NFs increased to 
about 50% at passage 20. 
Another type of change in IFF expression was seen in the variant SCLC 
cell lines NCI-H52A (Fig. 6) and NCI-H82 (Fig. 7). These cell lines 
normally grow as loosely packed floating aggregates, which do not attach to 
the bottom of culturing flasks, and express NFs in all cells (Figs. 6D, 
7A). CKs can not be detected in these floating cells (Figs. 6E, 7B). 
After a prolonged period of growing in the same culture flask, however, an 
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FIGURE 3. 
Immunofluorescence staining patterns of cell 1 
of the lung. Part of the cells react strongly 
also a strong reactivity is seen with the 
Double-label immunofluorescence studies (C-
reactive with RCK.102 (C, asterisk; x450) are a 
antibody (D, x450). In addition, some cells 
are positive with the pNF160 antibody (D). 
Double-label immunofluorescence in combination 
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also react with the pNF 160 antibody (F, x350) 
fluorescence suggest colocalization of the 
nuclear DNA staining (G, x350), however, shows 
sample do not contain CKs or NFs. 
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with RCK102 (A, x385), while 
pNF160 antibody (B, x450). 
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Iso stained by the pNF160 
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while the distribution of 
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increasing number of cells attached to the bottom (see e.g. Fig. 6A,B,C). 
Immunofluorescence studies showed that these adhering cells not only lost 
their NF expression in part of the cells, but also that some of these cells 
initiated the (co-)expression of CKs (Fig. 6F,G and 7C,D). Double 
immunofluoresence studies showed that in NCI-H524 some cells coexpress NFs 
and CKs, while other cells express only NFs (cf. Fig. 6H and I). The 
same phenomenon can be observed in NCI-H82, where some cells express CKs 
(Fig. 7E and H) and other cells express NFs (Figs. 7F and I), while 
occasionally a clear coexpression of CKs and NFs can be observed (cf. Fig. 
7H and I, asterisk). Counterstaining of the nuclear DNA with Hoechst shows 
that most cells in NCI-H82 express either CKs or NFs (Flg. 7G and J). 
FIGURE A 
Immunofluorescence staining patterns of SCLC-16H at an early passage number 
(p39·. A, B, C) and at a late passage number (p93; D, E). During early 
passages most cells reacted strongly with the CK antibody RCK102 (A, xA50). 
Most cells did not react with the pNF68 antibody (B, xA75), while in some 
cells a dot-like reaction pattern with this antibody was seen (С, x450). 
In the late passages all cells have lost CK expression (D, RCK102; xA50), 
while in about 10% of all cells a reaction with NF antibodies was found (E, 
pNF200; x550). 
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FIGURE 5. 
Immunofluorescence staining patterns of NCI 
different types of differentiation. In 
express CKs, showing no reaction with RGE53 
detectable with pNF 200 (В, xl75). Afte 
started to attach to the culturing flask (C 
floating cells started to express CKs, 
dot-like manner (C, xA75). Cells that grew 
CKs, reacting with RCK106 (D, χ 410) 
culture, CK positive cells were lost, while 
NFs, which were reactive with the pNF68 
pNF200 antibody (G, x475). 
N417 with (apparently) three 
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FIGURE 6. 
Phase-contrast (Α-C) and immunofluorescence (D-G) micrographs of the 
variant SCLC cell line NCI-H524. At first, this cell line grew as floating 
aggregates (A, xl05) with cells expressing NFs, showing a reaction in all 
cells with, for example, the pNF160 antibody (D, x475). No cells could be 
detected to be positive for CKs (E, RCK.106; x360). Upon culturing, an 
increasing number of cells started to grow adherent (B, x235j С, ХІ05). 
These adherent cells clearly expressed CKs, showing a reaction with RCK102 
(F, x435) and with RCK106 (G, x435). Double-label immunofluorescence 
experiments (H, I) show that some cells that were reactive with the pNF160 
antibody (H, x475) also reacted with RCK102 (G, x475). 
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FIGURE 7. 
Immunofluorescence staining patterns of the variant SCLC cell line NCI-H82. 
This cell line, growing as floating aggregates, expressed NFs, (A, pNF160j 
x310) and did not express CKs (B, RCK106; x420). However, after prolonged 
culturing some cells started to grow adherent, and selection of these cells 
resulted in a cell culture that was clearly positive with different CK 
antibodies, such as RCK102 (C, x460) and RCK106 (D, x410). Double-label 
immunofluorescence studies (compare E, F, G, with H, I, J) showed that 
within this cell culture some cells expressed CKs, reactive with RCK102 (E, 
x410; H, x345), while other cells were reactive with the pNF200 antibody 
(F, x410) or with the pNF68 antibody (I, x345). Nuclear DNA staining (G, 
x410; J, x345) showed that most cells were reactive with either CK or NF 
antibodies, while in one cell probably a coexpression of CKs and NFs was 
seen (compare H, I, J; asterisk). 
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Our Immunofluorescence data were confirmed by immunoblotting experiments 
using RCK106 as a marker for CK expression and pNF68 as a NF marker (Fig. 
Θ). A shows two weakly stained protein bands at the level of CK 18 (lane 
1) and the somewhat stronger reaction with the 68 kD NF protein (lane 2) in 
GLC-Al, and in В the early passage (p39) of SCLC-16HC was compared with a 
late passage (p93) of this cell line (SCLC-16HV). Lane 1 shows the 
presence of CK 18 in SCLC-16HC, while SCLC-16HV (lane 2) does not show a 
reaction with RCK106. Subsequent incubation with the pNF 68 antibody 
(lanes 3, 4) does not result in extra bands, probably owing to the low 
number of cells expressing NFs in SCLC-16HV. Fig. 8C shows the presence 
of CK·18 (lane 1) and of the 68 kD NF protein (lane 2) in the subset of 
cells from NCI-H524 that grows as an attached monolayer. Fig. BD shows 
the differences between CK and NF expression in the floating and the 
attached sublines of NCI-H82. Incubation with the CK 18 antibody shows the 
presence of this protein in the adherent cells (lane 2) and no reaction in 
the floating cells (lane 1). Subsequent incubation with the NF antibody 
shows that both cell types express the 68 kD NF protein (lanes 3, A). 
MONITORING OF CROSS-CONTAMINATION. 
To detect whether changes within cell lines might be due to possible 
cross-contamination with other cell lines simultaneously growing in our 
laboratory, flow cytometric analyses were performed at regular intervals. 
As an example, Fig. 9 shows the flow cytometric analysis of the floating 
fraction of NCI-H524, as compared with the adherent growing fraction of 
this cell line. No significant shift in DNA-index (DI), nor extra DNA 
peaks, indicating a possible contaminating cell line, were observed (cf. 
Fig. 9A, B). The DI value of both cell lines varied between 1.10 and 
1.23. In addition, the attached fraction was labelled with the CK antibody 
RCK102 and analysed in a two-dimensional fashion, in which DNA was stained 
with propidium iodide. The results show that about 15% of the adherent 
cells contained CKs (Fig. 9C). Floating cells did not contain CKs (not 
shown). 
The DI values of the two adherent growing variant SCLC cell lines 
(NCI-H82, 01=1.20-1.22; NCI-H52A, 01=1.10-1.23) were compared with those 
for other adherent growing lung cancer cell lines such as EPLC-32M1 
(01=1.50) EPLC-65M2 (DI=1.55), LCLC-103 (01=3.27) NCI-H23 (01=1.60), NL-AC1 
(DI=1.52), and non-lung cancer epithelial cell lines growing in our 
laboratory, such as T2A (01=1.57), and HeLa (01=1.48). Since the 01 values 
for the G0/G1 cells of these cell lines are all significantly higher than 
1.23, a cross-contamination with these cell lines can be excluded. In 
addition, the CK and NF expression patterns of the adherent growing variant 
SCLC cell lines appeared to be unique for these two cell lines. 
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FIGURE В 
One dimensional immunoblotting of different lung cancer cell lines. (A). 
Cell line GLC-Al shows a faint (double) band at the 45 kD level with the CK 
18 antibody RCK106 (lane 1). This weak reaction can be explained by the 
fact that CKs were detected in only 7% of all cells in immunofluorescence 
experiments. After subsequent incubation of the same immunoblot with the 
pNF68 antibody a stronger reaction is seen at the 68 kD level (lane 2). 
(Panel B) Early passage of SCLC-16HC (passage 39; lanes 1 and 3) compared 
with a late passage (SCLC-16HV, passage 93; lanes 2 and 4) of this cell 
line. SCLC-16HC shows a clear reaction with RCK106 (lane 1), while no 
reaction is seen with RCK106 in SCLC-16HV (lane 2). Incubation of the same 
blot with pNF68 did not result in an additional band at the 68 KD level in 
either cell line, confirming the immunofluorescence data of SCLC-16HC with 
this antibody. A discrepancy is seen with the positive immunofluorescence 
reaction with pNF68 in SCLC-16HV, which might be explained by the low 
number of cells reacting with this antibody. 
(C). Adherent growing culture of the variant SCLC cell line NCI-H524, 
incubated with RCK 106 (lane 1) and subsequently incubated with pNF68 (lane 
2). Note the presence of the CK 18 band and the 68 kDa NF band in this 
cell line. 
(D). Comparison of the floating (lanes 1, 3) and the adherent growing 
cells (lanes 2, 4) of the variant SCLC cell line H82. Incubation with 
RCK106 results in a reaction at the 45 kD level with the adherent growing 
cells only (compare lanes 1, 2), while subsequent incubation with pNF68 
shows that both cell types contain the 68 KD NF polypeptide. 
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FIGURE 9 . 
Comparison of flow cytometric analyses of floating (A) and adherent growing 
(B,C) cells of the variant SCLC cell line NCI-H524. The DNA indices (DI) 
found for both cell types did not differ significantly 
(C) Two-parameter flow cytometric analysis of cells from (B) separated 
according to their cytokeratin (CK) content, as determined with RCK102 
(labelled with rabbit anti-mouse FITC), and DNA content as determined by 
labelling with propidium iodide. It was calculated that about 15% of the 
adherent cells of NCI-H524 were positive with RCK102. 
DISCUSSION 
In this paper we describe changes in IFF expression in lung cancer 
cell lines during long term culture. We have especially focussed on CKs 
and NFs, since it is known that classic and variant SCLC cell lines exhibit 
different expression patterns of these IFPs (Broers et al. 1985, 1986). 
In the last decade lung carcinoma cell lines that have retained many 
characteristics of the in vivo cancers have been established (Gazdar et al. 
1981, 1985; Bergh et al. Т Ш ; Carney et al. 1984, 1985a,b; Bepler et al. 
1987a,b,1988b). Most of these cell lines form tumours when Injected into 
athymic nude mice with a histology similar to that of the original 
malignancy. Banks-Schlegel et al. (1985) stated that cell lines derived 
from different types of lung tumours continue to maintain a program of CK 
expression reflective of the native tumour. 
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CYTOKERATINS AND NEUROFILAMENTS IN LUNG CANCER CELL LINES. 
Our results on the IFF expression patterns in lung cancer cell lines 
are partly in accord with the findings in solid lung carcinomas with 
homogeneous morphology (Broers et al. 19Θ8). In general, one can state 
that classic and transitional SCLCs and ACs contain CKs typical of simple 
epithelia, i.e. CKs 8, 18 and sometimes 19. In addition to these CKs, AC 
cell lines are characterized by the presence of CK 7, which is absent in 
SCLC. Variant SCLC cell lines in general do not contain CKs but may 
express NFs (see also Broers et al. 1985, 1986). Some exceptions, 
however, were seen. 
1. Two cell lines derived from SQCs (EPLC-32M1 and EPLC-65M2) did not 
express the typical SQC CKs, i.e. CKs 10 and 13, but contained CKs 7, 8 
and 18, occurring in simple epithelia, in this way resembling poorly 
differentiated SQC in their expression pattern (see also Broers et al. 
1988). These changes are in accord with histological findings in mouse 
xenografts, in which these tumours were classified as undifferentiated 
large cell carcinomas (Bepler et al. 1988b). Furthermore, Blobel et al. 
(1984) have already shown that other cell lines derived from SQC mainly 
express CKs 7, 8 and 18. 
2. On the other hand, a cell line derived from an AC (GLC-A2) did express 
CKs 10 and 13, characteristic of SQC as well as CKs 7, 8 and 18, 
characteristic of ACs. 
3. Another cell line derived from an AC (GLC-A1) expressed NFs next to CKs, 
while CK 7, characteristic of ACs of the lung (see also Broers et al. 
1988), was present in only a few cells of this culture. Therefore, on the 
basis of IFF expression patterns, this cell line resembles variant SCLC 
cell lines rather than AC cell lines. 
4. One of the SCLC cell lines (GLC-3) exhibited SQC differentiation as 
concluded from its IFF expression pattern. Interestingly, this cell line 
was previously shown to express AC differentiation characteristics at the 
EM level (de Leij et al. 1985). 
These data clearly demonstrate heterogeneity within some cell lines in 
both degree and type of differentiation. However, results from most other 
cell lines show that cultured SCLC lines may serve as suitable models with 
which to study the biology of lung carcinoma subtypes (see also Gazdar & 
Minna, 1986). 
TRANSITIONS IN IFF EXPRESSION PATTERNS. 
In earlier studies, changes in growth pattern were observed during 
prolonged culturing of lung cancer cell lines. For instance, progression 
of classic to variant SCLC cell lines has been reported by several authors 
(Gazdar et al. 1981, 1985; Carney et al. 1985b; Graziano et al. 1987; 
Bepler et al. 1987b,c). Since classic SCLCs express CKs, while variant 
SCLCs may express NFs (Broers et al. 1985, 1986), we wondered whether such 
a progression would be accompanied by a change or loss of IFPs. In one of 
our cell lines (SCLC-16H), showing a progression towards variant SCLC, a 
transition from CK to NF expression was indeed seen. 
Two cell lines (NL-SCLC3 and NCI-N417) which at first did not express 
CKs or NFs, initiated the expression of NFs upon prolonged culturing, 
suggesting that the absence of CKs and NFs in some SCLC cell lines as well 
as in some solid SCLC tumour parts (see also Broers et al. 1987) may be a 
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temporary event occurring in some SCLC with a type of differentiation 
between classic and variant, the so-called transitional type of SCLC 
(Bepler et al. 1987c). In vitro the transitional cell type, in contrast 
to the classic cell type, expresses vimentin. Cytokeratin expression is 
found in varying degrees, and neurofilaments are absent or barely 
demonstrable. It remains to be determined to what extent the transitional 
type of SCLC can be compared with the so-called biochemical variant type of 
SCLC as defined by Gazdar et al. (1985). Examination of IFP expression 
patterns in these biochemical variant SCLC cell lines might elucidate this 
issue. 
Another conversion that seems to occur within our cell lines is that 
from variant SCLC to non-SCLC differentiation, as described by Gazdar et 
al. (1981). In vitro non-SCLC cell lines, which do not express the 
neuroendocrine-related biomarkers present in SCLC (Carney et al. 1985a,b; 
Gazdar et al. 1985), grow as monolayers, firmly attached to the surface of 
culturing flasks. By selecting cells within the variant SCLC cell lines 
that tended to attach, we were able to grow sublines consisting of 
predominantly attached cells. Interestingly, these cells lose the 
expression of the neuroendocrine marker MOC-1 (results not shown), and 
start to express CKs next to NFs, resulting in a coexpression of CKs and 
NFs within these cell lines or within individual cells. Whether these 
cells lose the expression of other biomarkers, characteristic of (variant) 
SCLC, remains to be examined. 
As far as the implications of these findings can be extrapolated to 
patient tumours it is important to note that there is growing evidence of 
heterogeneity of lung carcinomas. This heterogeneity can apparently also 
be found in (some) lung cancer cell lines and, even more interestingly, in 
cloned cell lines. Progression from classic to variant SCLC has been 
reported in vivo (Abeloff et al. 1979), especially after chemotherapy 
and/or irradiation of patients. Also conversions from SCLC to non-SCLC 
(Abeloff et al. 1979; Sehested et al. 1986) are often seen. In general, 
we can state that conversions from one cell type to another within cell 
lines are accompanied by a change in IFP expression patterns. The 
conversions observed in the cell lines closely resemble those occurring 
in vivo. Therefore, our in vitro findings strongly support the hypothesis 
that different types of lung carcinomas have a common origin (see also 
Gazdar et al. 1981; McDowell & Trump, 1983) and as a result heterogeneity 
in lung tumour types as well as conversions from one tumour type to another 
are likely to occur as a result of (trans)differentlatlon rather than 
derivation (Gould, 1986). 
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SUMMARY AND CONCLUSIONS 
In this thesis the expression of intermediate filament proteins in lung 
tissues, lung carcinomas and lung cancer cell lines has been examined. The 
picture of the expression of the different types of filaments in these 
tissues was hitherto rather incomplete and often contradictory. 
In chapter two we describe the expression of intermediate filament 
proteins in fetal and adult human lung tissues. In early stages of 
development only so-called simple cytokeratins are present in bronchial 
epithelial cells. With increasing age, the cytokeratin expression pattern 
becomes more complex. In adult lung a heterogenous cytokeratin expression 
pattern is observed, showing a large diversity within histologically 
similar epithelium. Vimentin is present in all mesenchymal tissues. In 
addition, however, in fetal lung expression of vimentin is seen in 
developing bronchial epithelium, which decreases with age. In adult 
bronchus a staining reaction with scattered columnar and basal cells was 
seen with the vimentin antibodies. Desmin filaments appear to alter their 
antigenic determinants upon maturation. In early stages of development 
smooth muscle cells of blood vessels are reactive with cytokeratin and 
desmin antibodies. With increasing age the reactivity of the cytokeratin 
antibodies decreases, while the reactivity with desmin antibodies 
increases. 
In chapter three the occurrence of cytokeratins in small cell lung 
cancer and in lung carcinoids is described. A previous investigation had 
demonstrated the presence of neurofilaments and the absence of cytokeratins 
in these tumors. Our results clearly indicate that the inability to 
demonstrate the presence of cytokeratins was a matter of fixation problems 
or lack of cross-reactivity of the antibodies used. Compared with other 
types of lung carcinomas, however, the amounts of cytokeratins, present in 
small cell lung cancer are low. 
In chapter four we report on the expression of cytokeratins, 
neurofilaments, and a neuroendocrine differentiation antigen in an extended 
series of freshly frozen, as well as paraffin-embedded cases of lung 
cancer. A profound heterogeneity within most tumors is seen, as 
demonstrated a) by the presence of the neuroendocrine differentiation 
marker in many non-neuroendocrine tumors, b) the presence of neurofilaments 
additional to cytokeratins in several neuroendocrine and non-neuroendocrine 
tumors, and c) the reactivity of a cytokeratin antibody, characteristic for 
columnar epithelia, in squamous cell carcinomas. 
In chapter five a number of cases from the series of tumors, 
investigated in chapter four were selected. We have examined the 
cytokeratin polypeptide expression patterns by immunoperoxidase as well as 
immunoblotting techniques, using chain-specific monoclonal cytokeratin 
antibodies, which recently have become available. On basis of cytokeratin 
expression patterns alone, a distinction between the main subtypes of lung 
carcinomas can be made. Meanwhile, however, again the profound 
heterogeneity in expression patterns within most tumors is striking. 
Chapter six describes the expression patterns of two different types 
of small cell lung cancer (SCLC) cell lines, i.e. the classic type and the 
variant type of SCLC. Since in general cell lines derived from a certain 
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type of tumor retain a number of biological and biochemical properties, 
characteristic for the original tumor, cell lines are a powerful tool to 
study the biology of a certain tumor subtype. Our results demonstrate 
differences in the expression of intermediate filament proteins between the 
two types of cell lines. Classic SCLC cell lines express only 
cytokeratlns, while variant SCLC cell lines do not express cytokeratins, 
but occasionally express neurofilaments. These findings partly explain why 
some investigators could detect neurofilaments in SCLC, while others could 
find only cytokeratins. 
In chapter seven we have extended our examinations on some of the cell 
lines, investigated in chapter six, to determine their exact cytokeratin 
and neurofilament profile. For this purpose we have used a large panel of 
Intermediate filament protein antibodies in immunocytochemlcal techniques. 
The immunocytochemical results were confirmed using one- and 
two-dimensional gel electrophoresis and one- and two-dimensional 
immunoblotting assays. Using these methods the absence of neurofilaments 
and presence of cytokeratins in classic, and the absence of cytokeratins 
and presence of neurofilaments in variant SCLC, was biochemically and 
immunochemically substantiated. 
In chapter eight we have examined the intermediate filament protein 
expression patterns in a series of twenty-eight lung carcinoma cell lines, 
obtained from four different institutes. We have paid special attention to 
classic, variant, and so-called transitional SCLC cell lines. These 
transitional SCLC cell lines have characteristics between the classic and 
variant type of SCLC. During long-term culture in some cell lines changes 
in morphology and in intermediate filament expression patterns can be 
observed. Changes from classic to variant SCLC, possibly via transitional 
SCLC, and from variant SCLC towards non-SCLC are seen. During these 
changes a clear coexpression of cytokeratins and neurofilaments within cell 
lines and even within individual tumor cells is noticed. 
The composition of an intermediate filament expression profile of lung and 
lung cancer goes beyond a merely descriptive investigation on the 
expression of a group of proteins of which the function in not even known. 
The investigations described in this thesis have proven to be of help in 
lung cancer diagnosis. For instance, histologic squamous cell carcinomas 
showing reaction with the antibody to cytokeratin 7 are diagnosed as 
adenosquamous carcinoma. Furthermore, antibodies indicating the degree of 
differentiation can be of help, since patients with well-differentiated 
carcinomas have a better prognosis than patients with poorly differentiated 
lung tumors. The presence of neuroendocrine differentiation markers in 
non-SCLC can indicate the presence of a small cell component within such 
cancers, which changes diagnosis and as a result the treatment regimen. 
Within most carcinomas certain tumor cells are sensitive to treatment, 
while other cells are not. These latter cells, which manage to escape from 
treatment, cause recurrence of the tumor, in many cases with a different 
histology as compared to the original tumor. Unfortunately, at this moment 
the tools to detect lung cancer at an early stage are not refined enough to 
benefit from the knowledge of the degree and type of differentiation. 
Therefore, to cope with the leading cancer killer in the Western world, 
attempts must be made to find new treatment regimens, based on our 
knowledge of lung cancer heterogeneity and its cell biological behaviour. 
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SAMENVATTING EN CONCLUSIES 
In dit proefschrift werd een onderzoek verricht naar de expressie van 
intermediaire filament-eiwitten in normale longweefsels en longcarcinomen. 
Doordat eerdere onderzoeken tot tegenstrijdige conclusies met betrekking 
tot intermediaire filament-expressie waren gekomen, hebben we getracht deze 
problemen systematisch op te sporen en uit te bannen. 
In hoofdstuk twee beschrijven we de expressie van intermediaire 
filament-eiwitten in foetaal en adult longweefsel. De vroege stadia van 
foetale ontwikkeling worden gekenmerkt door een expressie van uitsluitend 
zo genaamde "simpele" cytokeratines in bronchiaal epitheel. Met toenemende 
leeftijd wordt het cytokeratine-patroon steeds complexer, resulterend in 
een zeer heterogene reactie in adulte bronchi. Vimentine is niet alleen 
aanwezig in mesenchymale, maar ook in epitheliale cellen, vooral in de 
vroege stadia van ontwikkeling. Met leeftijdstoename neemt deze reactie in 
epitheliale cellen af. In adulte bronchi blijkt echter dat een aantal 
epitheliale cellen weer een expressie van vimentine vertonen. De 
reactiviteit van desmine antilichamen in gladde spiercellen van bloedvaten 
blijkt te veranderen met leeftijd. In vroege stadia reageert een desmine 
antilichaam in het geheel niet met deze gladde spiercellen, die in eerste 
instantie wel positief zijn met cytokeratine antilichamen. Met toenemende 
leeftijd neemt de reactiviteit van het desmine antilichaam toe, terwijl de 
reactiviteit van de cytokeratine antilichamen afneemt. 
In hoofdstuk drie beschrijven we het voorkomen van cytokeratines in 
kleincellige longcarcinomen en in long-carcinoïden. Eerdere onderzoeken 
hadden gesuggereerd dat deze carcinomen neurofilamenten en geen 
cytokeratines zouden bevatten. Op basis van onze resultaten lijken in 
ieder geval de negatieve resultaten met de cytokeratine antilichamen op een 
fixatie-artefact of gebrek aan kruisreactiviteit van de betreffende 
cytokeratine antilichamen te duiden. Dit lijkt aannemelijk, gezien het 
feit dat de hoeveelheid cytokeratines, aanwezig in deze tumoren, relatief 
gering is. 
In hoofdstuk vier beschrijven we een onderzoek naar de expressie van 
cytokeratines, neurofilamenten, en een neuro-endocrien 
differentiatie-antigeen in een uitgebreide serie van longcarcinomen. 
Opvallend aspect van dit onderzoek was de enorme heterogeniteit in 
expressie van deze markers binnen de verschillende typen longkanker. Zo 
kan in niet-kleincellige longcarcinomen vaak de expressie van neurale of 
neuro-endocriene componenten aangetoond worden, terwijl een cytokeratine 
antilichaam, dat normaal kenmerkend is voor cylindrisch epitheel, vaak 
wordt aangetroffen in plaveiselcelcarcinomen. 
In hoofdstuk vijf wordt een geselecteerde groep longcarcinomen verder 
onderzocht op de expressie van verschillende cytokeratine Polypeptiden. 
Doordat we de beschikking hebben over een panel van keten-specifieke 
monoclonale antilichamen, kunnen we op cellulair niveau de expressie van 
deze cytokeratine Polypeptiden onderzoeken. Op basis van deze 
expressie-patronen kunnen de belangrijkste groepen longcarcinomen 
onderscheiden worden, waarbij de heterogeniteit binnen de verschillende 
groepen opnieuw zeer opvallend is. 
Hoofdstuk zes beschrijft de reactiepatronen van twee groepen 
cellijnen, de klassiek- en de variant-kleincelligen. Aangezien in het 
algemeen blijkt dat cellijnen, afkomstig van een bepaald type tumor, een 
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groot aantal biologische en biochemische eigenschappen van de 
oorspronkeljke tumor behouden, zijn deze uitermate geschikt voor onderzoek 
naar het biologisch gedrag van de verschillende typen tumor. Op basis van 
de expressie van intermediaire filamenten kan een onderscheid gemaakt 
worden tussen deze twee groepen. Klassiek-kleincellige cellijnen brengen 
cytokeratines tot expressie, terwijl variant-kleincellige cellijnen geen 
cytokeratines, maar in een aantal gevallen neurofilamenten tot expressie 
brengen. Deze resultaten kunnen voor een deel verklaren waarom eerder door 
sommige onderzoekers uitsluitend cytokeratines en door anderen uitsluitend 
neurofilamenten werden gevonden. 
In hoofdstuk zeven hebben we ons onderzoek aan een groep cellijnen 
uitgediept met een groot aantal extra intermediaire filament antisera, om 
een zo volledig mogelijk beeld van de expressie van deze intermediaire 
filamenten te verkrijgen. Uit verder onderzoek met behulp van een- en 
twee-dimensionale gel-electroforese en immunoblotting werden onze eerdere 
resultaten biochemisch en immunochemisch bevestigd. 
In hoofdstuk acht beschrijven we expressie-patronen van intermediaire 
filamenten in 28 cellijnen, afkomstig van vier verschillende instituten. 
Onze belangstelling ging hierbij met name uit naar klassiek-, 
transitionele, en variant-kleincellige cellijnen. Overgangen van klassiek, 
waarschijnlijk via transitioneel, naar variant kleincellig kunnen 
waargenomen worden, maar ook overgangen van variant in de richting van 
niet-kleincellig. Deze veranderingen blijken gepaard te gaan met een 
verandering in het expressie-patroon van intermediaire filamenten. Tijdens 
deze veranderingen treedt een co-expressie van cytokeratines en 
neurofilamenten op, zowel op cellijn-niveau, alsmede binnen individuele 
cellen. 
Het samenstellen van een zo exact mogelijk profiel van de expressie 
van intermediaire filamenten in longcarcinomen heeft niet een louter 
beschrijvende betekenis, maar blijkt een goed hulpmiddel te zijn bij het 
diagnostiseren van longkanker. Bij voorbeeld de reactiviteit van een 
(histologisch) plaveiselcelcarcinoom met ons cytokeratine 7 antiserum 
wijzigt de diagnose in adeno-squameus carcinoom. Andere antilichamen 
kunnen de mate van differentiatie van een tumor nauwkeurig aangeven. 
Aangezien goed gedifferentieerde carcinomen in het algemeen een betere 
prognose hebben, is dit van klinische betekenis. De aanwezigheid van 
neuro-endocriene of neurale antigenen in een niet-kleincellig longcarcinoom 
duidt op de aanwezigheid van een kleincellige component binnen zo een 
tumor. Deze wijziging van de diagnose heeft tevens therapeutische 
gevolgen. 
Bij de behandeling van een longcarcinoom reageren vaak uitsluitend 
cellen met een bepaalde graad of type differentiatie, terwijl andere cellen 
zich aan deze behandeling kunnen onttrekken. Het gevolg hiervan is, dat na 
een in een eerste instantie goede respons, zoals deze vaak bij kleincellige 
carcinomen optreedt bij chemotherapie, een tumor manifest wordt, die niet 
gevoelig is voor deze behandeling. Deze tumoren hebben vaak een andere 
morfologie dan de oorspronkelijke. Helaas zijn er op dit moment geen 
methoden bekend voor de detectie van longcarcinomen in een vroeg stadium, 
waarbij optimaal gebruik gemaakt kan worden van onze kennis van de 
heterogeniteit van de longcarcinomen. Voor het bestrijden van longkanker 
zal derhalve gezocht moeten worden naar totaal nieuwe methodes die tumoren 
kunnen bestrijden gebaseerd op deze kennis van heterogeniteit en 
cel-biologisch gedrag van longcarcinomen. 
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CURRICULUM VITAE 
Jos Broers werd op 6 januari 1957 geboren in het kerkdorp Eckelrade, dat 
indertijd door ambtelijke willekeur uit de 19e eeuw voor een gedeelte 
ressorteerde onder de gemeente Gronsveld. 
Na het doorlopen van de lagere school aldaar, volgde hij in de grote stad 
Maastricht het Gymnasium-B van 1969 tot 1975 aan het Henric van Veldeke 
College. 
In 1975 vertrok hij naar Nijmegen,waar hij het Kandidaatsexamen Biologie 
behaalde in 1978 aan de Katholieke Universiteit. 
Het Doctoraalexamen Biologie behaalde hij in 1982 aan de Katholieke 
Universiteit te Nijmegen. 
Zijn doctoraalstudie bestond uit de volgende vakken: 
Hoofdrichting Dieroecologie (Hoofd Dr. Oomen): Populatie-dynamisch 
onderzoek aan reptielen in Nederland en in de Oostenrijkse Alpen. 
Bijvak Botanie Algemeen (Hoofd Prof. Dr. H.F. Linskens): Onderzoek naar 
allergeen-produktie bij xerofiele huisstofschimmel. 
Bijvak Ontwikkelingsbiologie der dieren (Hoofd Prof. Dr. J.M. Denucé): 
Immunocytochemisch onderzoek naar het voorkomen van neuropeptiden in de 
oogsteel van Palaemon serratus. 
Zijn lesbevoegdheid Ie graads Biologie behaalde hij In 1980. 
Na een korte periode van werken op de boerderij in Eckelrade besloot hij 
tot het verrichten van vrijwilligerswerk bij Dr. L.G. Poels op de 
afdeling Cyto/Histologie (Hoofd Prof. Dr. С Jeruzalem) van december 
1982 tot februari 1984, waar hij zich verder specialiseerde in biochemische 
en immunologische technieken, zoals de bereiding van monoclonale 
antilichamen tegen celoppervlakte-antigenen. 
Vanaf februari 1984 is hij werkzaam op de afdeling Pathologische Anatomie 
van het Academisch Ziekenhuis Nijmegen (Hoofd Prof. Dr. G.P. Vooijs) in het 
kader van een KWP-project (NUKC-1984-13), waar dit proefschrift tot stand 
kwam. 
In september 1985 is hij getrouwd met Marlet Roodink. 
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STELLINGEN 
1. De uitspraak van Gatter en co-auteurs: "The dream of a panel of 
anti-intermediate filament antibodies solving all the problem areas of 
histopathology is over", suggereert ten onrechte dat zulk een droom 
ooit bestaan zou hebben. 
Gatter КС et al. 19B6. J Clin Pathol 39: 950-954. 
2. Aangezien kleincellige longtumor cellijnen spontaan kunnen veranderen 
qua differentiatie-kenmerken verdient het aanbeveling om deze cellijnen 
periodiek hierop te controleren. 
Gazdar AF et al. 1985. Cancer Res 45: 2924-2930. 
Dit proefschrift. 
3. De detectie van neuro-endocriene differentiatie-kenmerken in 
niet-kleincellige longcarcinomen met behulp van monoclonale 
antilichamen kan een indicatie zijn om deze tumoren als kleincellige 
longcarcinomen te behandelen. 
Hammond ME, Sause WT. 1985. Cancer 56: 1624-1629. 
Dit proefschrift. 
4. Gezien de beperkte vooruitgang bij de behandeling van longkanker in het 
afgelopen decennium, verdient het aanbeveling om voorrang te verlenen 
aan de ontwikkeling van nieuwe, experimentele, behandelingstechnieken. 
5. Het feit, dat de Levendbarende Hagedis Lacerta vivipara in staat is 
zich te handhaven in het Oostenrijks hooggebergte, moet worden 
toegeschreven aan de flexibele voortplantingscyclus en de relatief lage 
predatiedruk. 
6. Toen de eerste suffragettes demonstratief een sigaar opstaken konden ze 
niet vermoeden dat, wellicht door dit gebaar, de vrouwenemancipatie 
later letterlijk over lijken zou gaan. 
Andrews JL et al. 1985. Lung cancer in women. Cancer 55: 2894-2898. 
Holleb ΑΙ. 1985. Lung cancer: a feminist issue. CA 35: 125-126. 
7. Een efficiënte bestrijding van longkanker is alleen mogelijk als de 
politieke bereidheid ontstaat om de volksgezondheid belangrijker te 
achten dan de financiële voordelen van accijns-inkomsten uit de 
sigarettenverkoop. 
8. De volksgezondheid zou gediend zijn als werkers in de gezondheidszorg 
in openbare ruimten niet zouden roken en er geen werkkleding zouden 
dragen. 
9. De alfabetische rangschikking van de nederlandse letter ij onder y in 
telefoonboeken is niet alleen een miskenning van deze taaieigen letter, 
maar ook gewoon knap lastig voor mensen die vaker woordenboeken dan 
telefoonboeken raadplegen. 
Nijmegen, 4 november 1988 J.L.V. Broers 

